BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358:929-939. [PMID: 18305268 DOI: 10.1056/nejmra071297] [Cited by in Crossref: 1206] [Cited by in F6Publishing: 530] [Article Influence: 86.1] [Reference Citation Analysis]
Number Citing Articles
1 Sui M, Lin Q, Xu Z, Han X, Xie R, Jia X, Guo X, Zhang W, Guan X, Ren H. Simultaneous positivity for anti-DNA, anti-nucleosome and anti-histone antibodies is a marker for more severe lupus nephritis. J Clin Immunol 2013;33:378-87. [PMID: 23100145 DOI: 10.1007/s10875-012-9825-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
2 Li BZ, Guo B, Zhang HY, Liu J, Tao SS, Pan HF, Ye DQ. Therapeutic potential of HO-1 in autoimmune diseases. Inflammation 2014;37:1779-88. [PMID: 24818708 DOI: 10.1007/s10753-014-9908-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
3 Zhao W, Wu C, Li LJ, Fan YG, Pan HF, Tao JH, Leng RX, Ye DQ. RNAi Silencing of HIF-1α Ameliorates Lupus Development in MRL/lpr Mice. Inflammation 2018;41:1717-30. [PMID: 30043119 DOI: 10.1007/s10753-018-0815-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
4 Ghiggeri GM, D'Alessandro M, Bartolomeo D, Degl'Innocenti ML, Magnasco A, Lugani F, Prunotto M, Bruschi M. An Update on Antibodies to Necleosome Components as Biomarkers of Sistemic Lupus Erythematosus and of Lupus Flares. Int J Mol Sci 2019;20:E5799. [PMID: 31752186 DOI: 10.3390/ijms20225799] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
5 Bhat R, Khan I, Mir T, Khan I, Wani M. Systemic lupus erythematosus presenting as acute adrenal insufficiency: a rare clinical presentation. Ann Med Health Sci Res 2014;4:140-2. [PMID: 24669348 DOI: 10.4103/2141-9248.126626] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
6 Ngamjanyaporn P, McCarthy EM, Sergeant JC, Reynolds J, Skeoch S, Parker B, Bruce IN. Clinicians approaches to management of background treatment in patients with SLE in clinical remission: results of an international observational survey. Lupus Sci Med 2017;4:e000173. [PMID: 29238601 DOI: 10.1136/lupus-2016-000173] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
7 Huang Q, Chen SS, Li J, Tao SS, Wang M, Leng RX, Pan HF, Ye DQ. miR-210 expression in PBMCs from patients with systemic lupus erythematosus and rheumatoid arthritis. Ir J Med Sci 2018;187:243-9. [PMID: 28560518 DOI: 10.1007/s11845-017-1634-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
8 Richard-Miceli C, Criswell LA. Emerging patterns of genetic overlap across autoimmune disorders. Genome Med. 2012;4:6. [PMID: 22284131 DOI: 10.1186/gm305] [Cited by in Crossref: 84] [Cited by in F6Publishing: 77] [Article Influence: 8.4] [Reference Citation Analysis]
9 Roldan CA, Joson J, Sharrar J, Qualls CR, Sibbitt WL Jr. Premature aortic atherosclerosis in systemic lupus erythematosus: a controlled transesophageal echocardiographic study. J Rheumatol 2010;37:71-8. [PMID: 19955049 DOI: 10.3899/jrheum.090665] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
10 Zhernakova A, van Diemen CC, Wijmenga C. Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat Rev Genet. 2009;10:43-55. [PMID: 19092835 DOI: 10.1038/nrg2489] [Cited by in Crossref: 363] [Cited by in F6Publishing: 334] [Article Influence: 27.9] [Reference Citation Analysis]
11 Fanton C, Furie R, Chindalore V, Levin R, Diab I, Dixit N, Haglund C, Gibbons J, Hanan N, Dickerson D, Zalevsky J, Kotzin BL. Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus. Journal of Translational Autoimmunity 2022. [DOI: 10.1016/j.jtauto.2022.100152] [Reference Citation Analysis]
12 Deng GM, Liu L, Kyttaris VC, Tsokos GC. Lupus serum IgG induces skin inflammation through the TNFR1 signaling pathway. J Immunol 2010;184:7154-61. [PMID: 20483718 DOI: 10.4049/jimmunol.0902514] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
13 El-garf AK, Gheith RE, Badran SN. Clinical pattern in Egyptian systemic lupus erythematosus patients with pleuropulmonary involvement. The Egyptian Rheumatologist 2017;39:83-8. [DOI: 10.1016/j.ejr.2017.02.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Katsumata Y, Kawaguchi Y, Baba S, Hattori S, Tahara K, Ito K, Iwasaki T, Yamaguchi N, Oyama M, Kozuka-Hata H, Hattori H, Nagata K, Yamanaka H, Hara M. Identification of three new autoantibodies associated with systemic lupus erythematosus using two proteomic approaches. Mol Cell Proteomics 2011;10:M110.005330. [PMID: 21474795 DOI: 10.1074/mcp.M110.005330] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
15 Allam R, Sayyed SG, Kulkarni OP, Lichtnekert J, Anders HJ. Mdm2 promotes systemic lupus erythematosus and lupus nephritis. J Am Soc Nephrol 2011;22:2016-27. [PMID: 21949095 DOI: 10.1681/ASN.2011010045] [Cited by in Crossref: 41] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
16 Aringer M, Finzel S, Voll RE. [Immunopathogenesis of systemic lupus erythematosus]. Z Rheumatol 2022. [PMID: 35551439 DOI: 10.1007/s00393-022-01214-4] [Reference Citation Analysis]
17 De la Cruz-Mosso U, Bucala R, Palafox-Sánchez CA, Parra-Rojas I, Padilla-Gutiérrez JR, Pereira-Suárez AL, Rangel-Villalobos H, Vázquez-Villamar M, Angel-Chávez LI, Muñoz-Valle JF. Macrophage migration inhibitory factor: association of -794 CATT5-8 and -173 G>C polymorphisms with TNF-α in systemic lupus erythematosus. Hum Immunol 2014;75:433-9. [PMID: 24530749 DOI: 10.1016/j.humimm.2014.02.014] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
18 Pan Q, Guo L, Wu J, Cai J, Liao H, Lan Q, Peng Y, He Y, Liu HF. Association between IgG4 Autoantibody and Complement Abnormalities in Systemic Lupus Erythematosus. Mediators Inflamm 2016;2016:2196986. [PMID: 27597802 DOI: 10.1155/2016/2196986] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
19 Yung S, Chan TM. Mechanisms of Kidney Injury in Lupus Nephritis - the Role of Anti-dsDNA Antibodies. Front Immunol 2015;6:475. [PMID: 26441980 DOI: 10.3389/fimmu.2015.00475] [Cited by in Crossref: 64] [Cited by in F6Publishing: 56] [Article Influence: 9.1] [Reference Citation Analysis]
20 van Dam LS, Osmani Z, Kamerling SWA, Kraaij T, Bakker JA, Scherer HU, Rabelink TJ, Voll RE, Alexander T, Isenberg DA, van Kooten C, Teng YKO. A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE. Rheumatology (Oxford) 2020;59:2734-45. [PMID: 31951278 DOI: 10.1093/rheumatology/kez623] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
21 Draborg AH, Duus K, Houen G. Epstein-Barr virus in systemic autoimmune diseases. Clin Dev Immunol 2013;2013:535738. [PMID: 24062777 DOI: 10.1155/2013/535738] [Cited by in Crossref: 113] [Cited by in F6Publishing: 96] [Article Influence: 12.6] [Reference Citation Analysis]
22 Crispín JC, Liossis SN, Kis-Toth K, Lieberman LA, Kyttaris VC, Juang YT, Tsokos GC. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med 2010;16:47-57. [PMID: 20138006 DOI: 10.1016/j.molmed.2009.12.005] [Cited by in Crossref: 247] [Cited by in F6Publishing: 213] [Article Influence: 20.6] [Reference Citation Analysis]
23 Losada-garcía A, Cortés-ramírez S, Cruz-burgos M, Morales-pacheco M, Cruz-hernández CD, Gonzalez-covarrubias V, Perez-plascencia C, Cerbón M, Rodríguez-dorantes M. Hormone-Related Cancer and Autoimmune Diseases: A Complex Interplay to be Discovered. Front Genet 2022;12:673180. [DOI: 10.3389/fgene.2021.673180] [Reference Citation Analysis]
24 Xiao G, Zuo X. Epigenetics in systemic lupus erythematosus. Biomed Rep 2016;4:135-9. [PMID: 26893827 DOI: 10.3892/br.2015.556] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
25 Parodis I, Zickert A, Sundelin B, Axelsson M, Gerhardsson J, Svenungsson E, Malmström V, Gunnarsson I. Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy. Lupus Sci Med 2015;2:e000061. [PMID: 25632350 DOI: 10.1136/lupus-2014-000061] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
26 Tiffin N, Adeyemo A, Okpechi I. A diverse array of genetic factors contribute to the pathogenesis of systemic lupus erythematosus. Orphanet J Rare Dis 2013;8:2. [PMID: 23289717 DOI: 10.1186/1750-1172-8-2] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 4.2] [Reference Citation Analysis]
27 Obermoser G, Pascual V. The interferon-alpha signature of systemic lupus erythematosus. Lupus 2010;19:1012-9. [PMID: 20693194 DOI: 10.1177/0961203310371161] [Cited by in Crossref: 161] [Cited by in F6Publishing: 140] [Article Influence: 13.4] [Reference Citation Analysis]
28 Bandyopadhyay S, Connolly SE, Jabado O, Ye J, Kelly S, Maldonado MA, Westhovens R, Nash P, Merrill JT, Townsend RM. Identification of biomarkers of response to abatacept in patients with SLE using deconvolution of whole blood transcriptomic data from a phase IIb clinical trial. Lupus Sci Med 2017;4:e000206. [PMID: 29214034 DOI: 10.1136/lupus-2017-000206] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
29 Choi EW, Song JW, Ha N, Choi YI, Kim S. CKD-506, a novel HDAC6-selective inhibitor, improves renal outcomes and survival in a mouse model of systemic lupus erythematosus. Sci Rep 2018;8:17297. [PMID: 30470828 DOI: 10.1038/s41598-018-35602-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
30 Wilmore JR, Gaudette BT, Gómez Atria D, Rosenthal RL, Reiser SK, Meng W, Rosenfeld AM, Luning Prak ET, Allman D. IgA Plasma Cells Are Long-Lived Residents of Gut and Bone Marrow That Express Isotype- and Tissue-Specific Gene Expression Patterns. Front Immunol 2021;12:791095. [PMID: 35003110 DOI: 10.3389/fimmu.2021.791095] [Reference Citation Analysis]
31 Le Buanec H, Gougeon ML, Mathian A, Lebon P, Dupont JM, Peltre G, Hemon P, Schmid M, Bizzini B, Künding T, Burny A, Bensussan A, Amoura Z, Gallo RC, Zagury D. IFN-α and CD46 stimulation are associated with active lupus and skew natural T regulatory cell differentiation to type 1 regulatory T (Tr1) cells. Proc Natl Acad Sci U S A 2011;108:18995-9000. [PMID: 22065791 DOI: 10.1073/pnas.1113301108] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 3.4] [Reference Citation Analysis]
32 Palanichamy A, Bauer JW, Yalavarthi S, Meednu N, Barnard J, Owen T, Cistrone C, Bird A, Rabinovich A, Nevarez S, Knight JS, Dedrick R, Rosenberg A, Wei C, Rangel-Moreno J, Liesveld J, Sanz I, Baechler E, Kaplan MJ, Anolik JH. Neutrophil-mediated IFN activation in the bone marrow alters B cell development in human and murine systemic lupus erythematosus. J Immunol 2014;192:906-18. [PMID: 24379124 DOI: 10.4049/jimmunol.1302112] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 5.4] [Reference Citation Analysis]
33 Morais SA, Vilas-Boas A, Isenberg DA. B-cell survival factors in autoimmune rheumatic disorders. Ther Adv Musculoskelet Dis 2015;7:122-51. [PMID: 26288664 DOI: 10.1177/1759720X15586782] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
34 Charles N, Hardwick D, Daugas E, Illei GG, Rivera J. Basophils and the T helper 2 environment can promote the development of lupus nephritis. Nat Med 2010;16:701-7. [PMID: 20512127 DOI: 10.1038/nm.2159] [Cited by in Crossref: 225] [Cited by in F6Publishing: 204] [Article Influence: 18.8] [Reference Citation Analysis]
35 Sakakibara S, Arimori T, Yamashita K, Jinzai H, Motooka D, Nakamura S, Li S, Takeda K, Katayama J, El Hussien MA, Narazaki M, Tanaka T, Standley DM, Takagi J, Kikutani H. Clonal evolution and antigen recognition of anti-nuclear antibodies in acute systemic lupus erythematosus. Sci Rep 2017;7:16428. [PMID: 29180749 DOI: 10.1038/s41598-017-16681-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
36 Kalergis AM, Iruretagoyena MI, Barrientos MJ, González PA, Herrada AA, Leiva ED, Gutiérrez MA, Riedel CA, Bueno SM, Jacobelli SH. Modulation of nuclear factor-kappaB activity can influence the susceptibility to systemic lupus erythematosus. Immunology 2009;128:e306-14. [PMID: 19016912 DOI: 10.1111/j.1365-2567.2008.02964.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 2.6] [Reference Citation Analysis]
37 Tam RC, Lee AL, Yang W, Lau CS, Chan VS. Systemic Lupus Erythematosus Patients Exhibit Reduced Expression of CLEC16A Isoforms in Peripheral Leukocytes. Int J Mol Sci 2015;16:14428-40. [PMID: 26121298 DOI: 10.3390/ijms160714428] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
38 Aringer M, Leuchten N, Johnson SR. New Criteria for Lupus. Curr Rheumatol Rep 2020;22:18. [PMID: 32405775 DOI: 10.1007/s11926-020-00896-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
39 Kawano M, Nagata S. Efferocytosis and autoimmune disease. Int Immunol 2018;30:551-8. [PMID: 30165442 DOI: 10.1093/intimm/dxy055] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
40 Cao W. Pivotal Functions of Plasmacytoid Dendritic Cells in Systemic Autoimmune Pathogenesis. J Clin Cell Immunol 2014;5:212. [PMID: 25077037 DOI: 10.4172/2155-9899.1000212] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
41 Qi C, Wang L, Zhang M, Shao X, Chang X, Fan Z, Cao Q, Mou S, Wang Q, Yan Y, Desir G, Ni Z. Serum Renalase Levels Correlate with Disease Activity in Lupus Nephritis. PLoS One 2015;10:e0139627. [PMID: 26431044 DOI: 10.1371/journal.pone.0139627] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
42 Furie R, Werth VP, Merola JF, Stevenson L, Reynolds TL, Naik H, Wang W, Christmann R, Gardet A, Pellerin A, Hamann S, Auluck P, Barbey C, Gulati P, Rabah D, Franchimont N. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. J Clin Invest 2019;129:1359-71. [PMID: 30645203 DOI: 10.1172/JCI124466] [Cited by in Crossref: 86] [Cited by in F6Publishing: 48] [Article Influence: 28.7] [Reference Citation Analysis]
43 Björk M, Dahlström Ö, Wetterö J, Sjöwall C. Quality of life and acquired organ damage are intimately related to activity limitations in patients with systemic lupus erythematosus. BMC Musculoskelet Disord 2015;16:188. [PMID: 26264937 DOI: 10.1186/s12891-015-0621-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
44 Tang Y, Ma X, Zhang H, Gu Z, Hou Y, Gilkeson GS, Lu L, Zeng X, Sun L. Gene expression profile reveals abnormalities of multiple signaling pathways in mesenchymal stem cell derived from patients with systemic lupus erythematosus. Clin Dev Immunol. 2012;2012:826182. [PMID: 22966240 DOI: 10.1155/2012/826182] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
45 Liu CJ, Tang SJ, Chou CC, Sun GH, Sun KH. In Vivo Suppression of Autophagy via Lentiviral shRNA Targeting Atg5 Improves Lupus-Like Syndrome. Biomed Res Int 2020;2020:8959726. [PMID: 32462028 DOI: 10.1155/2020/8959726] [Reference Citation Analysis]
46 Struemper H, Murtaugh T, Gilbert J, Barton ME, Fire J, Groark J, Fox NL, Roth D, Gordon D. Relative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector in Healthy Subjects. Clin Pharmacol Drug Dev 2016;5:208-15. [PMID: 27163500 DOI: 10.1002/cpdd.219] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
47 Li WX, Pan HF, Hu JL, Wang CZ, Zhang N, Li J, Li XP, Xu JH, Ye DQ. Assay of T- and NK-cell subsets and the expression of NKG2A and NKG2D in patients with new-onset systemic lupus erythematosus. Clin Rheumatol 2010;29:315-23. [PMID: 20012119 DOI: 10.1007/s10067-009-1322-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
48 Minocha M, Zeng J, Medema JK, Othman AA. Pharmacokinetics of the B-Cell Lymphoma 2 (Bcl-2) Inhibitor Venetoclax in Female Subjects with Systemic Lupus Erythematosus. Clin Pharmacokinet 2018;57:1185-98. [PMID: 29333561 DOI: 10.1007/s40262-017-0625-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
49 Afeltra A, Gigante A, Margiotta DP, Taffon C, Cianci R, Barbano B, Liberatori M, Amoroso A, Rossi Fanelli F. The involvement of T regulatory lymphocytes in a cohort of lupus nephritis patients: a pilot study. Intern Emerg Med 2015;10:677-83. [PMID: 25720575 DOI: 10.1007/s11739-015-1212-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
50 Robbins A, Hentzien M, Toquet S, Didier K, Servettaz A, Pham BN, Giusti D. Diagnostic Utility of Separate Anti-Ro60 and Anti-Ro52/TRIM21 Antibody Detection in Autoimmune Diseases. Front Immunol 2019;10:444. [PMID: 30915082 DOI: 10.3389/fimmu.2019.00444] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
51 Yuan J, Yu M, Cao AL, Chen X, Zhang LH, Song Y, Cheng X, Zhou ZH, Wang M, Guo HP, Du R, Liao YH. A novel epitope from CD22 regulates Th1 and Th17 cell function in systemic lupus erythematosus. PLoS One 2013;8:e64572. [PMID: 23704998 DOI: 10.1371/journal.pone.0064572] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
52 Liao X, Reihl AM, Luo XM. Breakdown of Immune Tolerance in Systemic Lupus Erythematosus by Dendritic Cells. J Immunol Res 2016;2016:6269157. [PMID: 27034965 DOI: 10.1155/2016/6269157] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
53 López P, de Paz B, Rodríguez-Carrio J, Hevia A, Sánchez B, Margolles A, Suárez A. Th17 responses and natural IgM antibodies are related to gut microbiota composition in systemic lupus erythematosus patients. Sci Rep 2016;6:24072. [PMID: 27044888 DOI: 10.1038/srep24072] [Cited by in Crossref: 102] [Cited by in F6Publishing: 93] [Article Influence: 17.0] [Reference Citation Analysis]
54 Zickert A, Palmblad K, Sundelin B, Chavan S, Tracey KJ, Bruchfeld A, Gunnarsson I. Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis. Arthritis Res Ther 2012;14:R36. [PMID: 22348591 DOI: 10.1186/ar3747] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 5.1] [Reference Citation Analysis]
55 Zagury D, Le Buanec H, Mathian A, Larcier P, Burnett R, Amoura Z, Emilie D, Peltre G, Bensussan A, Bizzini B, Gallo RC, Koutouzov S. IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. Proc Natl Acad Sci U S A 2009;106:5294-9. [PMID: 19279210 DOI: 10.1073/pnas.0900615106] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 5.3] [Reference Citation Analysis]
56 Jiang YW, Li H, Zhang YY, Li W, Jiang YF, Ou YY, Chen DF. Beneficial effect of Bupleurum polysaccharides on autoimmune-prone MRL-lpr mice. Clin Dev Immunol 2012;2012:842928. [PMID: 22701502 DOI: 10.1155/2012/842928] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
57 Liu CC, Kao AH, Hawkins DM, Manzi S, Sattar A, Wilson N, Ahearn JM. Lymphocyte-bound complement activation products as biomarkers for diagnosis of systemic lupus erythematosus. Clin Transl Sci 2009;2:300-8. [PMID: 20161444 DOI: 10.1111/j.1752-8062.2009.00135.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
58 J de AS, C A, P SG, S C. Systemic Lupus Erythematosus: Old and New Susceptibility Genes versus Clinical Manifestations. Curr Genomics 2014;15:52-65. [PMID: 24653663 DOI: 10.2174/138920291501140306113715] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
59 Li X, Zeng Q, Wang S, Li M, Chen X, Huang Y, Chen B, Zhou M, Lai Y, Guo C, Zhao S, Zhang H, Yang N. CRAC Channel Controls the Differentiation of Pathogenic B Cells in Lupus Nephritis. Front Immunol 2021;12:779560. [PMID: 34745151 DOI: 10.3389/fimmu.2021.779560] [Reference Citation Analysis]
60 Ioannou Y, Zhang JY, Qi M, Gao L, Qi JC, Yu DM, Lau H, Sturgess AD, Vlachoyiannopoulos PG, Moutsopoulos HM, Rahman A, Pericleous C, Atsumi T, Koike T, Heritier S, Giannakopoulos B, Krilis SA. Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen β2-glycoprotein I. Arthritis Rheum 2011;63:2774-82. [PMID: 21618459 DOI: 10.1002/art.30383] [Cited by in Crossref: 82] [Cited by in F6Publishing: 71] [Article Influence: 7.5] [Reference Citation Analysis]
61 Cai Y, Zhang W, Xiong S. Mannose-binding lectin blunts macrophage polarization and ameliorates lupus nephritis. PLoS One 2013;8:e62465. [PMID: 23626823 DOI: 10.1371/journal.pone.0062465] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
62 Chan VS, Tsang HH, Tam RC, Lu L, Lau CS. B-cell-targeted therapies in systemic lupus erythematosus. Cell Mol Immunol 2013;10:133-42. [PMID: 23455017 DOI: 10.1038/cmi.2012.64] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 5.1] [Reference Citation Analysis]
63 Sarrand J, Soyfoo M. Involvement of IL-33 in the Pathophysiology of Systemic Lupus Erythematosus: Review. Int J Mol Sci 2022;23:3138. [PMID: 35328556 DOI: 10.3390/ijms23063138] [Reference Citation Analysis]
64 Sari S, Cinar S, Yalcinkaya Y, Artim-esen B, Ozluk Y, Gul A, Ocal L, Deniz G, Inanc M. The relationship between serum A proliferation-inducing ligand and B-cell activating factor levels with disease activity and organ involvement in systemic lupus erythematosus. Lupus. [DOI: 10.1177/09612033221086123] [Reference Citation Analysis]
65 Lewis JS, Allen RP. An introduction to biomaterial-based strategies for curbing autoimmunity. Exp Biol Med (Maywood) 2016;241:1107-15. [PMID: 27229905 DOI: 10.1177/1535370216650294] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
66 D'Amico F, Skarmoutsou E, Lo LJ, Granata M, Trovato C, Rossi GA, Bellocchi C, Marchini M, Scorza R, Mazzarino MC, Keinan A. Association between rs2294020 in X-linked CCDC22 and susceptibility to autoimmune diseases with focus on systemic lupus erythematosus. Immunol Lett 2017;181:58-62. [PMID: 27888057 DOI: 10.1016/j.imlet.2016.11.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
67 Quinones-Valdez G, Tran SS, Jun HI, Bahn JH, Yang EW, Zhan L, Brümmer A, Wei X, Van Nostrand EL, Pratt GA, Yeo GW, Graveley BR, Xiao X. Regulation of RNA editing by RNA-binding proteins in human cells. Commun Biol 2019;2:19. [PMID: 30652130 DOI: 10.1038/s42003-018-0271-8] [Cited by in Crossref: 52] [Cited by in F6Publishing: 41] [Article Influence: 17.3] [Reference Citation Analysis]
68 Williams EM, Lorig K, Glover S, Kamen D, Back S, Merchant A, Zhang J, Oates JC. Intervention to Improve Quality of life for African-AmericaN lupus patients (IQAN): study protocol for a randomized controlled trial of a unique a la carte intervention approach to self-management of lupus in African Americans. BMC Health Serv Res 2016;16:339. [PMID: 27485509 DOI: 10.1186/s12913-016-1580-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
69 Michelotti B, Rizzo M, Moran SL. Connective tissue disorders associated with vasculitis and vaso-occlusive disease of the hand. Hand Clin 2015;31:63-73. [PMID: 25455357 DOI: 10.1016/j.hcl.2014.09.006] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
70 Girasoli L, Cazzador D, Padoan R, Nardello E, Felicetti M, Zanoletti E, Schiavon F, Bovo R. Update on Vertigo in Autoimmune Disorders, from Diagnosis to Treatment. J Immunol Res 2018;2018:5072582. [PMID: 30356417 DOI: 10.1155/2018/5072582] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
71 Levite M. Dopamine and T cells: dopamine receptors and potent effects on T cells, dopamine production in T cells, and abnormalities in the dopaminergic system in T cells in autoimmune, neurological and psychiatric diseases. Acta Physiol (Oxf) 2016;216:42-89. [PMID: 25728499 DOI: 10.1111/apha.12476] [Cited by in Crossref: 118] [Cited by in F6Publishing: 100] [Article Influence: 19.7] [Reference Citation Analysis]
72 Nielsen CT, Lood C, Ostergaard O, Iversen LV, Voss A, Bengtsson A, Jacobsen S, Heegaard NH. Plasma levels of galectin-3-binding protein reflect type I interferon activity and are increased in patients with systemic lupus erythematosus. Lupus Sci Med 2014;1:e000026. [PMID: 25452879 DOI: 10.1136/lupus-2014-000026] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
73 Anders HJ, Weening JJ. Kidney disease in lupus is not always 'lupus nephritis'. Arthritis Res Ther 2013;15:108. [PMID: 23448342 DOI: 10.1186/ar4166] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
74 Neehus AL, Moriya K, Nieto-Patlán A, Le Voyer T, Lévy R, Özen A, Karakoc-Aydiner E, Baris S, Yildiran A, Altundag E, Roynard M, Haake K, Migaud M, Dorgham K, Gorochov G, Abel L, Lachmann N, Dogu F, Haskologlu S, İnce E, El-Benna J, Uzel G, Kiykim A, Boztug K, Roderick MR, Shahrooei M, Brogan PA, Abolhassani H, Hancioglu G, Parvaneh N, Belot A, Ikinciogullari A, Casanova JL, Puel A, Bustamante J. Impaired respiratory burst contributes to infections in PKCδ-deficient patients. J Exp Med 2021;218:e20210501. [PMID: 34264265 DOI: 10.1084/jem.20210501] [Reference Citation Analysis]
75 Feng D, Yang L, Bi X, Stone RC, Patel P, Barnes BJ. Irf5-deficient mice are protected from pristane-induced lupus via increased Th2 cytokines and altered IgG class switching. Eur J Immunol 2012;42:1477-87. [PMID: 22678902 DOI: 10.1002/eji.201141642] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 4.7] [Reference Citation Analysis]
76 Yue C, Gao S, Li S, Xing Z, Qian H, Hu Y, Wang W, Hua C. TIGIT as a Promising Therapeutic Target in Autoimmune Diseases. Front Immunol 2022;13:911919. [DOI: 10.3389/fimmu.2022.911919] [Reference Citation Analysis]
77 Liu Y, Alookaran JJ, Rhoads JM. Probiotics in Autoimmune and Inflammatory Disorders. Nutrients 2018;10:E1537. [PMID: 30340338 DOI: 10.3390/nu10101537] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 11.0] [Reference Citation Analysis]
78 Hayakawa K, Fujishiro M, Yoshida Y, Kataoka Y, Sakuma S, Nishi T, Ikeda K, Morimoto S, Takamori K, Sekigawa I. Exposure of female NZBWF1 mice to imiquimod-induced lupus nephritis at an early age via a unique mechanism that differed from spontaneous onset. Clin Exp Immunol 2022:uxac012. [PMID: 35260898 DOI: 10.1093/cei/uxac012] [Reference Citation Analysis]
79 Leiss H, Salzberger W, Jacobs B, Gessl I, Kozakowski N, Blüml S, Puchner A, Kiss A, Podesser BK, Smolen JS, Stummvoll GH. MicroRNA 155-deficiency leads to decreased autoantibody levels and reduced severity of nephritis and pneumonitis in pristane-induced lupus. PLoS One 2017;12:e0181015. [PMID: 28719617 DOI: 10.1371/journal.pone.0181015] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
80 Keravis T, Monneaux F, Yougbaré I, Gazi L, Bourguignon JJ, Muller S, Lugnier C. Disease progression in MRL/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor. PLoS One 2012;7:e28899. [PMID: 22247763 DOI: 10.1371/journal.pone.0028899] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
81 Nossent JC, Becker-Merok A, Rischmueller M, Lester S. Susceptibility for Lupus Nephritis by Low Copy Number of the FCGR3B Gene Is Linked to Increased Levels of Pathogenic Autoantibodies. Autoimmune Dis 2013;2013:750814. [PMID: 23864940 DOI: 10.1155/2013/750814] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
82 Zhang Z, Shi L, Dawany N, Kelsen J, Petri MA, Sullivan KE. H3K4 tri-methylation breadth at transcription start sites impacts the transcriptome of systemic lupus erythematosus. Clin Epigenetics 2016;8:14. [PMID: 26839600 DOI: 10.1186/s13148-016-0179-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
83 He F, Luo Q, Lei M, Fan L, Shao X, Hu K, Qin S, Yu N, Cao J, Yang L. Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review. Clin Rheumatol 2020;39:2803-10. [PMID: 32725351 DOI: 10.1007/s10067-020-05230-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
84 Vega BA, Belinka BA Jr, Kachlany SC. Aggregatibacter actinomycetemcomitans Leukotoxin (LtxA; Leukothera®): Mechanisms of Action and Therapeutic Applications. Toxins (Basel) 2019;11:E489. [PMID: 31454891 DOI: 10.3390/toxins11090489] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
85 Roldan PC, Ratliff M, Snider R, Macias L, Rodriguez R, Sibbitt W, Roldan CA. Aortic Atherosclerosis in Systemic Lupus Erythematosus. Rheumatology (Sunnyvale) 2014;Suppl 5:S5-006. [PMID: 25593786 DOI: 10.4172/2161-1149.S5-006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
86 Karademas EC, Ktistaki G, Dimitraki G, Papastefanakis E, Mastorodemos V, Repa A, Gergianaki I, Bertsias G, Sidiropoulos P, Simos P. Patient and partner dispositional optimism as a long-term predictor of illness representations in autoimmune diseases. J Health Psychol 2017;22:1691-700. [PMID: 26962131 DOI: 10.1177/1359105316633287] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
87 Tokarska K, Majsterek I, Cuchra M, Woźniacka A. Immunometabolic disorders in the pathogenesis of systemic lupus erythematosus. Postepy Dermatol Alergol 2019;36:513-8. [PMID: 31839766 DOI: 10.5114/ada.2019.85251] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
88 Smyth P, Sasiwachirangkul J, Williams R, Scott CJ. Cathepsin S (CTSS) activity in health and disease - A treasure trove of untapped clinical potential. Mol Aspects Med 2022;88:101106. [PMID: 35868042 DOI: 10.1016/j.mam.2022.101106] [Reference Citation Analysis]
89 Davidov D, Sheiner E, Wainstock T, Miodownik S, Pariente G. Maternal Systemic Lupus Erythematosus (SLE) High Risk for Preterm Delivery and Not for Long-Term Neurological Morbidity of the Offspring. J Clin Med 2021;10:2952. [PMID: 34209187 DOI: 10.3390/jcm10132952] [Reference Citation Analysis]
90 Kim AHJ, Strand V, Atkinson JP. Reply. Arthritis Rheumatol 2019;71:1590-2. [PMID: 31074940 DOI: 10.1002/art.40923] [Reference Citation Analysis]
91 Hu Q, Yang C, Wang Q, Zeng H, Qin W. Demethylzeylasteral (T-96) Treatment Ameliorates Mice Lupus Nephritis Accompanied by Inhibiting Activation of NF-κB Pathway. PLoS One 2015;10:e0133724. [PMID: 26208003 DOI: 10.1371/journal.pone.0133724] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
92 Hamam HJ, Palaniyar N. Post-Translational Modifications in NETosis and NETs-Mediated Diseases. Biomolecules 2019;9:E369. [PMID: 31416265 DOI: 10.3390/biom9080369] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
93 Hsiao YP, Tsai JD, Muo CH, Tsai CH, Sung FC, Liao YT, Chang YJ, Yang JH. Atopic diseases and systemic lupus erythematosus: an epidemiological study of the risks and correlations. Int J Environ Res Public Health 2014;11:8112-22. [PMID: 25111878 DOI: 10.3390/ijerph110808112] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
94 Ulivieri C, Baldari CT. Regulation of T Cell Activation and Differentiation by Extracellular Vesicles and Their Pathogenic Role in Systemic Lupus Erythematosus and Multiple Sclerosis. Molecules 2017;22:E225. [PMID: 28157168 DOI: 10.3390/molecules22020225] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
95 Aganovic-Musinovic I, Karamehic J, Zecevic L, Gavrankapetanovic F, Avdagic N, Zaciragic A, Jukic T, Grcic N, Svrakic S. Evaluation of ENA-6 Profile by ELISA Immunoassay in Patients with Systemic Lupus Erythematodes. Autoimmune Dis 2012;2012:321614. [PMID: 23097694 DOI: 10.1155/2012/321614] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
96 Wang J, Wu H, Liu X, Jia H, Lu H. Effect of LPS on Cytokine Secretion from Peripheral Blood Monocytes in Juvenile Idiopathic Arthritis-Associated Uveitis Patients with Positive Antinuclear Antibody. J Immunol Res 2021;2021:6691681. [PMID: 34056011 DOI: 10.1155/2021/6691681] [Reference Citation Analysis]
97 Rönnblom L, Elkon KB. Cytokines as therapeutic targets in SLE. Nat Rev Rheumatol 2010;6:339-47. [PMID: 20440285 DOI: 10.1038/nrrheum.2010.64] [Cited by in Crossref: 88] [Cited by in F6Publishing: 89] [Article Influence: 7.3] [Reference Citation Analysis]
98 Leite CA, Galera MF, Espinosa MM, de Lima PR, Fernandes V, Borges ÁH, Dias EP. Prevalence of hyposalivation in patients with systemic lupus erythematosus in a brazilian subpopulation. Int J Rheumatol 2015;2015:730285. [PMID: 25649631 DOI: 10.1155/2015/730285] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
99 Zickert A, Sundelin B, Svenungsson E, Gunnarsson I. Role of early repeated renal biopsies in lupus nephritis. Lupus Sci Med 2014;1:e000018. [PMID: 25379188 DOI: 10.1136/lupus-2014-000018] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 7.0] [Reference Citation Analysis]
100 Umiker BR, McDonald G, Larbi A, Medina CO, Hobeika E, Reth M, Imanishi-Kari T. Production of IgG autoantibody requires expression of activation-induced deaminase in early-developing B cells in a mouse model of SLE. Eur J Immunol 2014;44:3093-108. [PMID: 25044405 DOI: 10.1002/eji.201344282] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
101 Ling GS, Cook HT, Botto M, Lau YL, Huang FP. An essential protective role of IL-10 in the immunological mechanism underlying resistance vs. susceptibility to lupus induction by dendritic cells and dying cells. Rheumatology (Oxford) 2011;50:1773-84. [PMID: 21727182 DOI: 10.1093/rheumatology/ker198] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
102 Jucaud V, Ravindranath MH, Terasaki PI, Morales-Buenrostro LE, Hiepe F, Rose T, Biesen R. Serum antibodies to human leucocyte antigen (HLA)-E, HLA-F and HLA-G in patients with systemic lupus erythematosus (SLE) during disease flares: Clinical relevance of HLA-F autoantibodies. Clin Exp Immunol 2016;183:326-40. [PMID: 26440212 DOI: 10.1111/cei.12724] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
103 Duhlin A, Chen Y, Wermeling F, Sedimbi SK, Lindh E, Shinde R, Halaby MJ, Kaiser Y, Winqvist O, McGaha TL, Karlsson MC. Selective Memory to Apoptotic Cell-Derived Self-Antigens with Implications for Systemic Lupus Erythematosus Development. J Immunol 2016;197:2618-26. [PMID: 27559051 DOI: 10.4049/jimmunol.1401129] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
104 Demirci FY, Dressen AS, Kammerer CM, Barmada MM, Kao AH, Ramsey-Goldman R, Manzi S, Kamboh MI. Functional polymorphisms of the coagulation factor II gene (F2) and susceptibility to systemic lupus erythematosus. J Rheumatol 2011;38:652-7. [PMID: 21239755 DOI: 10.3899/jrheum.100728] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
105 Enevold C, Nielsen CH, Jacobsen RS, Hermansen ML, Molbo D, Avlund K, Bendtzen K, Jacobsen S. Single nucleotide polymorphisms in genes encoding toll-like receptors 7, 8 and 9 in Danish patients with systemic lupus erythematosus. Mol Biol Rep 2014;41:5755-63. [PMID: 24919757 DOI: 10.1007/s11033-014-3447-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
106 Alshaiki F, Obaid E, Almuallim A, Taha R, El-Haddad H, Almoallim H. Outcomes of rituximab therapy in refractory lupus: A meta-analysis. Eur J Rheumatol 2018;5:118-26. [PMID: 30185361 DOI: 10.5152/eurjrheum.2018.17096] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
107 Sun Y, Li C, Zhu M, Zhang S, Cao Y, Yang Q, Zhao P, Huang G, Xu A. Enhanced migration and adhesion of peripheral blood neutrophils from SAPHO patients revealed by RNA-Seq. Orphanet J Rare Dis 2019;14:192. [PMID: 31395074 DOI: 10.1186/s13023-019-1169-3] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
108 Li Y, Zhao LD, Tong LS, Qian SN, Ren Y, Zhang L, Ding X, Chen Y, Wang YX, Zhang W, Zeng XF, Zhang FC, Tang FL, Zhang X, Ba DN, He W, Cao XT, Lipsky PE. Aberrant CD200/CD200R1 expression and function in systemic lupus erythematosus contributes to abnormal T-cell responsiveness and dendritic cell activity. Arthritis Res Ther 2012;14:R123. [PMID: 22621248 DOI: 10.1186/ar3853] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
109 Arai M, Mii A, Kashiwagi T, Shimizu A, Sakai Y. The severity of glomerular endothelial cell injury is associated with infiltrating macrophage heterogeneity in endocapillary proliferative glomerulonephritis. Sci Rep 2021;11:13339. [PMID: 34172770 DOI: 10.1038/s41598-021-92655-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
110 Tanaka Y, Mizukami A, Kobayashi A, Ito C, Matsuki T. Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: A retrospective, observational study. Int J Rheum Dis 2018;21:1609-18. [PMID: 30146745 DOI: 10.1111/1756-185X.13363] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
111 Ching KH, Burbelo PD, Tipton C, Wei C, Petri M, Sanz I, Iadarola MJ. Two major autoantibody clusters in systemic lupus erythematosus. PLoS One 2012;7:e32001. [PMID: 22363785 DOI: 10.1371/journal.pone.0032001] [Cited by in Crossref: 73] [Cited by in F6Publishing: 63] [Article Influence: 7.3] [Reference Citation Analysis]
112 Relle M, Schwarting A. Role of MHC-linked susceptibility genes in the pathogenesis of human and murine lupus. Clin Dev Immunol 2012;2012:584374. [PMID: 22761632 DOI: 10.1155/2012/584374] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
113 Sarra M, Monteleone G. Interleukin-21: a new mediator of inflammation in systemic lupus erythematosus. J Biomed Biotechnol 2010;2010:294582. [PMID: 20652041 DOI: 10.1155/2010/294582] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
114 Zhao LD, Liang D, Wu XN, Li Y, Niu JW, Zhou C, Wang L, Chen H, Zheng WJ, Fei YY, Tang FL, Li YZ, Zhang FC, He W, Cao XT, Zhang X. Contribution and underlying mechanisms of CXCR4 overexpression in patients with systemic lupus erythematosus. Cell Mol Immunol 2017;14:842-9. [PMID: 27665947 DOI: 10.1038/cmi.2016.47] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
115 Marcuzzi A, Piscianz E, Valencic E, Monasta L, Vecchi Brumatti L, Tommasini A. To Extinguish the Fire from Outside the Cell or to Shutdown the Gas Valve Inside? Novel Trends in Anti-Inflammatory Therapies. Int J Mol Sci 2015;16:21277-93. [PMID: 26370962 DOI: 10.3390/ijms160921277] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
116 Wen Z, Xu L, Xu W, Yin Z, Gao X, Xiong S. Interleukin-17 expression positively correlates with disease severity of lupus nephritis by increasing anti-double-stranded DNA antibody production in a lupus model induced by activated lymphocyte derived DNA. PLoS One 2013;8:e58161. [PMID: 23472149 DOI: 10.1371/journal.pone.0058161] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
117 Juang YT, Rauen T, Wang Y, Ichinose K, Benedyk K, Tenbrock K, Tsokos GC. Transcriptional activation of the cAMP-responsive modulator promoter in human T cells is regulated by protein phosphatase 2A-mediated dephosphorylation of SP-1 and reflects disease activity in patients with systemic lupus erythematosus. J Biol Chem 2011;286:1795-801. [PMID: 21097497 DOI: 10.1074/jbc.M110.166785] [Cited by in Crossref: 42] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
118 Wirestam L, Schierbeck H, Skogh T, Gunnarsson I, Ottosson L, Erlandsson-Harris H, Wetterö J, Sjöwall C. Antibodies against High Mobility Group Box protein-1 (HMGB1) versus other anti-nuclear antibody fine-specificities and disease activity in systemic lupus erythematosus. Arthritis Res Ther 2015;17:338. [PMID: 26596890 DOI: 10.1186/s13075-015-0856-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
119 Boedigheimer MJ, Martin DA, Amoura Z, Sánchez-Guerrero J, Romero-Diaz J, Kivitz A, Aranow C, Chan TM, Chong YB, Chiu K, Wang C, Sohn W, Arnold GE, Damore MA, Welcher AA, Sullivan BA, Kotzin BL, Chung JB. Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-γ monoclonal antibody, in SLE subjects without or with lupus nephritis. Lupus Sci Med 2017;4:e000226. [PMID: 29018537 DOI: 10.1136/lupus-2017-000226] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
120 Zhou A, Liu X, Xia T, Li F, Wang J, Li J. Estrogen receptor alpha gene (ESR1) polymorphism and its interaction with smoking and drinking contribute to susceptibility of systemic lupus erythematosus. Immunol Res 2017;65:951-6. [PMID: 28707126 DOI: 10.1007/s12026-017-8935-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
121 Mohan C, Putterman C. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nat Rev Nephrol 2015;11:329-41. [PMID: 25825084 DOI: 10.1038/nrneph.2015.33] [Cited by in Crossref: 181] [Cited by in F6Publishing: 165] [Article Influence: 25.9] [Reference Citation Analysis]
122 Fernandes NF, Castelo-Soccio L, Kim EJ, Werth VP. Sweet syndrome associated with new-onset systemic lupus erythematosus in a 25-year-old man. Arch Dermatol 2009;145:608-9. [PMID: 19451520 DOI: 10.1001/archdermatol.2009.82] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
123 Al-Rayes H, Huraib G, Julkhuf S, Arfin M, Tariq M, Al-Asmari A. Apolipoprotein E Gene Polymorphisms in Saudi Patients with Systemic Lupus Erythematosus. Clin Med Insights Arthritis Musculoskelet Disord 2016;9:81-7. [PMID: 27257397 DOI: 10.4137/CMAMD.S38090] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
124 Qiao W, Ding H, Zuo Y, Jiang L, Zhou J, Han X, Yu L, Du R, M Hedrich C, Deng GM. Lupus IgG deposition causes arthritis but inhibits bone destruction through competitive occupation of FcγRI and reduced RANKL signalling. Clin Transl Immunology 2020;9:e1174. [PMID: 32994999 DOI: 10.1002/cti2.1174] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
125 Ponticelli C, Meroni PL. Kallikreins and lupus nephritis. J Clin Invest 2009;119:768-71. [PMID: 19348047 DOI: 10.1172/jci38786] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
126 El-Reshaid K, Al-Bader S, Sallam HT. A Self-Limited Facial Rash in a Lupus Patient: The Case of Primary Facial Raynaud's Phenomenon. Case Rep Dermatol 2021;13:366-71. [PMID: 34413734 DOI: 10.1159/000517553] [Reference Citation Analysis]
127 Dema B, Pellefigues C, Hasni S, Gault N, Jiang C, Ricks TK, Bonelli MM, Scheffel J, Sacré K, Jablonski M, Gobert D, Papo T, Daugas E, Illei G, Charles N, Rivera J. Autoreactive IgE is prevalent in systemic lupus erythematosus and is associated with increased disease activity and nephritis. PLoS One 2014;9:e90424. [PMID: 24587356 DOI: 10.1371/journal.pone.0090424] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 9.0] [Reference Citation Analysis]
128 Aringer M, Alarcón-riquelme ME, Clowse M, Pons-estel GJ, Vital EM, Dall’era M. A glimpse into the future of systemic lupus erythematosus. Therapeutic Advances in Musculoskeletal 2022;14:1759720X2210867. [DOI: 10.1177/1759720x221086719] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
129 El-desoky MM, Shemies RS, El-bahnasawy AS, Mostafa N, Elhelaly M. Dysregulation in growth arrest-specific 5 and metastasis-associated lung adenocarcinoma transcript 1 gene expression predicts diagnosis and renal fibrosis in systemic lupus erythematosus patients. Egypt J Med Hum Genet 2021;22. [DOI: 10.1186/s43042-020-00112-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
130 Yazici MU, Orhan D, Kale G, Besbas N, Ozen S. Studying IFN-gamma, IL-17 and FOXP3 in pediatric lupus nephritis. Pediatr Nephrol 2014;29:853-62. [PMID: 24482023 DOI: 10.1007/s00467-013-2695-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
131 Sun X, Wiedeman A, Agrawal N, Teal TH, Tanaka L, Hudkins KL, Alpers CE, Bolland S, Buechler MB, Hamerman JA, Ledbetter JA, Liggitt D, Elkon KB. Increased ribonuclease expression reduces inflammation and prolongs survival in TLR7 transgenic mice. J Immunol 2013;190:2536-43. [PMID: 23382559 DOI: 10.4049/jimmunol.1202689] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
132 Inokuchi J, Nagafuku M. Gangliosides in T cell development and function of mice. Glycoconj J. [DOI: 10.1007/s10719-021-10037-5] [Reference Citation Analysis]
133 Sthoeger ZM, Bezalel S, Chapnik N, Asher I, Froy O. High alpha-defensin levels in patients with systemic lupus erythematosus. Immunology 2009;127:116-22. [PMID: 19191901 DOI: 10.1111/j.1365-2567.2008.02997.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 3.6] [Reference Citation Analysis]
134 Ho YY, Baechler EC, Ortmann W, Behrens TW, Graham RR, Bhangale TR, Pan W. Using gene expression to improve the power of genome-wide association analysis. Hum Hered 2014;78:94-103. [PMID: 25096029 DOI: 10.1159/000362837] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
135 Manfredini M, Pedroni G, Bigi L, Apponi R, Murri Dello Diago A, Dattola A, Farnetani F, Pellacani G. Acquired White Oral Lesions with Specific Patterns: Oral Lichen Planus and Lupus Erythematosus. Dermatol Pract Concept 2021;11:e2021074. [PMID: 34123565 DOI: 10.5826/dpc.1103a74] [Reference Citation Analysis]
136 Sugahara K, Maeda Y, Shimano K, Murase M, Mochiduki S, Takemoto K, Kakimoto T, Utsumi H, Oshita K, Kataoka H. Amiselimod (MT-1303), a Novel Sphingosine 1-Phosphate Receptor-1 Modulator, Potently Inhibits the Progression of Lupus Nephritis in Two Murine SLE Models. J Immunol Res 2019;2019:5821589. [PMID: 31930150 DOI: 10.1155/2019/5821589] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
137 Solati K, Mousavi M, Kheiri S, Hasanpour-Dehkordi A. The Effectiveness of Mindfulness-based Cognitive Therapy on Psychological Symptoms and Quality of Life in Systemic Lupus Erythematosus Patients: 
A Randomized Controlled Trial. Oman Med J 2017;32:378-85. [PMID: 29026469 DOI: 10.5001/omj.2017.73] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
138 Gianchecchi E, Crinò A, Giorda E, Luciano R, Perri V, Russo AL, Cappa M, Rosado MM, Fierabracci A. Altered B cell homeostasis and toll-like receptor 9-driven response in type 1 diabetes carriers of the C1858T PTPN22 allelic variant: implications in the disease pathogenesis. PLoS One 2014;9:e110755. [PMID: 25333705 DOI: 10.1371/journal.pone.0110755] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
139 Dammacco R. Systemic lupus erythematosus and ocular involvement: an overview. Clin Exp Med 2018;18:135-49. [PMID: 29243035 DOI: 10.1007/s10238-017-0479-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
140 Litvinov RI, Nabiullina RM, Zubairova LD, Shakurova MA, Andrianova IA, Weisel JW. Lytic Susceptibility, Structure, and Mechanical Properties of Fibrin in Systemic Lupus Erythematosus. Front Immunol. 2019;10:1626. [PMID: 31379831 DOI: 10.3389/fimmu.2019.01626] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
141 Meloni C, Schreiber C, Studt J, Kamm S, Di Chiara M, Herren T. Liver infarctions as the first manifestation of antiphospholipid antibody syndrome in pregnancy: a case report. J Med Case Reports 2022;16. [DOI: 10.1186/s13256-022-03324-8] [Reference Citation Analysis]
142 Losa F, Firinu D, Deidda M, Costanzo G, Del Giacco SR. Clinical pitfalls of leishmaniasis and Whipple's disease hidden behind systemic lupus erythematosus: A case series. Acta Microbiol Immunol Hung 2019;66:377-85. [PMID: 31096758 DOI: 10.1556/030.66.2019.013] [Reference Citation Analysis]
143 Zhang L, Bertucci AM, Ramsey-Goldman R, Burt RK, Datta SK. Regulatory T cell (Treg) subsets return in patients with refractory lupus following stem cell transplantation, and TGF-beta-producing CD8+ Treg cells are associated with immunological remission of lupus. J Immunol 2009;183:6346-58. [PMID: 19841178 DOI: 10.4049/jimmunol.0901773] [Cited by in Crossref: 116] [Cited by in F6Publishing: 101] [Article Influence: 8.9] [Reference Citation Analysis]
144 Papageorgiou L, Alkenaris H, Zervou MI, Vlachakis D, Matalliotakis I, Spandidos DA, Bertsias G, Goulielmos GN, Eliopoulos E. Epione application: An integrated web‑toolkit of clinical genomics and personalized medicine in systemic lupus erythematosus. Int J Mol Med 2022;49:8. [PMID: 34791504 DOI: 10.3892/ijmm.2021.5063] [Reference Citation Analysis]
145 Cheon SY, Lee JE. Extracellular Vesicles and Immune System in Ageing and Immune Diseases. Exp Neurobiol 2021;30:32-47. [PMID: 33632983 DOI: 10.5607/en20059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
146 Cipolla GA, de Oliveira JC, Salviano-Silva A, Lobo-Alves SC, Lemos DS, Oliveira LC, Jucoski TS, Mathias C, Pedroso GA, Zambalde EP, Gradia DF. Long Non-Coding RNAs in Multifactorial Diseases: Another Layer of Complexity. Noncoding RNA 2018;4:E13. [PMID: 29751665 DOI: 10.3390/ncrna4020013] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 7.3] [Reference Citation Analysis]
147 Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol 2019;71:1400-12. [PMID: 31385462 DOI: 10.1002/art.40930] [Cited by in Crossref: 280] [Cited by in F6Publishing: 214] [Article Influence: 93.3] [Reference Citation Analysis]
148 Mauri C, Menon M. The many faces of type I interferon in systemic lupus erythematosus. J Clin Invest 2015;125:2562-4. [PMID: 26098208 DOI: 10.1172/JCI82574] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
149 Friebus-Kardash J, Trendelenburg M, Eisenberger U, Ribi C, Chizzolini C, Huynh-Do U, Lang KS, Wilde B, Kribben A, Witzke O, Dolff S, Hardt C. Susceptibility of BAFF-var allele carriers to severe SLE with occurrence of lupus nephritis. BMC Nephrol 2019;20:430. [PMID: 31752784 DOI: 10.1186/s12882-019-1623-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
150 Plawecki M, Lheritier E, Clavarino G, Jourde-Chiche N, Ouili S, Paul S, Gout E, Sarrot-Reynauld F, Bardin N, Boëlle PY, Chiche L, Bouillet L, Thielens NM, Cesbron JY, Dumestre-Pérard C. Association between the Presence of Autoantibodies Targeting Ficolin-3 and Active Nephritis in Patients with Systemic Lupus Erythematosus. PLoS One 2016;11:e0160879. [PMID: 27631981 DOI: 10.1371/journal.pone.0160879] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
151 Costedoat-Chalumeau N, Houssiau F, Izmirly P, Le Guern V, Navarra S, Jolly M, Ruiz-Irastorza G, Baron G, Hachulla E, Agmon-Levin N, Shoenfeld Y, Dall'Ara F, Buyon J, Deligny C, Cervera R, Lazaro E, Bezanahary H, Leroux G, Morel N, Viallard JF, Pineau C, Galicier L, Van Vollenhoven R, Tincani A, Nguyen H, Gondran G, Zahr N, Pouchot J, Piette JC, Petri M, Isenberg D. A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. Clin Pharmacol Ther 2018;103:1074-82. [PMID: 28925027 DOI: 10.1002/cpt.885] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
152 Li W, Liu S, Zhong L, Chen C. Clinical and laboratory features, disease activity, and outcomes of juvenile systemic lupus erythematosus at diagnosis: a single-center study from southern China. Clin Rheumatol 2021. [PMID: 34142297 DOI: 10.1007/s10067-021-05784-7] [Reference Citation Analysis]
153 Mahmud SA, Binstadt BA. Autoantibodies in the Pathogenesis, Diagnosis, and Prognosis of Juvenile Idiopathic Arthritis. Front Immunol 2018;9:3168. [PMID: 30693002 DOI: 10.3389/fimmu.2018.03168] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
154 Tapia-Llanos R, Muñoz-Valle JF, Román-Fernández IV, Marín-Rosales M, Salazar-Camarena DC, Cruz A, Orozco-Barocio G, Guareña-Casillas JA, Oregon-Romero E, Palafox-Sánchez CA. Association of soluble CD40 levels with -1 C > T CD40 polymorphism and chronic kidney disease in systemic lupus erythematosus. Mol Genet Genomic Med 2019;7:e1014. [PMID: 31642196 DOI: 10.1002/mgg3.1014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
155 Wang X, Blanco LP, Carmona-Rivera C, Nakabo S, Pedersen HL, Yu ZX, Kaplan MJ. Effects of Gasdermin D in Modulating Murine Lupus and its Associated Organ Damage. Arthritis Rheumatol 2020;72:2118-29. [PMID: 32692482 DOI: 10.1002/art.41444] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
156 Colombo BM, Canevali P, Magnani O, Rossi E, Puppo F, Zocchi MR, Poggi A. Defective expression and function of the leukocyte associated Ig-like receptor 1 in B lymphocytes from systemic lupus erythematosus patients. PLoS One 2012;7:e31903. [PMID: 22355402 DOI: 10.1371/journal.pone.0031903] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
157 Al-Homood IA, Omran NE, Alwahibi AS, Aldosoghy M, Alharthy A, Aljohani GS. Depression in Patients with Systemic Lupus Erythematosus: A Multicenter Study. Saudi J Med Med Sci 2017;5:248-53. [PMID: 30787797 DOI: 10.4103/sjmms.sjmms_79_16] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
158 Tun-Kyi A, Finn G, Greenwood A, Nowak M, Lee TH, Asara JM, Tsokos GC, Fitzgerald K, Israel E, Li X, Exley M, Nicholson LK, Lu KP. Essential role for the prolyl isomerase Pin1 in Toll-like receptor signaling and type I interferon-mediated immunity. Nat Immunol 2011;12:733-41. [PMID: 21743479 DOI: 10.1038/ni.2069] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 5.0] [Reference Citation Analysis]
159 Thomson B, Joseph G, Clark WF, Hladunewich M, Patel A, Blake P, Eastabrook G, Matsui D, Sharma A, House A. Maternal, pregnancy and fetal outcomes in de novo anti-glomerular basement membrane antibody disease in pregnancy: a systematic review. Clin Kidney J 2014;7:450-6. [PMID: 25878776 DOI: 10.1093/ckj/sfu086] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
160 Huang H, Mu L, Zhang Z, Gao D, Hao Y, Zhou W. Treatments and outcomes in Chinese patients with serologically active clinically quiescent systemic lupus erythematosus: a retrospective observational study. Arthritis Res Ther 2021;23:275. [PMID: 34715915 DOI: 10.1186/s13075-021-02641-5] [Reference Citation Analysis]
161 Yu Y, Gui H, Xiong K, Fang X, He J. Progression of systemic lupus erythematosus associated with propofol administration: a case report. Eur J Hosp Pharm 2018;25:225-7. [PMID: 31157026 DOI: 10.1136/ejhpharm-2017-001255] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
162 Wu Y, Zhang F, Ma J, Zhang X, Wu L, Qu B, Xia S, Chen S, Tang Y, Shen N. Association of large intergenic noncoding RNA expression with disease activity and organ damage in systemic lupus erythematosus. Arthritis Res Ther 2015;17:131. [PMID: 25994030 DOI: 10.1186/s13075-015-0632-3] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 8.6] [Reference Citation Analysis]
163 Greene ER, Lanphere KR, Sharrar J, Roldan CA. Arterial distensibility in systemic lupus erythematosus. Annu Int Conf IEEE Eng Med Biol Soc 2009;2009:1109-12. [PMID: 19964750 DOI: 10.1109/IEMBS.2009.5334459] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
164 Boedecker SC, Philippi KFA, Neuberger E, Schmidt S, Pfirrmann D, Haller N, Schwarting A, Simon P, Weinmann-Menke J. Twelve-Week Internet-Based Individualized Exercise Program in Adults With Systemic Lupus Erythematosus: Protocol for a Randomized Controlled Trial. JMIR Res Protoc 2020;9:e18291. [PMID: 33141101 DOI: 10.2196/18291] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
165 Zhang Y, Day K, Absher DM. STAT3-mediated allelic imbalance of novel genetic variant Rs1047643 and B-cell-specific super-enhancer in association with systemic lupus erythematosus. Elife 2022;11:e72837. [PMID: 35188103 DOI: 10.7554/eLife.72837] [Reference Citation Analysis]
166 Zou YF, Xu JH, Gu YY, Pan FM, Tao JH, Wang DG, Xu SQ, Xiao H, Chen PL, Liu S, Cai J, Lian L, Liu SX, Liang CM, Tian G, Ye QL, Pan HF, Su H, Ye DQ. Single nucleotide polymorphisms of HSP90AA1 gene influence response of SLE patients to glucocorticoids treatment. Springerplus 2016;5:222. [PMID: 27026916 DOI: 10.1186/s40064-016-1911-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
167 Fahlquist Hagert C, Degn SE. T follicular regulatory cells: Guardians of the germinal centre? Scand J Immunol 2020;92:e12942. [PMID: 32697349 DOI: 10.1111/sji.12942] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
168 Lazarus MN, Turner-Stokes T, Chavele KM, Isenberg DA, Ehrenstein MR. B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels. Rheumatology (Oxford) 2012;51:1208-15. [PMID: 22337941 DOI: 10.1093/rheumatology/ker526] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 4.5] [Reference Citation Analysis]
169 Clatworthy MR, Aronin CE, Mathews RJ, Morgan NY, Smith KG, Germain RN. Immune complexes stimulate CCR7-dependent dendritic cell migration to lymph nodes. Nat Med 2014;20:1458-63. [PMID: 25384086 DOI: 10.1038/nm.3709] [Cited by in Crossref: 78] [Cited by in F6Publishing: 74] [Article Influence: 9.8] [Reference Citation Analysis]
170 Yung S, Chan TM. Molecular and Immunological Basis of Tubulo-Interstitial Injury in Lupus Nephritis: a Comprehensive Review. Clin Rev Allergy Immunol 2017;52:149-63. [PMID: 26961386 DOI: 10.1007/s12016-016-8533-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
171 Yang L, Feng D, Bi X, Stone RC, Barnes BJ. Monocytes from Irf5-/- mice have an intrinsic defect in their response to pristane-induced lupus. J Immunol 2012;189:3741-50. [PMID: 22933628 DOI: 10.4049/jimmunol.1201162] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 4.4] [Reference Citation Analysis]
172 Bremer HD, Vilson Å, Bonnett BN, Hansson-Hamlin H. Disease patterns and incidence of immune-mediated disease in insured Swedish Nova Scotia Duck Tolling Retrievers. Vet Rec 2015;177:74. [PMID: 26089352 DOI: 10.1136/vr.102960] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
173 Thiyagarajan D, Fismen S, Seredkina N, Jacobsen S, Elung-Jensen T, Kamper AL, Fenton CG, Rekvig OP, Mortensen ES. Silencing of renal DNaseI in murine lupus nephritis imposes exposure of large chromatin fragments and activation of Toll like receptors and the Clec4e. PLoS One 2012;7:e34080. [PMID: 22479529 DOI: 10.1371/journal.pone.0034080] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
174 Qi YY, Zhou XJ, Nath SK, Sun C, Wang YN, Hou P, Mu R, Li C, Guo JP, Li ZG, Wang G, Xu HJ, Hao YJ, Zhang ZL, Yue WH, Zhang H, Zhao MH, Zhang H. A Rare Variant (rs933717) at FBXO31-MAP1LC3B in Chinese Is Associated With Systemic Lupus Erythematosus. Arthritis Rheumatol 2018;70:287-97. [PMID: 29044928 DOI: 10.1002/art.40353] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
175 Zhang X, Ma H, Huang J, Dai Y. Characterization of the Phosphoproteome in SLE Patients. PLoS One 2012;7:e53129. [PMID: 23285258 DOI: 10.1371/journal.pone.0053129] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
176 Ebihara S, Tajima H, Ono M. Nuclear factor erythroid 2-related factor 2 is a critical target for the treatment of glucocorticoid-resistant lupus nephritis. Arthritis Res Ther 2016;18:139. [PMID: 27301376 DOI: 10.1186/s13075-016-1039-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
177 Elkon KB, Stone VV. Type I interferon and systemic lupus erythematosus. J Interferon Cytokine Res 2011;31:803-12. [PMID: 21859344 DOI: 10.1089/jir.2011.0045] [Cited by in Crossref: 70] [Cited by in F6Publishing: 69] [Article Influence: 6.4] [Reference Citation Analysis]
178 Beckerman NL, Auerbach C, Blanco I. Psychosocial dimensions of SLE: implications for the health care team. J Multidiscip Healthc 2011;4:63-72. [PMID: 21594059 DOI: 10.2147/JMDH.S19303] [Cited by in Crossref: 26] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
179 Cros J, Cagnard N, Woollard K, Patey N, Zhang SY, Senechal B, Puel A, Biswas SK, Moshous D, Picard C, Jais JP, D'Cruz D, Casanova JL, Trouillet C, Geissmann F. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 2010;33:375-86. [PMID: 20832340 DOI: 10.1016/j.immuni.2010.08.012] [Cited by in Crossref: 782] [Cited by in F6Publishing: 746] [Article Influence: 65.2] [Reference Citation Analysis]
180 Dahal LN, Basu N, Youssef H, Khanolkar RC, Barker RN, Erwig LP, Ward FJ. Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus. Arthritis Res Ther 2016;18:180. [PMID: 27487771 DOI: 10.1186/s13075-016-1075-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
181 Montero-Olvera PR, Berebichez-Fridman R, Velázquez-Álvarez L, Ríos-Morales JR, Rodríguez-Guiza MA. Late diagnosis of systemic lupus erythematosus and antiphospholipid syndrome in an older woman with psychosis: a case report and review of the literature. Clin Case Rep 2017;5:1819-25. [PMID: 29152278 DOI: 10.1002/ccr3.1185] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
182 Baxter RM, Kong DS, Garcia-Perez JE, O'Gorman WE, Hsieh EWY. Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry. J Vis Exp 2018. [PMID: 30010641 DOI: 10.3791/57780] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
183 Zervou MI, Andreou A, Matalliotakis M, Spandidos DA, Goulielmos GN, Eliopoulos EE. Association of the DNASE1L3 rs35677470 polymorphism with systemic lupus erythematosus, rheumatoid arthritis and systemic sclerosis: Structural biological insights. Mol Med Rep 2020;22:4492-8. [PMID: 33173951 DOI: 10.3892/mmr.2020.11547] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
184 Quintana López G, Muñetón López G, Coral-alvarado P, Méndez Patarroyo P, Molina J, Chalem P, Díaz J. Design and validation of LupusCol, an instrument for the evaluation of health-related quality of life in Colombian adult patients with systemic lupus erythematosus. Rheumatology 2015;54:104-12. [DOI: 10.1093/rheumatology/keu277] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
185 Wilbe M, Kozyrev SV, Farias FH, Bremer HD, Hedlund A, Pielberg GR, Seppälä EH, Gustafson U, Lohi H, Carlborg Ö, Andersson G, Hansson-Hamlin H, Lindblad-Toh K. Multiple Changes of Gene Expression and Function Reveal Genomic and Phenotypic Complexity in SLE-like Disease. PLoS Genet 2015;11:e1005248. [PMID: 26057447 DOI: 10.1371/journal.pgen.1005248] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
186 Ma Y, Xu X, Li M, Cai J, Wei Q, Niu H. Gut microbiota promote the inflammatory response in the pathogenesis of systemic lupus erythematosus. Mol Med 2019;25:35. [PMID: 31370803 DOI: 10.1186/s10020-019-0102-5] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 10.7] [Reference Citation Analysis]
187 Yap DY, Lai KN. Pathogenesis of renal disease in systemic lupus erythematosus--the role of autoantibodies and lymphocytes subset abnormalities. Int J Mol Sci 2015;16:7917-31. [PMID: 25860947 DOI: 10.3390/ijms16047917] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
188 Postal M, Sinicato NA, Appenzeller S, Niewold TB. Drugs in early clinical development for Systemic Lupus Erythematosus. Expert Opin Investig Drugs 2016;25:573-83. [PMID: 26950689 DOI: 10.1517/13543784.2016.1162291] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
189 Fang WL, Zhou B, Wang YY, Chen Y, Zhang L. Analysis of adiponectin gene polymorphisms in Chinese population with systemic lupus erythematosus. J Biomed Biotechnol 2010;2010:401537. [PMID: 20414354 DOI: 10.1155/2010/401537] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
190 Bendorius M, Po C, Muller S, Jeltsch-David H. From Systemic Inflammation to Neuroinflammation: The Case of Neurolupus. Int J Mol Sci 2018;19:E3588. [PMID: 30428632 DOI: 10.3390/ijms19113588] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
191 Gu Z, Tan W, Ji J, Feng G, Meng Y, Da Z, Guo G, Xia Y, Zhu X, Shi G, Cheng C. Rapamycin reverses the senescent phenotype and improves immunoregulation of mesenchymal stem cells from MRL/lpr mice and systemic lupus erythematosus patients through inhibition of the mTOR signaling pathway. Aging (Albany NY) 2016;8:1102-14. [PMID: 27048648 DOI: 10.18632/aging.100925] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 11.6] [Reference Citation Analysis]
192 Wen Q, Tang X, Zhou Q, Chen W, Yu X. Clinicopathological Patterns and Outcomes in Patients with Lupus Nephritis and Hyperuricemia. JCM 2022;11:3075. [DOI: 10.3390/jcm11113075] [Reference Citation Analysis]
193 Giles BM, Boackle SA. Linking complement and anti-dsDNA antibodies in the pathogenesis of systemic lupus erythematosus. Immunol Res 2013;55:10-21. [PMID: 22941560 DOI: 10.1007/s12026-012-8345-z] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
194 Schramm AM, Clowse ME. Aspirin for prevention of preeclampsia in lupus pregnancy. Autoimmune Dis 2014;2014:920467. [PMID: 24778868 DOI: 10.1155/2014/920467] [Cited by in Crossref: 7] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
195 Gottschalk TA, Tsantikos E, Hibbs ML. Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus. Front Immunol 2015;6:550. [PMID: 26579125 DOI: 10.3389/fimmu.2015.00550] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 7.9] [Reference Citation Analysis]
196 Rivera-Correa J, Conroy AL, Opoka RO, Batte A, Namazzi R, Ouma B, Bangirana P, Idro R, Schwaderer AL, John CC, Rodriguez A. Autoantibody levels are associated with acute kidney injury, anemia and post-discharge morbidity and mortality in Ugandan children with severe malaria. Sci Rep 2019;9:14940. [PMID: 31624288 DOI: 10.1038/s41598-019-51426-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
197 Selvaraja M, Chin VK, Abdullah M, Arip M, Amin-Nordin S. HLA-DRB1*04 as a Risk Allele to Systemic Lupus Erythematosus and Lupus Nephritis in the Malay Population of Malaysia. Front Med (Lausanne) 2020;7:598665. [PMID: 33644084 DOI: 10.3389/fmed.2020.598665] [Reference Citation Analysis]
198 Hickman RA, Hira-Kazal R, Yee CS, Toescu V, Gordon C. The efficacy and safety of rituximab in a chart review study of 15 patients with systemic lupus erythematosus. Clin Rheumatol 2015;34:263-71. [PMID: 25564308 DOI: 10.1007/s10067-014-2839-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
199 Putterman C, Furie R, Ramsey-Goldman R, Askanase A, Buyon J, Kalunian K, Chatham WW, Massarotti E, Kirou K, Jordan N, Blanco I, Weinstein A, Chitkara P, Manzi S, Ahearn J, O'Malley T, Conklin J, Ibarra C, Barken D, Dervieux T. Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements. Lupus Sci Med 2014;1:e000056. [PMID: 25396070 DOI: 10.1136/lupus-2014-000056] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 6.4] [Reference Citation Analysis]
200 Pradhan V, Pandit P, Surve P, Lecerf M, Rajadhyaksha A, Nadkar M, Khadilkar PV, Chougule DA, Naigaonkar AA, Lacroix-Desmazes S, Bayry J, Ghosh K, Kaveri SV. Catalytic antibodies in patients with systemic lupus erythematosus. Eur J Rheumatol 2018;5:173-8. [PMID: 30185370 DOI: 10.5152/eurjrheum.2018.17194] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
201 Bellocchi C, Carandina A, Montinaro B, Targetti E, Furlan L, Rodrigues GD, Tobaldini E, Montano N. The Interplay between Autonomic Nervous System and Inflammation across Systemic Autoimmune Diseases. Int J Mol Sci 2022;23:2449. [PMID: 35269591 DOI: 10.3390/ijms23052449] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
202 Wang D, Li J, Zhang Y, Zhang M, Chen J, Li X, Hu X, Jiang S, Shi S, Sun L. Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study. Arthritis Res Ther. 2014;16:R79. [PMID: 24661633 DOI: 10.1186/ar4520] [Cited by in Crossref: 164] [Cited by in F6Publishing: 153] [Article Influence: 20.5] [Reference Citation Analysis]
203 Lech M, Kulkarni OP, Pfeiffer S, Savarese E, Krug A, Garlanda C, Mantovani A, Anders HJ. Tir8/Sigirr prevents murine lupus by suppressing the immunostimulatory effects of lupus autoantigens. J Exp Med 2008;205:1879-88. [PMID: 18644972 DOI: 10.1084/jem.20072646] [Cited by in Crossref: 83] [Cited by in F6Publishing: 81] [Article Influence: 5.9] [Reference Citation Analysis]
204 Du P, Xu L, Qiu W, Zeng D, Yue J, Wang S, Huang P, Sun Z. A fully human monoclonal antibody with novel binding epitope and excellent neutralizing activity to multiple human IFN-α subtypes: A candidate therapy for systemic lupus erythematosus. MAbs 2015;7:969-80. [PMID: 26048268 DOI: 10.1080/19420862.2015.1055443] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
205 Liao C, Hsu J, Kim Y, Hu DQ, Xu D, Zhang J, Pashine A, Menke J, Whittard T, Romero N, Truitt T, Slade M, Lukacs C, Hermann J, Zhou M, Lucas M, Narula S, DeMartino J, Tan SL. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy. Arthritis Res Ther 2013;15:R146. [PMID: 24286216 DOI: 10.1186/ar4329] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
206 Crampton SP, Morawski PA, Bolland S. Linking susceptibility genes and pathogenesis mechanisms using mouse models of systemic lupus erythematosus. Dis Model Mech 2014;7:1033-46. [PMID: 25147296 DOI: 10.1242/dmm.016451] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 6.4] [Reference Citation Analysis]
207 Sitrin J, Suto E, Wuster A, Eastham-Anderson J, Kim JM, Austin CD, Lee WP, Behrens TW. The Ox40/Ox40 Ligand Pathway Promotes Pathogenic Th Cell Responses, Plasmablast Accumulation, and Lupus Nephritis in NZB/W F1 Mice. J Immunol 2017;199:1238-49. [PMID: 28696253 DOI: 10.4049/jimmunol.1700608] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
208 Eisenberg R. Why can't we find a new treatment for SLE? J Autoimmun 2009;32:223-30. [PMID: 19329279 DOI: 10.1016/j.jaut.2009.02.006] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 2.6] [Reference Citation Analysis]
209 Kalantari S, Chashmniam S, Nafar M, Zakeri Z, Parvin M. Metabolomics approach reveals urine biomarkers and pathways associated with the pathogenesis of lupus nephritis. Iran J Basic Med Sci 2019;22:1288-95. [PMID: 32128093 DOI: 10.22038/ijbms.2019.38713.9178] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
210 Green K, Wittenborn TR, Fahlquist-Hagert C, Terczynska-Dyla E, van Campen N, Jensen L, Reinert L, Hartmann R, Paludan SR, Degn SE. B Cell Intrinsic STING Signaling Is Not Required for Autoreactive Germinal Center Participation. Front Immunol 2021;12:782558. [PMID: 34938294 DOI: 10.3389/fimmu.2021.782558] [Reference Citation Analysis]
211 Knight CL, Nelson-Piercy C. Management of systemic lupus erythematosus during pregnancy: challenges and solutions. Open Access Rheumatol 2017;9:37-53. [PMID: 28331377 DOI: 10.2147/OARRR.S87828] [Cited by in Crossref: 34] [Cited by in F6Publishing: 8] [Article Influence: 6.8] [Reference Citation Analysis]
212 Zhang F, Bae SC, Bass D, Chu M, Egginton S, Gordon D, Roth DA, Zheng J, Tanaka Y. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis 2018;77:355-63. [PMID: 29295825 DOI: 10.1136/annrheumdis-2017-211631] [Cited by in Crossref: 73] [Cited by in F6Publishing: 70] [Article Influence: 18.3] [Reference Citation Analysis]
213 Shelton KA, Cline JM, Cann JA. 17-β Estradiol reduces atherosclerosis without exacerbating lupus in ovariectomized systemic lupus erythematosus-susceptible LDLr(-/-) mice. Atherosclerosis 2013;227:228-35. [PMID: 23395521 DOI: 10.1016/j.atherosclerosis.2012.12.031] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
214 Blair PA, Chavez-Rueda KA, Evans JG, Shlomchik MJ, Eddaoudi A, Isenberg DA, Ehrenstein MR, Mauri C. Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice. J Immunol 2009;182:3492-502. [PMID: 19265127 DOI: 10.4049/jimmunol.0803052] [Cited by in Crossref: 215] [Cited by in F6Publishing: 204] [Article Influence: 16.5] [Reference Citation Analysis]
215 Faith TD, Flournoy-Floyd M, Ortiz K, Egede LE, Oates JC, Williams EM. My life with lupus: contextual responses of African-American women with systemic lupus participating in a peer mentoring intervention to improve disease self-management. BMJ Open 2018;8:e022701. [PMID: 30413505 DOI: 10.1136/bmjopen-2018-022701] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
216 Ludvigsson JF, Rubio-Tapia A, Chowdhary V, Murray JA, Simard JF. Increased risk of systemic lupus erythematosus in 29,000 patients with biopsy-verified celiac disease. J Rheumatol 2012;39:1964-70. [PMID: 22859356 DOI: 10.3899/jrheum.120493] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
217 Terrier B, Derian N, Schoindre Y, Chaara W, Geri G, Zahr N, Mariampillai K, Rosenzwajg M, Carpentier W, Musset L, Piette JC, Six A, Klatzmann D, Saadoun D, Patrice C, Costedoat-Chalumeau N. Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through vitamin D supplementation. Arthritis Res Ther 2012;14:R221. [PMID: 23075451 DOI: 10.1186/ar4060] [Cited by in Crossref: 117] [Cited by in F6Publishing: 95] [Article Influence: 11.7] [Reference Citation Analysis]
218 Kinzel S, Lehmann-Horn K, Torke S, Häusler D, Winkler A, Stadelmann C, Payne N, Feldmann L, Saiz A, Reindl M, Lalive PH, Bernard CC, Brück W, Weber MS. Myelin-reactive antibodies initiate T cell-mediated CNS autoimmune disease by opsonization of endogenous antigen. Acta Neuropathol 2016;132:43-58. [PMID: 27022743 DOI: 10.1007/s00401-016-1559-8] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 8.8] [Reference Citation Analysis]
219 Rekvig OP. The Anti-DNA Antibodies: Their Specificities for Unique DNA Structures and Their Unresolved Clinical Impact-A System Criticism and a Hypothesis. Front Immunol 2021;12:808008. [PMID: 35087528 DOI: 10.3389/fimmu.2021.808008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
220 Suzuki K, Kameda H, Amano K, Nagasawa H, Takei H, Nishi E, Okuyama A, Tsuzaka K, Takeuchi T. Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus. Rheumatol Int. 2011;31:757-763. [PMID: 20169348 DOI: 10.1007/s00296-010-1366-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
221 Wen Z, Xu L, Xu W, Xiong S. Detection of dynamic frequencies of Th17 cells and their associations with clinical parameters in patients with systemic lupus erythematosus receiving standard therapy. Clin Rheumatol 2014;33:1451-8. [PMID: 24810699 DOI: 10.1007/s10067-014-2656-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
222 Ju Y, Wei Y, Hsieh M, Wang J, Wu J. Transient Congenital Complete Heart Block: A Case Report. Children 2021;8:790. [DOI: 10.3390/children8090790] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
223 Richez C, Yasuda K, Bonegio RG, Watkins AA, Aprahamian T, Busto P, Richards RJ, Liu CL, Cheung R, Utz PJ, Marshak-Rothstein A, Rifkin IR. IFN regulatory factor 5 is required for disease development in the FcgammaRIIB-/-Yaa and FcgammaRIIB-/- mouse models of systemic lupus erythematosus. J Immunol 2010;184:796-806. [PMID: 20007534 DOI: 10.4049/jimmunol.0901748] [Cited by in Crossref: 73] [Cited by in F6Publishing: 70] [Article Influence: 5.6] [Reference Citation Analysis]
224 Chong Z, Bao C, He J, Chen T, Zhong L, Li G, Li H, Fang L, Song Y, Fu G, Yang X, Lai L, Liu Y, Wang Q. E3 ligase FBXW7 aggravates TMPD-induced systemic lupus erythematosus by promoting cell apoptosis. Cell Mol Immunol 2018;15:1057-70. [PMID: 30275535 DOI: 10.1038/s41423-018-0167-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
225 Barkhudarova F, Dähnrich C, Rosemann A, Schneider U, Stöcker W, Burmester GR, Egerer K, Schlumberger W, Hiepe F, Biesen R. Diagnostic value and clinical laboratory associations of antibodies against recombinant ribosomal P0, P1 and P2 proteins and their native heterocomplex in a Caucasian cohort with systemic lupus erythematosus. Arthritis Res Ther 2011;13:R20. [PMID: 21310064 DOI: 10.1186/ar3244] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
226 Watanabe R, Ishiura N, Nakashima H, Kuwano Y, Okochi H, Tamaki K, Sato S, Tedder TF, Fujimoto M. Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic autoimmunity. J Immunol. 2010;184:4801-4809. [PMID: 20368271 DOI: 10.4049/jimmunol.0902385] [Cited by in Crossref: 216] [Cited by in F6Publishing: 206] [Article Influence: 18.0] [Reference Citation Analysis]
227 Zheng X, Xiao ZX, Hu L, Fang X, Luo L, Chen L. Dendritic cell-associated B7-H3 suppresses the production of autoantibodies and renal inflammation in a mouse model of systemic lupus erythematosus. Cell Death Dis 2019;10:393. [PMID: 31113935 DOI: 10.1038/s41419-019-1623-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
228 Williams EM, Egede L, Oates JC, Dismuke CL, Ramakrishnan V, Faith TD, Johnson H, Rose J. Peer approaches to self-management (PALS): comparing a peer mentoring approach for disease self-management in African American women with lupus with a social support control: study protocol for a randomized controlled trial. Trials 2019;20:529. [PMID: 31443732 DOI: 10.1186/s13063-019-3580-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
229 Banham-Hall E, Clatworthy MR, Okkenhaug K. The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases. Open Rheumatol J 2012;6:245-58. [PMID: 23028409 DOI: 10.2174/1874312901206010245] [Cited by in Crossref: 68] [Cited by in F6Publishing: 61] [Article Influence: 6.8] [Reference Citation Analysis]
230 Wallace DJ, Silverman SL, Conklin J, Barken D, Dervieux T. Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products. Lupus Sci Med 2016;3:e000127. [PMID: 26870391 DOI: 10.1136/lupus-2015-000127] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
231 Bakshi J, Segura BT, Wincup C, Rahman A. Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus. Clin Rev Allergy Immunol 2018;55:352-67. [PMID: 28853005 DOI: 10.1007/s12016-017-8640-5] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 11.3] [Reference Citation Analysis]
232 Petri M, Wallace DJ, Spindler A, Chindalore V, Kalunian K, Mysler E, Neuwelt CM, Robbie G, White WI, Higgs BW, Yao Y, Wang L, Ethgen D, Greth W. Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum 2013;65:1011-21. [PMID: 23400715 DOI: 10.1002/art.37824] [Cited by in Crossref: 179] [Cited by in F6Publishing: 170] [Article Influence: 19.9] [Reference Citation Analysis]
233 Chen X, Wen Z, Xu W, Xiong S. Granulin exacerbates lupus nephritis via enhancing macrophage M2b polarization. PLoS One 2013;8:e65542. [PMID: 23755248 DOI: 10.1371/journal.pone.0065542] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
234 de Salort J, Cuenca M, Terhorst C, Engel P, Romero X. Ly9 (CD229) Cell-Surface Receptor is Crucial for the Development of Spontaneous Autoantibody Production to Nuclear Antigens. Front Immunol 2013;4:225. [PMID: 23914190 DOI: 10.3389/fimmu.2013.00225] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
235 Kang HK, Ecklund D, Liu M, Datta SK. Apigenin, a non-mutagenic dietary flavonoid, suppresses lupus by inhibiting autoantigen presentation for expansion of autoreactive Th1 and Th17 cells. Arthritis Res Ther 2009;11:R59. [PMID: 19405952 DOI: 10.1186/ar2682] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 4.3] [Reference Citation Analysis]
236 Chen DN, Fan L, Wu YX, Zhou Q, Chen W, Yu XQ. A Predictive Model for Estimation Risk of Proliferative Lupus Nephritis. Chin Med J (Engl) 2018;131:1275-81. [PMID: 29786038 DOI: 10.4103/0366-6999.232809] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
237 Hu L, Hu J, Chen L, Zhang Y, Wang Q, Yang X. Interleukin-22 From Type 3 Innate Lymphoid Cells Aggravates Lupus Nephritis by Promoting Macrophage Infiltration in Lupus-Prone Mice. Front Immunol 2021;12:584414. [PMID: 33717066 DOI: 10.3389/fimmu.2021.584414] [Reference Citation Analysis]
238 Anders HJ, Weidenbusch M, Rovin B. Unmet medical needs in lupus nephritis: solutions through evidence-based, personalized medicine. Clin Kidney J 2015;8:492-502. [PMID: 26413272 DOI: 10.1093/ckj/sfv072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
239 Schleinitz N, Vély F, Harlé JR, Vivier E. Natural killer cells in human autoimmune diseases. Immunology 2010;131:451-8. [PMID: 21039469 DOI: 10.1111/j.1365-2567.2010.03360.x] [Cited by in Crossref: 100] [Cited by in F6Publishing: 98] [Article Influence: 8.3] [Reference Citation Analysis]
240 Liu J, Huang X, Hao S, Wang Y, Liu M, Xu J, Zhang X, Yu T, Gan S, Dai D, Luo X, Lu Q, Mao C, Zhang Y, Shen N, Li B, Huang M, Zhu X, Jin J, Cheng X, Sun SC, Xiao Y. Peli1 negatively regulates noncanonical NF-κB signaling to restrain systemic lupus erythematosus. Nat Commun 2018;9:1136. [PMID: 29555915 DOI: 10.1038/s41467-018-03530-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
241 Hua Z, Gross AJ, Lamagna C, Ramos-Hernández N, Scapini P, Ji M, Shao H, Lowell CA, Hou B, DeFranco AL. Requirement for MyD88 signaling in B cells and dendritic cells for germinal center anti-nuclear antibody production in Lyn-deficient mice. J Immunol 2014;192:875-85. [PMID: 24379120 DOI: 10.4049/jimmunol.1300683] [Cited by in Crossref: 64] [Cited by in F6Publishing: 62] [Article Influence: 7.1] [Reference Citation Analysis]
242 Furukawa H, Oka S, Tsuchiya N, Shimada K, Hashimoto A, Tohma S, Kawasaki A. The role of common protective alleles HLA-DRB1*13 among systemic autoimmune diseases. Genes Immun 2017;18:1-7. [PMID: 27829665 DOI: 10.1038/gene.2016.40] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
243 . Bibliography. Current world literature. Neuro opthalmology. Curr Opin Ophthalmol 2008;19:541-4. [PMID: 18854700 DOI: 10.1097/ICU.0b013e328317c7c4] [Reference Citation Analysis]
244 Tan G, Baby B, Zhou Y, Wu T. Emerging Molecular Markers Towards Potential Diagnostic Panels for Lupus. Front Immunol 2021;12:808839. [PMID: 35095896 DOI: 10.3389/fimmu.2021.808839] [Reference Citation Analysis]
245 Bonegio RG, Lin JD, Beaudette-Zlatanova B, York MR, Menn-Josephy H, Yasuda K. Lupus-Associated Immune Complexes Activate Human Neutrophils in an FcγRIIA-Dependent but TLR-Independent Response. J Immunol 2019;202:675-83. [PMID: 30610165 DOI: 10.4049/jimmunol.1800300] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
246 Pellefigues C, Charles N. The deleterious role of basophils in systemic lupus erythematosus. Curr Opin Immunol 2013;25:704-11. [PMID: 24209595 DOI: 10.1016/j.coi.2013.10.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
247 Gosselin D, Rivest S. Immune mechanisms underlying the beneficial effects of autologous hematopoietic stem cell transplantation in multiple sclerosis. Neurotherapeutics 2011;8:643-9. [PMID: 21904792 DOI: 10.1007/s13311-011-0062-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
248 Moudi B, Salimi S, Farajian Mashhadi F, Sandoughi M, Zakeri Z. Association of FAS and FAS ligand genes polymorphism and risk of systemic lupus erythematosus. ScientificWorldJournal 2013;2013:176741. [PMID: 24348139 DOI: 10.1155/2013/176741] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
249 Morgan C, Bland AR, Maker C, Dunnage J, Bruce IN. Individuals living with lupus: findings from the LUPUS UK Members Survey 2014. Lupus 2018;27:681-7. [PMID: 29310537 DOI: 10.1177/0961203317749746] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
250 Mazzi MT, Hajdu KL, Ribeiro PR, Bonamino MH. CAR-T cells leave the comfort zone: current and future applications beyond cancer. Immunotherapy Advances 2021;1:ltaa006. [DOI: 10.1093/immadv/ltaa006] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
251 Azab SF, Ali YF, Farghaly MAA, Hamed ME, Allah MAN, Emam AA, Abdelsalam NI, Hashem MIA, Gawish HH, Nabil RM, Kamel LM, Fahmy DS, Alsayed SF, Al Azizi NM, Al-Akad GM, Noah MA, Abdelrahman HM, Ahmed AR, Bendary EA. Vitamin D receptor gene BsmI polymorphisms in Egyptian children and adolescents with systemic lupus erythematosus: A case-control study. Medicine (Baltimore) 2016;95:e5233. [PMID: 27861345 DOI: 10.1097/MD.0000000000005233] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
252 Wang G, Tam LS, Kwan BC, Li EK, Chow KM, Luk CC, Li PK, Szeto CC. Expression of miR-146a and miR-155 in the urinary sediment of systemic lupus erythematosus. Clin Rheumatol 2012;31:435-40. [PMID: 21987229 DOI: 10.1007/s10067-011-1857-4] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 5.8] [Reference Citation Analysis]
253 Shrivastav M, Niewold TB. Nucleic Acid sensors and type I interferon production in systemic lupus erythematosus. Front Immunol 2013;4:319. [PMID: 24109483 DOI: 10.3389/fimmu.2013.00319] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 6.1] [Reference Citation Analysis]
254 Guzman M, Hui-Yuen JS. Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab. Drug Des Devel Ther 2020;14:2503-13. [PMID: 32612353 DOI: 10.2147/DDDT.S216193] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
255 Ronco P, Debiec H. Pathophysiological lessons from rare associations of immunological disorders. Pediatr Nephrol 2009;24:3-8. [PMID: 18853201 DOI: 10.1007/s00467-008-1009-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
256 Yuan Y, Kasar S, Underbayev C, Vollenweider D, Salerno E, Kotenko SV, Raveche E. Role of microRNA-15a in autoantibody production in interferon-augmented murine model of lupus. Mol Immunol 2012;52:61-70. [PMID: 22578383 DOI: 10.1016/j.molimm.2012.04.007] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
257 Zhu H, Luo H, Yan M, Zuo X, Li QZ. Autoantigen Microarray for High-throughput Autoantibody Profiling in Systemic Lupus Erythematosus. Genomics Proteomics Bioinformatics 2015;13:210-8. [PMID: 26415621 DOI: 10.1016/j.gpb.2015.09.001] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 7.4] [Reference Citation Analysis]
258 Karimzadeh H, Shirzadi M, Karimifar M. The effect of Vitamin D supplementation in disease activity of systemic lupus erythematosus patients with Vitamin D deficiency: A randomized clinical trial. J Res Med Sci 2017;22:4. [PMID: 28400826 DOI: 10.4103/1735-1995.199089] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
259 Kamen DL, Aranow C. The link between vitamin D deficiency and systemic lupus erythematosus. Curr Rheumatol Rep 2008;10:273-80. [PMID: 18662506 DOI: 10.1007/s11926-008-0044-3] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 3.1] [Reference Citation Analysis]
260 Tanha N, Pilely K, Faurschou M, Garred P, Jacobsen S. Plasma ficolin levels and risk of nephritis in Danish patients with systemic lupus erythematosus. Clin Rheumatol 2017;36:335-41. [PMID: 27981461 DOI: 10.1007/s10067-016-3508-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
261 Lin Y, Zou QH, Wang J, Wang Y, Zhou DQ, Zhang RH, Zhang YW, Lii HT, Fang YF. Localization of cerebral functional deficits in patients with non-neuropsychiatric systemic lupus erythematosus. Hum Brain Mapp 2011;32:1847-55. [PMID: 21170956 DOI: 10.1002/hbm.21158] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
262 Liphaus BL, Umetsu N, Jesus AA, Bando SY, Silva CA, Carneiro-Sampaio M. Molecular characterization of the complement C1q, C2 and C4 genes in Brazilian patients with juvenile systemic lupus erythematosus. Clinics (Sao Paulo) 2015;70:220-7. [PMID: 26017655 DOI: 10.6061/clinics/2015(03)12] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
263 Berthier CC, Kretzler M, Davidson A. From the Large Scale Expression Analysis of Lupus Nephritis to Targeted Molecular Medicine. J Data Mining Genomics Proteomics 2012;3:1000123. [PMID: 23626922 DOI: 10.4172/2153-0602.1000123] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
264 Smilowitz NR, Katz G, Buyon JP, Clancy RM, Berger JS. Systemic lupus erythematosus and the risk of perioperative major adverse cardiovascular events. J Thromb Thrombolysis 2018;45:13-7. [PMID: 29230625 DOI: 10.1007/s11239-017-1591-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
265 Grönwall C, Akhter E, Oh C, Burlingame RW, Petri M, Silverman GJ. IgM autoantibodies to distinct apoptosis-associated antigens correlate with protection from cardiovascular events and renal disease in patients with SLE. Clin Immunol 2012;142:390-8. [PMID: 22297166 DOI: 10.1016/j.clim.2012.01.002] [Cited by in Crossref: 82] [Cited by in F6Publishing: 76] [Article Influence: 8.2] [Reference Citation Analysis]
266 Hui-Yuen JS, Li XQ, Askanase AD. Belimumab in systemic lupus erythematosus: a perspective review. Ther Adv Musculoskelet Dis 2015;7:115-21. [PMID: 26288663 DOI: 10.1177/1759720X15588514] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
267 Charles N, Rivera J. Basophils and autoreactive IgE in the pathogenesis of systemic lupus erythematosus. Curr Allergy Asthma Rep 2011;11:378-87. [PMID: 21805094 DOI: 10.1007/s11882-011-0216-5] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
268 Kanold AM, Svenungsson E, Gunnarsson I, Götherström C, Padyukov L, Papadogiannakis N, Uzunel M, Westgren M. A research study of the association between maternal microchimerism and systemic lupus erythematosus in adults: a comparison between patients and healthy controls based on single-nucleotide polymorphism using quantitative real-time PCR. PLoS One 2013;8:e74534. [PMID: 24040274 DOI: 10.1371/journal.pone.0074534] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
269 Zhao J, Wu H, Khosravi M, Cui H, Qian X, Kelly JA, Kaufman KM, Langefeld CD, Williams AH, Comeau ME, Ziegler JT, Marion MC, Adler A, Glenn SB, Alarcón-Riquelme ME, Pons-Estel BA, Harley JB, Bae SC, Bang SY, Cho SK, Jacob CO, Vyse TJ, Niewold TB, Gaffney PM, Moser KL, Kimberly RP, Edberg JC, Brown EE, Alarcon GS, Petri MA, Ramsey-Goldman R, Vilá LM, Reveille JD, James JA, Gilkeson GS, Kamen DL, Freedman BI, Anaya JM, Merrill JT, Criswell LA, Scofield RH, Stevens AM, Guthridge JM, Chang DM, Song YW, Park JA, Lee EY, Boackle SA, Grossman JM, Hahn BH, Goodship TH, Cantor RM, Yu CY, Shen N, Tsao BP; BIOLUPUS Network., GENLES Network. Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet 2011;7:e1002079. [PMID: 21637784 DOI: 10.1371/journal.pgen.1002079] [Cited by in Crossref: 135] [Cited by in F6Publishing: 125] [Article Influence: 12.3] [Reference Citation Analysis]
270 Dacoba TG, Olivera A, Torres D, Crecente-Campo J, Alonso MJ. Modulating the immune system through nanotechnology. Semin Immunol 2017;34:78-102. [PMID: 29032891 DOI: 10.1016/j.smim.2017.09.007] [Cited by in Crossref: 52] [Cited by in F6Publishing: 42] [Article Influence: 10.4] [Reference Citation Analysis]
271 Pugh ME, Hemnes AR. Development of pulmonary arterial hypertension in women: interplay of sex hormones and pulmonary vascular disease. Womens Health (Lond) 2010;6:285-96. [PMID: 20187732 DOI: 10.2217/whe.09.88] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
272 Al-Ejeh F, Darby JM, Brown MP. Chemotherapy synergizes with radioimmunotherapy targeting La autoantigen in tumors. PLoS One. 2009;4:e4630. [PMID: 19247485 DOI: 10.1371/journal.pone.0004630] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
273 Tangtanatakul P, Thumarat C, Satproedprai N, Kunhapan P, Chaiyasung T, Klinchanhom S, Wang YF, Wei W, Wongshinsri J, Chiewchengchol D, Rodsaward P, Ngamjanyaporn P, Suangtamai T, Mahasirimongkol S, Pisitkun P, Hirankarn N. Meta-analysis of genome-wide association study identifies FBN2 as a novel locus associated with systemic lupus erythematosus in Thai population. Arthritis Res Ther 2020;22:185. [PMID: 32771030 DOI: 10.1186/s13075-020-02276-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
274 Corradetti C, Jog NR, Gallucci S, Madaio M, Balachandran S, Caricchio R. Immune-Mediated Nephropathy and Systemic Autoimmunity in Mice Does Not Require Receptor Interacting Protein Kinase 3 (RIPK3). PLoS One 2016;11:e0163611. [PMID: 27669412 DOI: 10.1371/journal.pone.0163611] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
275 Torres-Salido MT, Sanchis M, Solé C, Moliné T, Vidal M, Vidal X, Solà A, Hotter G, Ordi-Ros J, Cortés-Hernández J. Urinary Neuropilin-1: A Predictive Biomarker for Renal Outcome in Lupus Nephritis. Int J Mol Sci 2019;20:E4601. [PMID: 31533337 DOI: 10.3390/ijms20184601] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
276 Halade GV, Rahman MM, Bhattacharya A, Barnes JL, Chandrasekar B, Fernandes G. Docosahexaenoic acid-enriched fish oil attenuates kidney disease and prolongs median and maximal life span of autoimmune lupus-prone mice. J Immunol. 2010;184:5280-5286. [PMID: 20368275 DOI: 10.4049/jimmunol.0903282] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 5.1] [Reference Citation Analysis]
277 Strand V, Petri M, Kalunian K, Gordon C, Wallace DJ, Hobbs K, Kelley L, Kilgallen B, Wegener WA, Goldenberg DM. Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006. Rheumatology (Oxford). 2014;53:502-511. [PMID: 24273022 DOI: 10.1093/rheumatology/ket378] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 5.1] [Reference Citation Analysis]
278 Berardi S, Giardullo L, Corrado A, Cantatore FP. Vitamin D and connective tissue diseases. Inflamm Res 2020;69:453-62. [PMID: 32172354 DOI: 10.1007/s00011-020-01337-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
279 Tsai JD, Lin CL, Lin CC, Sung FC, Lue KH. Risk of epilepsy in patients with systemic lupus erythematosus - a retrospective cohort study. Neuropsychiatr Dis Treat 2014;10:1635-43. [PMID: 25214788 DOI: 10.2147/NDT.S64323] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
280 Harirchian MH, Saberi H, Najafizadeh SR, Hashemi SA. Evaluation of brain and cervical MRI abnormality rates in patients with systemic lupus erythematosus with or without neurological manifestations. Iran J Radiol 2011;8:157-60. [PMID: 23329933 DOI: 10.5812/kmp.iranjradiol.17351065.3138] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
281 Scapini P, Hu Y, Chu CL, Migone TS, Defranco AL, Cassatella MA, Lowell CA. Myeloid cells, BAFF, and IFN-gamma establish an inflammatory loop that exacerbates autoimmunity in Lyn-deficient mice. J Exp Med 2010;207:1757-73. [PMID: 20624892 DOI: 10.1084/jem.20100086] [Cited by in Crossref: 84] [Cited by in F6Publishing: 83] [Article Influence: 7.0] [Reference Citation Analysis]
282 Anders HJ. Pigmented villonodular synovitis of the hip in systemic lupus erythematosus: a case report. J Med Case Rep 2011;5:443. [PMID: 21899757 DOI: 10.1186/1752-1947-5-443] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
283 Yang J, Xu Z, Sui M, Han J, Sun L, Jia X, Zhang H, Han C, Jin X, Gao F, Liu Y, Li Y, Cao J, Ling H, Zhang F, Ren H. Co-Positivity for Anti-dsDNA, -Nucleosome and -Histone Antibodies in Lupus Nephritis Is Indicative of High Serum Levels and Severe Nephropathy. PLoS One 2015;10:e0140441. [PMID: 26465327 DOI: 10.1371/journal.pone.0140441] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
284 Abdallah E, Waked E, Abdelwahab MA. Evaluating the association of interleukin-10 gene promoter -592 A/C polymorphism with lupus nephritis susceptibility. Kidney Res Clin Pract 2016;35:29-34. [PMID: 27069855 DOI: 10.1016/j.krcp.2015.11.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
285 Yan S, Yim LY, Lu L, Lau CS, Chan VS. MicroRNA Regulation in Systemic Lupus Erythematosus Pathogenesis. Immune Netw 2014;14:138-48. [PMID: 24999310 DOI: 10.4110/in.2014.14.3.138] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 5.1] [Reference Citation Analysis]
286 Leone P, Prete M, Malerba E, Bray A, Susca N, Ingravallo G, Racanelli V. Lupus Vasculitis: An Overview. Biomedicines 2021;9:1626. [PMID: 34829857 DOI: 10.3390/biomedicines9111626] [Reference Citation Analysis]
287 Buyon J, Furie R, Putterman C, Ramsey-Goldman R, Kalunian K, Barken D, Conklin J, Dervieux T. Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus. Lupus Sci Med 2016;3:e000165. [PMID: 27752336 DOI: 10.1136/lupus-2016-000165] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
288 Szumilas N, Corneth OBJ, Lehmann CHK, Schmitt H, Cunz S, Cullen JG, Chu T, Marosan A, Mócsai A, Benes V, Zehn D, Dudziak D, Hendriks RW, Nitschke L. Siglec-H-Deficient Mice Show Enhanced Type I IFN Responses, but Do Not Develop Autoimmunity After Influenza or LCMV Infections. Front Immunol 2021;12:698420. [PMID: 34497606 DOI: 10.3389/fimmu.2021.698420] [Reference Citation Analysis]
289 Schreiber J, Eisenberger U, de Groot K. [Lupus nephritis]. Internist (Berl) 2019;60:468-77. [PMID: 30840107 DOI: 10.1007/s00108-019-0574-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
290 Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, Ginzler EM, D'Cruz DP, Doria A, Cooper S, Zhong ZJ, Hough D, Freimuth W, Petri MA; BLISS-52 and BLISS-76 Study Groups. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 2012;71:1833-8. [PMID: 22550315 DOI: 10.1136/annrheumdis-2011-200831] [Cited by in Crossref: 251] [Cited by in F6Publishing: 217] [Article Influence: 25.1] [Reference Citation Analysis]
291 Pacheco R, Contreras F, Zouali M. The dopaminergic system in autoimmune diseases. Front Immunol. 2014;5:117. [PMID: 24711809 DOI: 10.3389/fimmu.2014.00117] [Cited by in Crossref: 87] [Cited by in F6Publishing: 81] [Article Influence: 10.9] [Reference Citation Analysis]
292 Chen LY, Shi ZR, Tan GZ, Han YF, Tang ZQ, Wang L. Systemic lupus erythematosus with and without a family history: a meta-analysis. Lupus 2018;27:716-21. [PMID: 29087262 DOI: 10.1177/0961203317739133] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
293 Pérez-Sánchez C, Cecchi I, Barbarroja N, Patiño-Trives AM, Luque-Tévar M, Pérez-Sánchez L, Ibáñez-Costa A, Arias de la Rosa I, Ortega R, Escudero A, Castro MC, Radin M, Roccatello D, Sciascia S, Aguirre MÁ, Collantes E, López-Pedrera C; BIOSAR Study Group. Early restoration of immune and vascular phenotypes in systemic lupus erythematosus and rheumatoid arthritis patients after B cell depletion. J Cell Mol Med 2019;23:6308-18. [PMID: 31347786 DOI: 10.1111/jcmm.14517] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
294 Schwarting A, Dooley MA, Roth DA, Edwards L, Thompson A, Wilson B. Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus. Lupus 2016;25:1587-96. [PMID: 27488472 DOI: 10.1177/0961203316655215] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
295 Elsayed SA, Kamaly HM, Esmail MA. Co-positivity of anti-dsDNA, anti-nucleosome, and anti-smith autoantibodies as serological biomarkers for disease activity in systemic lupus erythematosus. Egypt Rheumatol Rehabil 2022;49. [DOI: 10.1186/s43166-021-00110-0] [Reference Citation Analysis]
296 Chen K, Wang JM, Yuan R, Yi X, Li L, Gong W, Yang T, Li L, Su S. Tissue-resident dendritic cells and diseases involving dendritic cell malfunction. Int Immunopharmacol 2016;34:1-15. [PMID: 26906720 DOI: 10.1016/j.intimp.2016.02.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
297 Belot A, Kasher PR, Trotter EW, Foray AP, Debaud AL, Rice GI, Szynkiewicz M, Zabot MT, Rouvet I, Bhaskar SS, Daly SB, Dickerson JE, Mayer J, O'Sullivan J, Juillard L, Urquhart JE, Fawdar S, Marusiak AA, Stephenson N, Waszkowycz B, W Beresford M, Biesecker LG, C M Black G, René C, Eliaou JF, Fabien N, Ranchin B, Cochat P, Gaffney PM, Rozenberg F, Lebon P, Malcus C, Crow YJ, Brognard J, Bonnefoy N. Protein kinase cδ deficiency causes mendelian systemic lupus erythematosus with B cell-defective apoptosis and hyperproliferation. Arthritis Rheum 2013;65:2161-71. [PMID: 23666743 DOI: 10.1002/art.38008] [Cited by in Crossref: 118] [Cited by in F6Publishing: 86] [Article Influence: 13.1] [Reference Citation Analysis]
298 Bortoluzzi A, Vincenzi F, Govoni M, Padovan M, Ravani A, Borea PA, Varani K. A2A adenosine receptor upregulation correlates with disease activity in patients with systemic lupus erythematosus. Arthritis Res Ther 2016;18:192. [PMID: 27566294 DOI: 10.1186/s13075-016-1089-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
299 Gilbert EL, Ryan MJ. Estrogen in cardiovascular disease during systemic lupus erythematosus. Clin Ther. 2014;36:1901-1912. [PMID: 25194860 DOI: 10.1016/j.clinthera.2014.07.021] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
300 Xing Y, Zhao J, Zhou M, Jing S, Zhao X, Mao P, Qian J, Huang C, Tian Z, Wang Q, Zeng X, Li M, Yang J. The LPS induced pyroptosis exacerbates BMPR2 signaling deficiency to potentiate SLE-PAH. FASEB J 2021;35:e22044. [PMID: 34818449 DOI: 10.1096/fj.202100851RR] [Reference Citation Analysis]
301 Olsen NJ, Li QZ, Quan J, Wang L, Mutwally A, Karp DR. Autoantibody profiling to follow evolution of lupus syndromes. Arthritis Res Ther 2012;14:R174. [PMID: 22838636 DOI: 10.1186/ar3927] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 4.8] [Reference Citation Analysis]
302 Ramaiah SK, Günthner R, Lech M, Anders HJ. Toll-like receptor and accessory molecule mRNA expression in humans and mice as well as in murine autoimmunity, transient inflammation, and progressive fibrosis. Int J Mol Sci 2013;14:13213-30. [PMID: 23803655 DOI: 10.3390/ijms140713213] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
303 Datta SK. Harnessing Tolerogenic Histone Peptide Epitopes From Nucleosomes for Selective Down-Regulation of Pathogenic Autoimmune Response in Lupus (Past, Present, and Future). Front Immunol 2021;12:629807. [PMID: 33936042 DOI: 10.3389/fimmu.2021.629807] [Reference Citation Analysis]
304 Halade GV, Williams PJ, Veigas JM, Barnes JL, Fernandes G. Concentrated fish oil (Lovaza(R)) extends lifespan and attenuates kidney disease in lupus-prone short-lived (NZBxNZW)F1 mice. Exp Biol Med (Maywood) 2013;238:610-22. [PMID: 23918873 DOI: 10.1177/1535370213489485] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
305 Pacheco GV, Cruz DC, González Herrera LJ, Pérez Mendoza GJ, Adrián Amaro GI, Nakazawa Ueji YE, Angulo Ramírez AV. Copy Number Variation of TLR-7 Gene and its Association with the Development of Systemic Lupus Erythematosus in Female Patients from Yucatan Mexico. Genet Epigenet 2014;6:31-6. [PMID: 25512712 DOI: 10.4137/GEG.S16707] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
306 Gandino IJ, Scolnik M, Bertiller E, Scaglioni V, Catoggio LJ, Soriano ER. Complement levels and risk of organ involvement in patients with systemic lupus erythematosus. Lupus Sci Med 2017;4:e000209. [PMID: 29259790 DOI: 10.1136/lupus-2017-000209] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
307 Abdelaziz MM, Goma SH, Sayed SK, El-hammady DH, Gamal RM, Sayed DS. Influence of prolactin and estrogen on disease activity in patients with systemic lupus erythematosus. Egypt Rheumatol Rehabil 2018;45:117-23. [DOI: 10.4103/err.err_18_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
308 Asano T, Ito H, Kariya Y, Hoshi K, Yoshihara A, Ugawa Y, Sekine H, Hirohata S, Yamaguchi Y, Sato S, Kobayashi H, Migita K, Ohira H, Hashimoto Y, Watanabe H. Evaluation of blood-brain barrier function by quotient alpha2 macroglobulin and its relationship with interleukin-6 and complement component 3 levels in neuropsychiatric systemic lupus erythematosus. PLoS One 2017;12:e0186414. [PMID: 29036223 DOI: 10.1371/journal.pone.0186414] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
309 Nieves-Plaza M, Ortiz AP, Colón M, Molina MJ, Castro-Santana LE, Rodríguez VE, Mayor AM, Vilá LM. Outcome and predictors of kidney disease progression in Puerto Ricans with systemic lupus erythematosus initially presenting with mild renal involvement. J Clin Rheumatol 2011;17:179-84. [PMID: 21617555 DOI: 10.1097/RHU.0b013e31821c020a] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
310 Beisel C, Weiler-Normann C, Teufel A, Lohse AW. Association of autoimmune hepatitis and systemic lupus erythematodes: A case series and review of the literature. World J Gastroenterol 2014; 20(35): 12662-12667 [PMID: 25253972 DOI: 10.3748/wjg.v20.i35.12662] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
311 Kariuki SN, Niewold TB. Genetic regulation of serum cytokines in systemic lupus erythematosus. Transl Res 2010;155:109-17. [PMID: 20171594 DOI: 10.1016/j.trsl.2009.08.012] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 3.9] [Reference Citation Analysis]
312 Kavanagh D, Spitzer D, Kothari PH, Shaikh A, Liszewski MK, Richards A, Atkinson JP. New roles for the major human 3'-5' exonuclease TREX1 in human disease. Cell Cycle 2008;7:1718-25. [PMID: 18583934 DOI: 10.4161/cc.7.12.6162] [Cited by in Crossref: 93] [Cited by in F6Publishing: 81] [Article Influence: 6.6] [Reference Citation Analysis]
313 Buonavoglia A, Leone P, Prete M, Solimando AG, Guastadisegno C, Lanave G, Camero M, Martella V, Lo Muzio L, Racanelli V. Epstein-Barr Virus in Salivary Samples from Systemic Lupus Erythematosus Patients with Oral Lesions. J Clin Med 2021;10:4995. [PMID: 34768514 DOI: 10.3390/jcm10214995] [Reference Citation Analysis]
314 Aggarwal R, Sestak AL, D'Souza A, Dillon SP, Namjou B, Scofield RH. Complete complement deficiency in a large cohort of familial systemic lupus erythematosus. Lupus 2010;19:52-7. [PMID: 19910391 DOI: 10.1177/0961203309346508] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
315 Wadi W, Elhefny NE, Mahgoub EH, Almogren A, Hamam KD, Al-Hamed HA, Gasim GI. Relation between HLA typing and clinical presentations in Systemic Lupus Erythematosus patients in Al-Qassim region, Saudi Arabia. Int J Health Sci (Qassim) 2014;8:159-65. [PMID: 25246883 DOI: 10.12816/0006082] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
316 Cai Z, Xie C, Qiao W, Fei X, Guo X, Liu H, Li X, Fang X, Xu G, Dou H, Deng GM. The Role of Estrogen Membrane Receptor (G Protein-Coupled Estrogen Receptor 1) in Skin Inflammation Induced by Systemic Lupus Erythematosus Serum IgG. Front Immunol 2017;8:1723. [PMID: 29255468 DOI: 10.3389/fimmu.2017.01723] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
317 Rekvig OP, Van der Vlag J. The pathogenesis and diagnosis of systemic lupus erythematosus: still not resolved. Semin Immunopathol 2014;36:301-11. [PMID: 24763531 DOI: 10.1007/s00281-014-0428-6] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 6.8] [Reference Citation Analysis]
318 Hobeika L, Ng L, Lee IJ. Moving Forward With Biologics in Lupus Nephritis. Adv Chronic Kidney Dis 2019;26:338-50. [PMID: 31733718 DOI: 10.1053/j.ackd.2019.08.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
319 Chen HH, Yuan H, Cho H, Feng Y, Ngoy S, Kumar AT, Liao R, Chao W, Josephson L, Sosnovik DE. Theranostic Nucleic Acid Binding Nanoprobe Exerts Anti-inflammatory and Cytoprotective Effects in Ischemic Injury. Theranostics 2017;7:814-25. [PMID: 28382156 DOI: 10.7150/thno.17366] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
320 Singh R, Pradhan V, Patwardhan M, Ghosh K. APO-1/Fas gene: Structural and functional characteristics in systemic lupus erythematosus and other autoimmune diseases. Indian J Hum Genet 2009;15:98-102. [PMID: 21088713 DOI: 10.4103/0971-6866.60184] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
321 Riva M, Källberg E, Björk P, Hancz D, Vogl T, Roth J, Ivars F, Leanderson T. Induction of nuclear factor-κB responses by the S100A9 protein is Toll-like receptor-4-dependent. Immunology 2012;137:172-82. [PMID: 22804476 DOI: 10.1111/j.1365-2567.2012.03619.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 81] [Article Influence: 7.9] [Reference Citation Analysis]
322 Yeo JG, Leong J, Arkachaisri T, Cai Y, Teo BH, Tan JH, Das L, Lu J. Proteolytic inactivation of nuclear alarmin high-mobility group box 1 by complement protease C1s during apoptosis. Cell Death Discov 2016;2:16069. [PMID: 27648302 DOI: 10.1038/cddiscovery.2016.69] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
323 Sezin T, Vorobyev A, Sadik CD, Zillikens D, Gupta Y, Ludwig RJ. Gene Expression Analysis Reveals Novel Shared Gene Signatures and Candidate Molecular Mechanisms between Pemphigus and Systemic Lupus Erythematosus in CD4+ T Cells. Front Immunol 2017;8:1992. [PMID: 29387060 DOI: 10.3389/fimmu.2017.01992] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
324 Shu W, Guan S, Yang X, Liang L, Li J, Chen Z, Zhang Y, Chen L, Wang X, Huang M. Genetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus. Br J Clin Pharmacol 2016;81:327-40. [PMID: 26456622 DOI: 10.1111/bcp.12800] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
325 Suh CH, Hilliard B, Li S, Merrill JT, Cohen PL. TAM receptor ligands in lupus: protein S but not Gas6 levels reflect disease activity in systemic lupus erythematosus. Arthritis Res Ther 2010;12:R146. [PMID: 20637106 DOI: 10.1186/ar3088] [Cited by in Crossref: 74] [Cited by in F6Publishing: 63] [Article Influence: 6.2] [Reference Citation Analysis]
326 Linterman MA, Rigby RJ, Wong RK, Yu D, Brink R, Cannons JL, Schwartzberg PL, Cook MC, Walters GD, Vinuesa CG. Follicular helper T cells are required for systemic autoimmunity. J Exp Med 2009;206:561-76. [PMID: 19221396 DOI: 10.1084/jem.20081886] [Cited by in Crossref: 446] [Cited by in F6Publishing: 420] [Article Influence: 34.3] [Reference Citation Analysis]
327 Okamoto H, Kobayashi A, Yamanaka H. Cytokines and chemokines in neuropsychiatric syndromes of systemic lupus erythematosus. J Biomed Biotechnol 2010;2010:268436. [PMID: 20617145 DOI: 10.1155/2010/268436] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
328 El Guindy NM, Abdel Ghaffar HA, El Refai RM, El Hawary RE. Cytotoxic T lymphocyte antigen-4 gene polymorphism in systemic lupus erythematosus Egyptian patients. Comp Clin Pathol 2015;24:41-5. [DOI: 10.1007/s00580-013-1852-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
329 Sun L, Akiyama K, Zhang H, Yamaza T, Hou Y, Zhao S, Xu T, Le A, Shi S. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells. 2009;27:1421-1432. [PMID: 19489103 DOI: 10.1002/stem.68] [Cited by in Crossref: 391] [Cited by in F6Publishing: 371] [Article Influence: 30.1] [Reference Citation Analysis]
330 Ji J, Xu J, Li F, Li X, Gong W, Song Y, Dou H, Hou Y. A benzenediamine derivate FC-99 attenuates lupus nephritis in MRL/lpr mice via inhibiting myeloid dendritic cell-secreted BAFF. Acta Biochim Biophys Sin (Shanghai) 2016;48:411-9. [PMID: 27121231 DOI: 10.1093/abbs/gmw017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
331 Ganesan K, Quiles JL, Daglia M, Xiao J, Xu B. Dietary phytochemicals modulate intestinal epithelial barrier dysfunction and autoimmune diseases. Food Frontiers 2021;2:357-82. [DOI: 10.1002/fft2.102] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
332 Jang DH, Lee JI, Bae JY, Jung HJ, Park MY, Ahn J. Facial erythema after the treatment of dupilumab in SLE patient. Allergy Asthma Clin Immunol 2020;16:60. [PMID: 32944024 DOI: 10.1186/s13223-020-00458-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
333 Carlsson A, Wuttge DM, Ingvarsson J, Bengtsson AA, Sturfelt G, Borrebaeck CA, Wingren C. Serum protein profiling of systemic lupus erythematosus and systemic sclerosis using recombinant antibody microarrays. Mol Cell Proteomics 2011;10:M110.005033. [PMID: 21350050 DOI: 10.1074/mcp.M110.005033] [Cited by in Crossref: 54] [Cited by in F6Publishing: 22] [Article Influence: 4.9] [Reference Citation Analysis]
334 Crispín JC, Oukka M, Bayliss G, Cohen RA, Van Beek CA, Stillman IE, Kyttaris VC, Juang YT, Tsokos GC. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol 2008;181:8761-6. [PMID: 19050297 DOI: 10.4049/jimmunol.181.12.8761] [Cited by in Crossref: 490] [Cited by in F6Publishing: 464] [Article Influence: 37.7] [Reference Citation Analysis]
335 Infante B, Rossini M, Leo S, Troise D, Netti GS, Ranieri E, Gesualdo L, Castellano G, Stallone G. Recurrent Glomerulonephritis after Renal Transplantation: The Clinical Problem. Int J Mol Sci 2020;21:E5954. [PMID: 32824988 DOI: 10.3390/ijms21175954] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
336 López P, Alonso-Pérez E, Rodríguez-Carrio J, Suárez A. Influence of Atg5 mutation in SLE depends on functional IL-10 genotype. PLoS One 2013;8:e78756. [PMID: 24205307 DOI: 10.1371/journal.pone.0078756] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
337 Applyrs DL, Williams EM, Faith TD, Kamen DL, Vazques E, Jurkowski JM. Cultural and quality-of-life considerations when administering corticosteroids as a therapeutic strategy for African American women living with systemic lupus erythematosus. Patient Prefer Adherence 2018;12:1007-14. [PMID: 29928116 DOI: 10.2147/PPA.S156457] [Reference Citation Analysis]
338 Li Y, Wu Z, Zhang S, Chen S, Li P, Li J, Cao C, Liu B, Zhang F, Li Y. Genetic Variants of IκB Kinase β (IKBKB) and Polymerase β (POLB) Were Not Associated with Systemic Lupus Erythematosus Risk in a Chinese Han Population. PLoS One 2015;10:e0132556. [PMID: 26167925 DOI: 10.1371/journal.pone.0132556] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
339 Oliveira ALB, Monteiro VVS, Navegantes-Lima KC, Reis JF, Gomes RS, Rodrigues DVS, Gaspar SLF, Monteiro MC. Resveratrol Role in Autoimmune Disease-A Mini-Review. Nutrients 2017;9:E1306. [PMID: 29194364 DOI: 10.3390/nu9121306] [Cited by in Crossref: 59] [Cited by in F6Publishing: 39] [Article Influence: 11.8] [Reference Citation Analysis]
340 Ge Y, Jiang C, Sung SS, Bagavant H, Dai C, Wang H, Kannapell CC, Cathro HP, Gaskin F, Fu SM. Cgnz1 allele confers kidney resistance to damage preventing progression of immune complex-mediated acute lupus glomerulonephritis. J Exp Med 2013;210:2387-401. [PMID: 24101379 DOI: 10.1084/jem.20130731] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
341 Biesen R, Dähnrich C, Rosemann A, Barkhudarova F, Rose T, Jakob O, Bruns A, Backhaus M, Stöcker W, Burmester GR, Schlumberger W, Egerer K, Hiepe F. Anti-dsDNA-NcX ELISA: dsDNA-loaded nucleosomes improve diagnosis and monitoring of disease activity in systemic lupus erythematosus. Arthritis Res Ther 2011;13:R26. [PMID: 21329504 DOI: 10.1186/ar3250] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
342 Umiker BR, Andersson S, Fernandez L, Korgaokar P, Larbi A, Pilichowska M, Weinkauf CC, Wortis HH, Kearney JF, Imanishi-Kari T. Dosage of X-linked Toll-like receptor 8 determines gender differences in the development of systemic lupus erythematosus. Eur J Immunol 2014;44:1503-16. [PMID: 24500834 DOI: 10.1002/eji.201344283] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
343 Yamaza T, Kentaro A, Chen C, Liu Y, Shi Y, Gronthos S, Wang S, Shi S. Immunomodulatory properties of stem cells from human exfoliated deciduous teeth. Stem Cell Res Ther. 2010;1:5. [PMID: 20504286 DOI: 10.1186/scrt5] [Cited by in Crossref: 191] [Cited by in F6Publishing: 177] [Article Influence: 15.9] [Reference Citation Analysis]
344 Pretel M, Marquès L, España A. Drug-Induced Lupus Erythematosus. Actas Dermo-Sifiliográficas (English Edition) 2014;105:18-30. [DOI: 10.1016/j.adengl.2012.09.025] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
345 Pan Q, Li Y, Ye L, Deng Z, Li L, Feng Y, Liu W, Liu H. Geographical distribution, a risk factor for the incidence of lupus nephritis in China. BMC Nephrol 2014;15:67. [PMID: 24885458 DOI: 10.1186/1471-2369-15-67] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
346 Bosch X, Lozano F, Cervera R, Ramos-Casals M, Min B. Basophils, IgE, and autoantibody-mediated kidney disease. J Immunol 2011;186:6083-90. [PMID: 21597041 DOI: 10.4049/jimmunol.1002648] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
347 Porteous H, Morgan N, Lanfranco J, Garcia-Buitrago M, Young L, Lenz O. Systemic lupus erythematosus associated with type 4 renal tubular acidosis: a case report and review of the literature. J Med Case Rep 2011;5:114. [PMID: 21435204 DOI: 10.1186/1752-1947-5-114] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
348 Yamada J, Peracchi OA, Terreri MT, de Moraes-Pinto MI. Cell activation, PD-1 expression and in vitro cytokine production in patients with juvenile systemic lupus erythematosus. Lupus 2022;:9612033221112809. [PMID: 35849633 DOI: 10.1177/09612033221112809] [Reference Citation Analysis]
349 Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, Chatham WW, Strand V, Weinstein A, Chevrier MR, Zhong ZJ, Freimuth WW. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009;61:1143-51. [PMID: 19714615 DOI: 10.1002/art.24698] [Cited by in Crossref: 289] [Cited by in F6Publishing: 254] [Article Influence: 22.2] [Reference Citation Analysis]
350 Xue Z, Zhang X, Chen M, Lu X, Deng R, Ma Y. Dendritic Cells Transduced with Single Immunoglobulin IL-1-Related Receptor Exhibit Immature Properties and Prolong Islet Allograft Survival. Front Immunol 2017;8:1671. [PMID: 29250066 DOI: 10.3389/fimmu.2017.01671] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
351 Luo Q, Ye J, Zeng L, Li X, Fang L, Ju B, Huang Z, Li J. Elevated expression of TIGIT on CD3+CD4+ T cells correlates with disease activity in systemic lupus erythematosus. Allergy Asthma Clin Immunol 2017;13:15. [PMID: 28261278 DOI: 10.1186/s13223-017-0188-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
352 Noble PW, Young MR, Bernatsky S, Weisbart RH, Hansen JE. A nucleolytic lupus autoantibody is toxic to BRCA2-deficient cancer cells. Sci Rep 2014;4:5958. [PMID: 25091037 DOI: 10.1038/srep05958] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
353 Tsai YG, Lee CY, Lin TY, Lin CY. CD8+ Treg cells associated with decreasing disease activity after intravenous methylprednisolone pulse therapy in lupus nephritis with heavy proteinuria. PLoS One. 2014;9:e81344. [PMID: 24475019 DOI: 10.1371/journal.pone.0081344] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
354 Sreih A, Ezzeddine R, Leng L, LaChance A, Yu G, Mizue Y, Subrahmanyan L, Pons-Estel BA, Abelson AK, Gunnarsson I, Svenungsson E, Cavett J, Glenn S, Zhang L, Montgomery R, Perl A, Salmon J, Alarcón-Riquelme ME, Harley JB, Bucala R. Dual effect of the macrophage migration inhibitory factor gene on the development and severity of human systemic lupus erythematosus. Arthritis Rheum 2011;63:3942-51. [PMID: 22127710 DOI: 10.1002/art.30624] [Cited by in Crossref: 72] [Cited by in F6Publishing: 73] [Article Influence: 7.2] [Reference Citation Analysis]
355 Merrill JT, Immermann F, Whitley M, Zhou T, Hill A, O'Toole M, Reddy P, Honczarenko M, Thanou A, Rawdon J, Guthridge JM, James JA, Sridharan S. The Biomarkers of Lupus Disease Study: A Bold Approach May Mitigate Interference of Background Immunosuppressants in Clinical Trials. Arthritis Rheumatol 2017;69:1257-66. [PMID: 28257602 DOI: 10.1002/art.40086] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
356 Zidan HE, Sabbah NA, Hagrass HA, Tantawy EA, El-Shahawy EE, Nageeb GS, Abdul-Sattar AB. Association of FcγRIIB and FcγRIIA R131H gene polymorphisms with renal involvement in Egyptian systemic lupus erythematosus patients. Mol Biol Rep 2014;41:733-9. [PMID: 24366619 DOI: 10.1007/s11033-013-2912-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
357 Di Piazza A, Vernuccio F, Costanzo M, Scopelliti L, Picone D, Midiri F, Salvaggi F, Cupido F, Galia M, Salerno S, Lo Casto A, Midiri M, Lo Re G, Lagalla R. The Videofluorographic Swallowing Study in Rheumatologic Diseases: A Comprehensive Review. Gastroenterol Res Pract 2017;2017:7659273. [PMID: 28706536 DOI: 10.1155/2017/7659273] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
358 Reshetnyak TM, Doroshkevich IA, Seredavkina NV, Nasonov EL, Maev IV, Reshetnyak VI. The Contribution of Drugs and Helicobacter pylori to Gastric Mucosa Changes in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome. Int J Rheumatol. 2019;2019:9698086. [PMID: 31191660 DOI: 10.1155/2019/9698086] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
359 Neumann K, Tiegs G. Immune regulation in renal inflammation. Cell Tissue Res 2021. [PMID: 33496881 DOI: 10.1007/s00441-020-03351-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
360 Aringer M, Vital E. Lots of autoantibodies equal lupus? Arthritis Res Ther 2013;15:102. [PMID: 23347779 DOI: 10.1186/ar4126] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
361 Liu S, Liu D, Chen C, Hamamura K, Moshaverinia A, Yang R, Liu Y, Jin Y, Shi S. MSC Transplantation Improves Osteopenia via Epigenetic Regulation of Notch Signaling in Lupus. Cell Metab 2015;22:606-18. [PMID: 26365178 DOI: 10.1016/j.cmet.2015.08.018] [Cited by in Crossref: 122] [Cited by in F6Publishing: 126] [Article Influence: 17.4] [Reference Citation Analysis]
362 Lodolce JP, Kolodziej LE, Rhee L, Kariuki SN, Franek BS, McGreal NM, Logsdon MF, Bartulis SJ, Perera MA, Ellis NA, Adams EJ, Hanauer SB, Jolly M, Niewold TB, Boone DL. African-derived genetic polymorphisms in TNFAIP3 mediate risk for autoimmunity. J Immunol 2010;184:7001-9. [PMID: 20483768 DOI: 10.4049/jimmunol.1000324] [Cited by in Crossref: 75] [Cited by in F6Publishing: 75] [Article Influence: 6.3] [Reference Citation Analysis]
363 Zickert A, Amoudruz P, Sundström Y, Rönnelid J, Malmström V, Gunnarsson I. IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment. BMC Immunol 2015;16:7. [PMID: 25887118 DOI: 10.1186/s12865-015-0070-7] [Cited by in Crossref: 62] [Cited by in F6Publishing: 65] [Article Influence: 8.9] [Reference Citation Analysis]
364 Zhang W, Zhou Q, Xu W, Cai Y, Yin Z, Gao X, Xiong S. DNA-dependent activator of interferon-regulatory factors (DAI) promotes lupus nephritis by activating the calcium pathway. J Biol Chem 2013;288:13534-50. [PMID: 23553627 DOI: 10.1074/jbc.M113.457218] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
365 Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62:222-233. [PMID: 20039413 DOI: 10.1002/art.27233] [Cited by in Crossref: 787] [Cited by in F6Publishing: 649] [Article Influence: 65.6] [Reference Citation Analysis]
366 Bollain-Y-Goytia JJ, González-Castañeda M, Torres-Del-Muro F, Daza-Benitez L, Zapata-Benavides P, Rodríguez-Padilla C, Avalos-Díaz E, Herrera-Esparza R. Increased excretion of urinary podocytes in lupus nephritis. Indian J Nephrol 2011;21:166-71. [PMID: 21886975 DOI: 10.4103/0971-4065.83029] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
367 Taddeo A, Khodadadi L, Voigt C, Mumtaz IM, Cheng Q, Moser K, Alexander T, Manz RA, Radbruch A, Hiepe F, Hoyer BF. Long-lived plasma cells are early and constantly generated in New Zealand Black/New Zealand White F1 mice and their therapeutic depletion requires a combined targeting of autoreactive plasma cells and their precursors. Arthritis Res Ther 2015;17:39. [PMID: 25889236 DOI: 10.1186/s13075-015-0551-3] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 5.9] [Reference Citation Analysis]
368 Danila MI, Pons-Estel GJ, Zhang J, Vilá LM, Reveille JD, Alarcón GS. Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort. Rheumatology (Oxford) 2009;48:542-5. [PMID: 19233884 DOI: 10.1093/rheumatology/kep012] [Cited by in Crossref: 130] [Cited by in F6Publishing: 110] [Article Influence: 10.0] [Reference Citation Analysis]
369 Todorova N, Rangelov M, Bogoeva V, Stoyanova V, Yordanova A, Nikolova G, Georgiev H, Dimitrova D, Mohedin S, Stoyanova K, Tsacheva I. Anti-Idiotype scFv Localizes an Autoepitope in the Globular Domain of C1q. Int J Mol Sci 2021;22:8288. [PMID: 34361054 DOI: 10.3390/ijms22158288] [Reference Citation Analysis]
370 Faith TD, Egede L, Williams EM. Research Ethics in Behavioral Interventions Among Special Populations: Lessons From the Peer Approaches to Lupus Self-Management Study. Am J Med Sci 2018;355:104-12. [PMID: 29406037 DOI: 10.1016/j.amjms.2017.08.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
371 Du AX, Gniadecki R, Osman M. Biomarkers of B cell activation in autoimmune connective tissue diseases: More than markers of disease activity. Clin Biochem 2021:S0009-9120(21)00308-8. [PMID: 34822848 DOI: 10.1016/j.clinbiochem.2021.11.009] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
372 Wang W, Yao T, Zhang T, Quan M, Wang C, Wang C, Zhang L, Tang X, Jian S, Song H. Selective immunoglobulin A deficiency (SIgAD) primarily leads to recurrent infections and autoimmune diseases: A retrospective study of Chinese patients in the past 40 years. Genes Dis 2020;7:115-21. [PMID: 32181282 DOI: 10.1016/j.gendis.2019.10.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
373 Kumar N, Goldminz AM, Kim N, Gottlieb AB. Phosphodiesterase 4-targeted treatments for autoimmune diseases. BMC Med 2013;11:96. [PMID: 23557064 DOI: 10.1186/1741-7015-11-96] [Cited by in Crossref: 67] [Cited by in F6Publishing: 62] [Article Influence: 7.4] [Reference Citation Analysis]
374 Aguilar-Vazquez A, Chavarria-Avila E, Pizano-Martinez O, Ramos-Hernandez A, Andrade-Ortega L, Rubio-Arellano ED, Vazquez-Del Mercado M. Geographical Latitude Remains as an Important Factor for the Prevalence of Some Myositis Autoantibodies: A Systematic Review. Front Immunol 2021;12:672008. [PMID: 33968081 DOI: 10.3389/fimmu.2021.672008] [Reference Citation Analysis]
375 Smith BJ. Systemic Lupus Erythematosus. Physician Assistant Clinics 2021;6:61-73. [DOI: 10.1016/j.cpha.2020.08.005] [Reference Citation Analysis]
376 Ahn SS, Yoo J, Jung SM, Song JJ, Park YB, Lee SW. Comparison of clinical features and outcomes between patients with early and delayed lupus nephritis. BMC Nephrol 2020;21:258. [PMID: 32635898 DOI: 10.1186/s12882-020-01915-5] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
377 Afzali P, Isaeian A, Sadeghi P, Moazzami B, Parvaneh N, Robatjazi M, Ziaee V. Complement deficiency in pediatric-onset systemic lupus erythematosus. J Lab Physicians 2018;10:232-6. [PMID: 29692593 DOI: 10.4103/JLP.JLP_171_17] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
378 Williams EM, Hyer JM, Viswanathan R, Faith TD, Egede L, Oates JC, Marshall GD. Cytokine balance and behavioral intervention; findings from the Peer Approaches to Lupus Self-Management (PALS) project. Hum Immunol 2017;78:574-81. [PMID: 28716698 DOI: 10.1016/j.humimm.2017.07.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
379 Degn SE, van der Poel CE, Carroll MC. Targeting autoreactive germinal centers to curb autoimmunity. Oncotarget 2017;8:90624-5. [PMID: 29207586 DOI: 10.18632/oncotarget.21701] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
380 Frodlund M, Dahlström O, Kastbom A, Skogh T, Sjöwall C. Associations between antinuclear antibody staining patterns and clinical features of systemic lupus erythematosus: analysis of a regional Swedish register. BMJ Open 2013;3:e003608. [PMID: 24163206 DOI: 10.1136/bmjopen-2013-003608] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
381 Zhang Y, Xie L, Lu W, Lv J, Li Y, Shao Y, Sun J. LncRNA MIAT enhances systemic lupus erythematosus by upregulating CFHR5 expression via miR-222 degradation. Cent Eur J Immunol 2021;46:17-26. [PMID: 33897280 DOI: 10.5114/ceji.2021.105242] [Reference Citation Analysis]
382 van Nieuwenhuijze AE, Cauwe B, Klatt D, Humblet-Baron S, Liston A. Lpr-induced systemic autoimmunity is unaffected by mast cell deficiency. Immunol Cell Biol 2015;93:841-8. [PMID: 25849740 DOI: 10.1038/icb.2015.49] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
383 Pushparajah D, Jimenez S, Wong S, Alattas H, Nafissi N, Slavcev RA. Advances in gene-based vaccine platforms to address the COVID-19 pandemic. Adv Drug Deliv Rev 2021;170:113-41. [PMID: 33422546 DOI: 10.1016/j.addr.2021.01.003] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 34.0] [Reference Citation Analysis]
384 Woan KV, Sahakian E, Sotomayor EM, Seto E, Villagra A. Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer. Immunol Cell Biol. 2012;90:55-65. [PMID: 22105512 DOI: 10.1038/icb.2011.96] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 4.2] [Reference Citation Analysis]
385 Song L, Wang Y, Zhang J, Song N, Xu X, Lu Y. The risks of cancer development in systemic lupus erythematosus (SLE) patients: a systematic review and meta-analysis. Arthritis Res Ther 2018;20:270. [PMID: 30522515 DOI: 10.1186/s13075-018-1760-3] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 10.0] [Reference Citation Analysis]
386 Nie Y, Zhao L, Zhang X. B Cell Aberrance in Lupus: the Ringleader and the Solution. Clin Rev Allergy Immunol 2021. [PMID: 33534064 DOI: 10.1007/s12016-020-08820-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
387 Schiffer L, Worthmann K, Haller H, Schiffer M. CXCL13 as a new biomarker of systemic lupus erythematosus and lupus nephritis - from bench to bedside? Clin Exp Immunol 2015;179:85-9. [PMID: 25138065 DOI: 10.1111/cei.12439] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
388 Matsuda S, Kotani T, Saito T, Suzuka T, Mori T, Takeuchi T. Low-Molecular-Weight Heparin Enhanced Therapeutic Effects of Human Adipose-Derived Stem Cell Administration in a Mouse Model of Lupus Nephritis. Front Immunol 2021;12:792739. [PMID: 35095868 DOI: 10.3389/fimmu.2021.792739] [Reference Citation Analysis]
389 Dimitrova M, Zenarruzabeitia O, Borrego F, Simhadri VR. CD300c is uniquely expressed on CD56 bright Natural Killer Cells and differs from CD300a upon ligand recognition. Sci Rep 2016;6:23942. [PMID: 27040328 DOI: 10.1038/srep23942] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
390 Hoffecker BM, Raffield LM, Kamen DL, Nowling TK. Systemic lupus erythematosus and vitamin D deficiency are associated with shorter telomere length among African Americans: a case-control study. PLoS One 2013;8:e63725. [PMID: 23700431 DOI: 10.1371/journal.pone.0063725] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
391 Bell CF, Ajmera MR, Meyers J. An evaluation of costs associated with overall organ damage in patients with systemic lupus erythematosus in the United States. Lupus 2022;:9612033211073670. [PMID: 35060407 DOI: 10.1177/09612033211073670] [Reference Citation Analysis]
392 Degn SE, van der Poel CE, Firl DJ, Ayoglu B, Al Qureshah FA, Bajic G, Mesin L, Reynaud CA, Weill JC, Utz PJ, Victora GD, Carroll MC. Clonal Evolution of Autoreactive Germinal Centers. Cell 2017;170:913-926.e19. [PMID: 28841417 DOI: 10.1016/j.cell.2017.07.026] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 10.0] [Reference Citation Analysis]
393 McDonald G, Deepak S, Miguel L, Hall CJ, Isenberg DA, Magee AI, Butters T, Jury EC. Normalizing glycosphingolipids restores function in CD4+ T cells from lupus patients. J Clin Invest 2014;124:712-24. [PMID: 24463447 DOI: 10.1172/JCI69571] [Cited by in Crossref: 84] [Cited by in F6Publishing: 55] [Article Influence: 10.5] [Reference Citation Analysis]
394 Ugarte-gil MF, Mak A, Leong J, Dharmadhikari B, Kow NY, Reátegui-sokolova C, Elera-fitzcarrald C, Aranow C, Arnaud L, Askanase AD, Bae S, Bernatsky S, Bruce IN, Buyon J, Costedoat-chalumeau N, Dooley MA, Fortin PR, Ginzler EM, Gladman DD, Hanly J, Inanc M, Isenberg D, Jacobsen S, James JA, Jönsen A, Kalunian K, Kamen DL, Lim SS, Morand E, Mosca M, Peschken C, Pons-estel BA, Rahman A, Ramsey-goldman R, Reynolds J, Romero-diaz J, Ruiz-irastorza G, Sánchez-guerrero J, Svenungsson E, Urowitz M, Vinet E, van Vollenhoven RF, Voskuyl A, Wallace DJ, Petri MA, Manzi S, Clarke AE, Cheung M, Farewell V, Alarcon GS. Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Sci Med 2021;8:e000590. [DOI: 10.1136/lupus-2021-000590] [Reference Citation Analysis]
395 Morawski PA, Bolland S. Expanding the B Cell-Centric View of Systemic Lupus Erythematosus. Trends Immunol 2017;38:373-82. [PMID: 28274696 DOI: 10.1016/j.it.2017.02.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
396 Sciascia S, Radin M, Roccatello D, Sanna G, Bertolaccini ML. Recent advances in the management of systemic lupus erythematosus. F1000Res 2018;7:F1000 Faculty Rev-970. [PMID: 30026918 DOI: 10.12688/f1000research.13941.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
397 Delgado-Vega AM, Martínez-Bueno M, Oparina NY, López Herráez D, Kristjansdottir H, Steinsson K, Kozyrev SV, Alarcón-Riquelme ME. Whole Exome Sequencing of Patients from Multicase Families with Systemic Lupus Erythematosus Identifies Multiple Rare Variants. Sci Rep 2018;8:8775. [PMID: 29884787 DOI: 10.1038/s41598-018-26274-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
398 Flournoy-Floyd M, Ortiz K, Egede L, Oates JC, Faith TD, Williams EM. "We Would Still Find Things to Talk About": Assessment of Mentor Perspectives in a Systemic Lupus Erythematosus Intervention to Improve Disease Self-Management, Empowering SLE Patients. J Natl Med Assoc 2018;110:182-9. [PMID: 29580453 DOI: 10.1016/j.jnma.2017.05.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
399 Lee J, Jang S, Choi M, Kang M, Lim SG, Kim SY, Jang S, Ko J, Kim E, Yi J, Choo Y, Kim MO, Ryoo ZY. Overexpression of cathepsin S exacerbates lupus pathogenesis through upregulation TLR7 and IFN-α in transgenic mice. Sci Rep 2021;11:16348. [PMID: 34381063 DOI: 10.1038/s41598-021-94855-5] [Reference Citation Analysis]
400 Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, Ginzler EM, D’Cruz DP, Doria A, Cooper S. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012;71:1833-1838. [PMID: 22550315 DOI: 10.1136/annrheumdis-2011-200831.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
401 Puerta G, De Paz D, Aguirre-valencia D, Ahumada F, Silva N, Bravo JC, Echeverri A. TAFRO syndrome mimicking systemic lupus erythematosus: Case report and literature review. Revista Colombiana de Reumatología 2021. [DOI: 10.1016/j.rcreu.2021.01.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
402 White AA, Smalls BL, Ba A, Faith TD, Ramakrishnan V, Johnson H, Rose J, Dismuke-Greer CL, Oates JC, Egede LE, Williams EM. The Effect of Travel Burden on Depression and Anxiety in African American Women Living with Systemic Lupus. Healthcare (Basel) 2021;9:1507. [PMID: 34828553 DOI: 10.3390/healthcare9111507] [Reference Citation Analysis]
403 Batool S, Ahmad NM, Saeed MA, Farman S. Pattern of initial clinical manifestations of systemic lupus erythematosus in a tertiary care hospital. Pak J Med Sci 2016;32:1066-70. [PMID: 27881995 DOI: 10.12669/pjms.325.11480] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
404 Schmitt H, Sell S, Koch J, Seefried M, Sonnewald S, Daniel C, Winkler TH, Nitschke L. Siglec-H protects from virus-triggered severe systemic autoimmunity. J Exp Med 2016;213:1627-44. [PMID: 27377589 DOI: 10.1084/jem.20160189] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
405 Al-Shamahy HA, Dhaifallah NH, Al-Ezzy YM. Clinical and laboratory manifestations of yemeni patients with systemic lupus erythematosus. Sultan Qaboos Univ Med J 2014;14:e80-7. [PMID: 24516759 DOI: 10.12816/0003340] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
406 Andrade D, Redecha PB, Vukelic M, Qing X, Perino G, Salmon JE, Koo GC. Engraftment of peripheral blood mononuclear cells from systemic lupus erythematosus and antiphospholipid syndrome patient donors into BALB-RAG-2-/- IL-2Rγ-/- mice: a promising model for studying human disease. Arthritis Rheum 2011;63:2764-73. [PMID: 21560114 DOI: 10.1002/art.30424] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
407 Reddy PS, Legault HM, Sypek JP, Collins MJ, Goad E, Goldman SJ, Liu W, Murray S, Dorner AJ, O'Toole M. Mapping similarities in mTOR pathway perturbations in mouse lupus nephritis models and human lupus nephritis. Arthritis Res Ther 2008;10:R127. [PMID: 18980674 DOI: 10.1186/ar2541] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
408 Lee T, Pelletier J. The biology of DHX9 and its potential as a therapeutic target. Oncotarget 2016;7:42716-39. [PMID: 27034008 DOI: 10.18632/oncotarget.8446] [Cited by in Crossref: 61] [Cited by in F6Publishing: 62] [Article Influence: 15.3] [Reference Citation Analysis]
409 Moreth K, Brodbeck R, Babelova A, Gretz N, Spieker T, Zeng-Brouwers J, Pfeilschifter J, Young MF, Schaefer RM, Schaefer L. The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritis. J Clin Invest 2010;120:4251-72. [PMID: 21084753 DOI: 10.1172/JCI42213] [Cited by in Crossref: 128] [Cited by in F6Publishing: 84] [Article Influence: 10.7] [Reference Citation Analysis]
410 Gracia-Tello B, Ezeonyeji A, Isenberg D. The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: long-term steroid saving capacity and clinical effectiveness. Lupus Sci Med 2017;4:e000182. [PMID: 28243455 DOI: 10.1136/lupus-2016-000182] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 4.2] [Reference Citation Analysis]
411 Look M, Stern E, Wang QA, DiPlacido LD, Kashgarian M, Craft J, Fahmy TM. Nanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus in mice. J Clin Invest 2013;123:1741-9. [PMID: 23454752 DOI: 10.1172/JCI65907] [Cited by in Crossref: 77] [Cited by in F6Publishing: 40] [Article Influence: 8.6] [Reference Citation Analysis]
412 Iwata Y, Furuichi K, Kaneko S, Wada T. The role of cytokine in the lupus nephritis. J Biomed Biotechnol 2011;2011:594809. [PMID: 22028590 DOI: 10.1155/2011/594809] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
413 Wang ZL, Luo XF, Li MT, Xu D, Zhou S, Chen HZ, Gao N, Chen Z, Zhang LL, Zeng XF. Resveratrol possesses protective effects in a pristane-induced lupus mouse model. PLoS One 2014;9:e114792. [PMID: 25501752 DOI: 10.1371/journal.pone.0114792] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
414 Wu S, Wang Y, Zhang J, Han B, Wang B, Gao W, Zhang N, Zhang C, Yan F, Li Z. Efficacy and safety of rituximab for systemic lupus erythematosus treatment: a meta-analysis. Afr Health Sci 2020;20:871-84. [PMID: 33163054 DOI: 10.4314/ahs.v20i2.41] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
415 Yelin E, Tonner C, Trupin L, Panopalis P, Yazdany J, Julian L, Katz P, Criswell LA. Work loss and work entry among persons with systemic lupus erythematosus: comparisons with a national matched sample. Arthritis Rheum 2009;61:247-58. [PMID: 19177546 DOI: 10.1002/art.24213] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
416 Wiesik-Szewczyk E, Olesinska M. B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab. Biologics 2012;6:347-54. [PMID: 23055692 DOI: 10.2147/BTT.S25407] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
417 Squatrito D, Emmi G, Silvestri E, Ciucciarelli L, D'Elios MM, Prisco D, Emmi L. Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedside. Auto Immun Highlights 2014;5:33-45. [PMID: 26000154 DOI: 10.1007/s13317-014-0058-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
418 Luo F, Ye Q, Shen J. Systemic lupus erythematosus with trisomy X: a case report and review of the literature. J Med Case Rep 2022;16:281. [PMID: 35850774 DOI: 10.1186/s13256-022-03478-5] [Reference Citation Analysis]
419 Saettini F, Cattoni A, Redaelli M, Silvestri D, Ferrari GM, Biondi A, Jankovic M, Spinelli M. Primary immunodeficiencies, autoimmune hyperthyroidism, coeliac disease and systemic lupus erythematosus in childhood immune thrombocytopenia. Acta Paediatr 2021;110:643-51. [PMID: 33025591 DOI: 10.1111/apa.15593] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
420 Mao L, Hou H, Wu S, Zhou Y, Wang J, Yu J, Wu X, Lu Y, Mao L, Bosco MJ, Wang F, Sun Z. TIGIT signalling pathway negatively regulates CD4+ T-cell responses in systemic lupus erythematosus. Immunology 2017;151:280-90. [PMID: 28108989 DOI: 10.1111/imm.12715] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
421 Draborg AH, Sandhu N, Larsen N, Lisander Larsen J, Jacobsen S, Houen G. Impaired Cytokine Responses to Epstein-Barr Virus Antigens in Systemic Lupus Erythematosus Patients. J Immunol Res 2016;2016:6473204. [PMID: 27110576 DOI: 10.1155/2016/6473204] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
422 Draborg AH, Jacobsen S, Westergaard M, Mortensen S, Larsen JL, Houen G, Duus K. Reduced response to Epstein-Barr virus antigens by T-cells in systemic lupus erythematosus patients. Lupus Sci Med 2014;1:e000015. [PMID: 25396062 DOI: 10.1136/lupus-2014-000015] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
423 Ntatsaki E, Velo-Garcia A, Vassiliou VS, Salama AD, Isenberg DA. Impact of pre-transplant time on dialysis on survival in patients with lupus nephritis. Clin Rheumatol 2018;37:2399-404. [PMID: 29748727 DOI: 10.1007/s10067-018-4115-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
424 Marion TN, Postlethwaite AE. Chance, genetics, and the heterogeneity of disease and pathogenesis in systemic lupus erythematosus. Semin Immunopathol 2014;36:495-517. [PMID: 25102991 DOI: 10.1007/s00281-014-0440-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
425 Karademas EC, Dimitraki G, Papastefanakis E, Ktistaki G, Repa A, Gergianaki I, Bertsias G, Sidiropoulos P, Simos P. Adaptation to inflammatory rheumatic disease: Do illness representations predict patients' physical functioning over time? A complex relationship. J Behav Med 2018;41:232-42. [PMID: 28936564 DOI: 10.1007/s10865-017-9889-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
426 Hur K, Kim SH, Kim JM. Potential Implications of Long Noncoding RNAs in Autoimmune Diseases. Immune Netw 2019;19:e4. [PMID: 30838159 DOI: 10.4110/in.2019.19.e4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 10.7] [Reference Citation Analysis]
427 Lech M, Römmele C, Kulkarni OP, Susanti HE, Migliorini A, Garlanda C, Mantovani A, Anders HJ. Lack of the long pentraxin PTX3 promotes autoimmune lung disease but not glomerulonephritis in murine systemic lupus erythematosus. PLoS One 2011;6:e20118. [PMID: 21637713 DOI: 10.1371/journal.pone.0020118] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
428 Zenewicz LA, Abraham C, Flavell RA, Cho JH. Unraveling the genetics of autoimmunity. Cell 2010;140:791-7. [PMID: 20303870 DOI: 10.1016/j.cell.2010.03.003] [Cited by in Crossref: 89] [Cited by in F6Publishing: 88] [Article Influence: 7.4] [Reference Citation Analysis]
429 Olson SW, Lee JJ, Poirier M, Little DJ, Prince LK, Baker TP, Edison JD, Abbott KC. Anti-Myeloperoxidase Antibodies Associate with Future Proliferative Lupus Nephritis. Autoimmune Dis 2017;2017:1872846. [PMID: 29435367 DOI: 10.1155/2017/1872846] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
430 Lee-Kirsch MA, Wolf C, Günther C. Aicardi-Goutières syndrome: a model disease for systemic autoimmunity. Clin Exp Immunol 2014;175:17-24. [PMID: 23786362 DOI: 10.1111/cei.12160] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 5.5] [Reference Citation Analysis]
431 Leng L, Chen L, Fan J, Greven D, Arjona A, Du X, Austin D, Kashgarian M, Yin Z, Huang XR, Lan HY, Lolis E, Nikolic-Paterson D, Bucala R. A small-molecule macrophage migration inhibitory factor antagonist protects against glomerulonephritis in lupus-prone NZB/NZW F1 and MRL/lpr mice. J Immunol 2011;186:527-38. [PMID: 21106847 DOI: 10.4049/jimmunol.1001767] [Cited by in Crossref: 100] [Cited by in F6Publishing: 87] [Article Influence: 8.3] [Reference Citation Analysis]
432 Gomez Mendez LM, Cascino MD, Garg J, Katsumoto TR, Brakeman P, Dall'Era M, Looney RJ, Rovin B, Dragone L, Brunetta P. Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis. Clin J Am Soc Nephrol 2018;13:1502-9. [PMID: 30089664 DOI: 10.2215/CJN.01070118] [Cited by in Crossref: 42] [Cited by in F6Publishing: 20] [Article Influence: 10.5] [Reference Citation Analysis]
433 Wang JH, Liu XL, Sun JM, Yang JH, Xu DH, Yan SS. Role of mesenchymal stem cell derived extracellular vesicles in autoimmunity: A systematic review. World J Stem Cells 2020; 12(8): 879-896 [PMID: 32952864 DOI: 10.4252/wjsc.v12.i8.879] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
434 Ben Amer HM. Clinical Presentation of Pediatric SLE at Outpatient Clinic. MOJOR 2015;2. [DOI: 10.15406/mojor.2015.02.00032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
435 Vilà L, Roglans N, Baena M, Barroso E, Alegret M, Merlos M, Laguna JC. Metabolic alterations and increased liver mTOR expression precede the development of autoimmune disease in a murine model of lupus erythematosus. PLoS One 2012;7:e51118. [PMID: 23226562 DOI: 10.1371/journal.pone.0051118] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
436 Tipton CM, Hom JR, Fucile CF, Rosenberg AF, Sanz I. Understanding B-cell activation and autoantibody repertoire selection in systemic lupus erythematosus: A B-cell immunomics approach. Immunol Rev 2018;284:120-31. [PMID: 29944759 DOI: 10.1111/imr.12660] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
437 Yung S, Chan TM. Autoantibodies and resident renal cells in the pathogenesis of lupus nephritis: getting to know the unknown. Clin Dev Immunol 2012;2012:139365. [PMID: 22761629 DOI: 10.1155/2012/139365] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 5.8] [Reference Citation Analysis]
438 Sjöwall C, Zickert A, Skogh T, Wetterö J, Gunnarsson I. Serum levels of autoantibodies against C-reactive protein correlate with renal disease activity and response to therapy in lupus nephritis. Arthritis Res Ther 2009;11:R188. [PMID: 20003354 DOI: 10.1186/ar2880] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
439 Xing C, Zhu G, Xiao H, Fang Y, Liu X, Han G, Chen G, Hou C, Shen B, Li Y, Ma N, Wang R. B cells regulate thymic CD8+T cell differentiation in lupus-prone mice. Oncotarget 2017;8:89486-99. [PMID: 29163765 DOI: 10.18632/oncotarget.19002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
440 Fredi M, Gregorini G, Zatti S, Lojacono A, Tincani A. Identifying and managing lupus nephritis during pregnancy. Expert Opinion on Orphan Drugs 2016;4:1021-31. [DOI: 10.1080/21678707.2016.1228452] [Reference Citation Analysis]
441 Baker M, Chaichian Y, Genovese M, Derebail V, Rao P, Chatham W, Bubb M, Lim S, Hajian H, Gurtovaya O, Patel U, Tumlin J. Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy. RMD Open 2020;6:e001490. [PMID: 33380521 DOI: 10.1136/rmdopen-2020-001490] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
442 Zhang W, Wu J, Qiao B, Xu W, Xiong S. Amelioration of lupus nephritis by serum amyloid P component gene therapy with distinct mechanisms varied from different stage of the disease. PLoS One 2011;6:e22659. [PMID: 21799927 DOI: 10.1371/journal.pone.0022659] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
443 Favas C, Isenberg DA. B-cell-depletion therapy in SLE--what are the current prospects for its acceptance? Nat Rev Rheumatol 2009;5:711-6. [PMID: 19946298 DOI: 10.1038/nrrheum.2009.218] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 4.1] [Reference Citation Analysis]
444 Awadh NI, Gorial FI, Hammadi RA, Ibrahim MK, Majeed SH, Mohammed MJ. Mean platelet volume to lymphocyte ratio and platelet distribution width to lymphocyte ratio in Iraqi patients diagnosed with systemic lupus erythematosus. Reumatologia 2022;60:173-82. [PMID: 35875718 DOI: 10.5114/reum.2022.117837] [Reference Citation Analysis]
445 Li J, Wei MM, Song Q, Guo XH, Shao L, Liu Y. Anti-CD22 epratuzumab for systemic lupus erythematosus: A systematic review and meta-analysis of randomized controlled trials. Exp Ther Med 2019;18:1500-6. [PMID: 31316634 DOI: 10.3892/etm.2019.7630] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
446 Lin J, Li N, Chen H, Liu C, Yang B, Ou Q. Serum Cyr61 is associated with clinical disease activity and inflammation in patients with systemic lupus erythematosus. Medicine (Baltimore) 2015;94:e834. [PMID: 25984669 DOI: 10.1097/MD.0000000000000834] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
447 Xing C, Ma N, Xiao H, Wang X, Zheng M, Han G, Chen G, Hou C, Shen B, Li Y, Wang R. Critical role for thymic CD19+CD5+CD1dhiIL-10+ regulatory B cells in immune homeostasis. J Leukoc Biol 2015;97:547-56. [PMID: 25516754 DOI: 10.1189/jlb.3A0414-213RR] [Cited by in Crossref: 39] [Cited by in F6Publishing: 26] [Article Influence: 4.9] [Reference Citation Analysis]
448 Anaya JM, Ramirez-Santana C, Alzate MA, Molano-Gonzalez N, Rojas-Villarraga A. The Autoimmune Ecology. Front Immunol 2016;7:139. [PMID: 27199979 DOI: 10.3389/fimmu.2016.00139] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 8.7] [Reference Citation Analysis]
449 Furukawa H, Kawasaki A, Oka S, Ito I, Shimada K, Sugii S, Hashimoto A, Komiya A, Fukui N, Kondo Y, Ito S, Hayashi T, Matsumoto I, Kusaoi M, Amano H, Nagai T, Hirohata S, Setoguchi K, Kono H, Okamoto A, Chiba N, Suematsu E, Katayama M, Migita K, Suda A, Ohno S, Hashimoto H, Takasaki Y, Sumida T, Nagaoka S, Tsuchiya N, Tohma S. Human leukocyte antigens and systemic lupus erythematosus: a protective role for the HLA-DR6 alleles DRB1*13:02 and *14:03. PLoS One 2014;9:e87792. [PMID: 24498373 DOI: 10.1371/journal.pone.0087792] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
450 Choubey D, Panchanathan R. Absent in Melanoma 2 proteins in SLE. Clin Immunol 2017;176:42-8. [PMID: 28062222 DOI: 10.1016/j.clim.2016.12.011] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
451 Jing C, Castro-Dopico T, Richoz N, Tuong ZK, Ferdinand JR, Lok LSC, Loudon KW, Banham GD, Mathews RJ, Cader Z, Fitzpatrick S, Bashant KR, Kaplan MJ, Kaser A, Johnson RS, Murphy MP, Siegel RM, Clatworthy MR. Macrophage metabolic reprogramming presents a therapeutic target in lupus nephritis. Proc Natl Acad Sci U S A 2020;117:15160-71. [PMID: 32541026 DOI: 10.1073/pnas.2000943117] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
452 Bang SY, Lee CK, Kang YM, Kim HA, Suh CH, Chung WT, Park YB, Choe JY, Kim TJ, Park YW, Yoo DH, Bae SC, Lee HS. Multicenter retrospective analysis of the effectiveness and safety of rituximab in korean patients with refractory systemic lupus erythematosus. Autoimmune Dis 2012;2012:565039. [PMID: 23304457 DOI: 10.1155/2012/565039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
453 Yi YS, Son YJ, Ryou C, Sung GH, Kim JH, Cho JY. Functional roles of Syk in macrophage-mediated inflammatory responses. Mediators Inflamm 2014;2014:270302. [PMID: 25045209 DOI: 10.1155/2014/270302] [Cited by in Crossref: 79] [Cited by in F6Publishing: 86] [Article Influence: 9.9] [Reference Citation Analysis]
454 Gregersen JW, Jayne DR. B-cell depletion in the treatment of lupus nephritis. Nat Rev Nephrol 2012;8:505-14. [PMID: 22801948 DOI: 10.1038/nrneph.2012.141] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 5.3] [Reference Citation Analysis]
455 Lichtman EI, Helfgott SM, Kriegel MA. Emerging therapies for systemic lupus erythematosus--focus on targeting interferon-alpha. Clin Immunol 2012;143:210-21. [PMID: 22525889 DOI: 10.1016/j.clim.2012.03.005] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 6.0] [Reference Citation Analysis]
456 Sowa M, Trezzi B, Hiemann R, Schierack P, Grossmann K, Scholz J, Somma V, Sinico RA, Roggenbuck D, Radice A. Simultaneous comprehensive multiplex autoantibody analysis for rapidly progressive glomerulonephritis. Medicine (Baltimore) 2016;95:e5225. [PMID: 27858870 DOI: 10.1097/MD.0000000000005225] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
457 Zhou Y, Chen H, Liu L, Yu X, Sukhova GK, Yang M, Kyttaris VC, Stillman IE, Gelb B, Libby P, Tsokos GC, Shi GP. Cathepsin K Deficiency Ameliorates Systemic Lupus Erythematosus-like Manifestations in Faslpr Mice. J Immunol 2017;198:1846-54. [PMID: 28093526 DOI: 10.4049/jimmunol.1501145] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
458 Zecevic L, Karamehic J, Coric J, Stubljar D, Avdagic N, Selmanovic K, Jukic T, Savic S. Potential Immune Biomarkers in Diagnosis and Clinical Management for Systemic Lupus Erythematosus. J Med Biochem 2018;37:163-71. [PMID: 30581353 DOI: 10.1515/jomb-2017-0048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
459 Liu CC, Kao AH, Manzi S, Ahearn JM. Biomarkers in systemic lupus erythematosus: challenges and prospects for the future. Ther Adv Musculoskelet Dis 2013;5:210-33. [PMID: 23904865 DOI: 10.1177/1759720X13485503] [Cited by in Crossref: 59] [Cited by in F6Publishing: 25] [Article Influence: 6.6] [Reference Citation Analysis]
460 Wang D, Chen X, Fu M, Li Z. Transcriptomics analysis of sirolimus treatment in lupus nephritis. Mol Med Rep 2019;20:245-51. [PMID: 31115581 DOI: 10.3892/mmr.2019.10238] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
461 Fang X, Zaman MH, Guo X, Ding H, Xie C, Zhang X, Deng GM. Role of Hepatic Deposited Immunoglobulin G in the Pathogenesis of Liver Damage in Systemic Lupus Erythematosus. Front Immunol 2018;9:1457. [PMID: 29988500 DOI: 10.3389/fimmu.2018.01457] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
462 Liu Y, Zhou S, Qian J, Wang Y, Yu X, Dai D, Dai M, Wu L, Liao Z, Xue Z, Wang J, Hou G, Ma J, Harley JB, Tang Y, Shen N. T-bet+CD11c+ B cells are critical for antichromatin immunoglobulin G production in the development of lupus. Arthritis Res Ther 2017;19:225. [PMID: 28982388 DOI: 10.1186/s13075-017-1438-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
463 Honarpisheh M, Desai J, Marschner JA, Weidenbusch M, Lech M, Vielhauer V, Anders HJ, Mulay SR. Regulated necrosis-related molecule mRNA expression in humans and mice and in murine acute tissue injury and systemic autoimmunity leading to progressive organ damage, and progressive fibrosis. Biosci Rep. 2016;36. [PMID: 27811014 DOI: 10.1042/bsr20160336] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
464 Nasonov EL, Beketova TV, Ananyeva LP, Vasilyev VI, Solovyev SK, Avdeeva AS. PROSPECTS FOR ANTI-B-CELL THERAPY IN IMMUNO-INFLAMMATORY RHEUMATIC DISEASES. Naučno-praktičeskaâ revmatologiâ 2019;57:1-40. [DOI: 10.14412/1995-4484-2019-3-40] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
465 Lu M, Yu S, Xu W, Gao B, Xiong S. HMGB1 Promotes Systemic Lupus Erythematosus by Enhancing Macrophage Inflammatory Response. J Immunol Res 2015;2015:946748. [PMID: 26078984 DOI: 10.1155/2015/946748] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 5.1] [Reference Citation Analysis]
466 Schlicher L, Kulig P, von Münchow A, Murphy MJ, Keller MP. In Vitro Characterization of Sphingosine 1-Phosphate Receptor 1 (S1P1) Expression and Mediated Migration of Primary Human T and B Cells in the Context of Cenerimod, a Novel, Selective S1P1 Receptor Modulator. Int J Mol Sci 2022;23:1191. [PMID: 35163112 DOI: 10.3390/ijms23031191] [Reference Citation Analysis]
467 Binder E, Edelbauer M. Use of biomarkers in the management of children with lupus. Curr Rheumatol Rep 2013;15:312. [PMID: 23355230 DOI: 10.1007/s11926-012-0312-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
468 Pradhan V, Patwardhan M, Rajadhyksha A, Umare V, Khadilkar P, Kaveri SV, Ghosh K. Association of clinical presentation with anti-nuclear antibody specificities among patients with systemic lupus erythematosus. Indian J Nephrol 2015;25:391-2. [PMID: 26664225 DOI: 10.4103/0971-4065.160338] [Reference Citation Analysis]
469 Al-Hashimi H, Bhowmik A. Generalised lymphadenopathy as the first manifestation of lupus nephritis. BMJ Case Rep 2010;2010:bcr0820092221. [PMID: 22736318 DOI: 10.1136/bcr.08.2009.2221] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
470 Zhang W, Cai Y, Xu W, Xiong S. C-reactive protein functions as a negative regulator of macrophage activation induced by apoptotic DNA. Protein Cell 2011;2:672-9. [PMID: 21904982 DOI: 10.1007/s13238-011-1084-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
471 Kröger W, Mapiye D, Entfellner JD, Tiffin N. A meta-analysis of public microarray data identifies gene regulatory pathways deregulated in peripheral blood mononuclear cells from individuals with Systemic Lupus Erythematosus compared to those without. BMC Med Genomics 2016;9:66. [PMID: 27846842 DOI: 10.1186/s12920-016-0227-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
472 Auerbach C, Beckerman NL. Locus of control and lupus: patients' beliefs, perspectives, and disease activity. Soc Work Health Care 2012;51:613-26. [PMID: 22905977 DOI: 10.1080/00981389.2012.683685] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
473 Biajoux V, Bignon A, Freitas C, Martinez V, Thelen M, Lima G, Jakez-Ocampo J, Emilie D, Llorente L, Balabanian K. Expression of CXCL12 receptors in B cells from Mexican Mestizos patients with systemic Lupus erythematosus. J Transl Med 2012;10:251. [PMID: 23244336 DOI: 10.1186/1479-5876-10-251] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
474 Shang X, Ren L, Sun G, Yu T, Yao Y, Wang L, Liu F, Zhang L, He X, Liu M. Anti-dsDNA, anti-nucleosome, anti-C1q, and anti-histone antibodies as markers of active lupus nephritis and systemic lupus erythematosus disease activity. Immun Inflamm Dis 2021;9:407-18. [PMID: 33470559 DOI: 10.1002/iid3.401] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
475 Yang Z, Liang Y, Xi W, Li C, Zhong R. Association of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population. Clin Exp Med 2011;11:75-80. [PMID: 20963466 DOI: 10.1007/s10238-010-0115-4] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 4.3] [Reference Citation Analysis]
476 Nystedt J, Nilsson M, Jönsen A, Nilsson P, Bengtsson A, Lilja Å, Lätt J, Mannfolk P, Sundgren PC. Altered white matter microstructure in lupus patients: a diffusion tensor imaging study. Arthritis Res Ther 2018;20:21. [PMID: 29415762 DOI: 10.1186/s13075-018-1516-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
477 Pan Y, Jia T, Zhang Y, Zhang K, Zhang R, Li J, Wang L. MS2 VLP-based delivery of microRNA-146a inhibits autoantibody production in lupus-prone mice. Int J Nanomedicine 2012;7:5957-67. [PMID: 23233803 DOI: 10.2147/IJN.S37990] [Cited by in Crossref: 60] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
478 Mathis KW. An impaired neuroimmune pathway promotes the development of hypertension in systemic lupus erythematosus. Am J Physiol Regul Integr Comp Physiol 2015;309:R1074-7. [PMID: 26084696 DOI: 10.1152/ajpregu.00143.2015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
479 Stone RC, Du P, Feng D, Dhawan K, Rönnblom L, Eloranta ML, Donnelly R, Barnes BJ. RNA-Seq for enrichment and analysis of IRF5 transcript expression in SLE. PLoS One 2013;8:e54487. [PMID: 23349905 DOI: 10.1371/journal.pone.0054487] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 4.0] [Reference Citation Analysis]
480 Wermeling F, Anthony RM, Brombacher F, Ravetch JV. Acute inflammation primes myeloid effector cells for anti-inflammatory STAT6 signaling. Proc Natl Acad Sci U S A 2013;110:13487-91. [PMID: 23898202 DOI: 10.1073/pnas.1312525110] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
481 Jang E, Cho S, Pyo S, Nam JW, Youn J. An Inflammatory Loop Between Spleen-Derived Myeloid Cells and CD4+ T Cells Leads to Accumulation of Long-Lived Plasma Cells That Exacerbates Lupus Autoimmunity. Front Immunol 2021;12:631472. [PMID: 33643317 DOI: 10.3389/fimmu.2021.631472] [Reference Citation Analysis]
482 McLaughlin KA, Wucherpfennig KW. B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseases. Adv Immunol 2008;98:121-49. [PMID: 18772005 DOI: 10.1016/S0065-2776(08)00404-5] [Cited by in Crossref: 59] [Cited by in F6Publishing: 31] [Article Influence: 4.2] [Reference Citation Analysis]
483 Fakhfakh R, Feki S, Elleuch A, Neifar M, Marzouk S, Elloumi N, Hachicha H, Abida O, Bahloul Z, Ayadi F, Masmoudi H. Vitamin D status and CYP27B1-1260 promoter polymorphism in Tunisian patients with systemic lupus erythematosus. Mol Genet Genomic Med 2021;9:e1618. [PMID: 33594806 DOI: 10.1002/mgg3.1618] [Reference Citation Analysis]
484 Luo X, Yang W, Ye DQ, Cui H, Zhang Y, Hirankarn N, Qian X, Tang Y, Lau YL, de Vries N, Tak PP, Tsao BP, Shen N. A functional variant in microRNA-146a promoter modulates its expression and confers disease risk for systemic lupus erythematosus. PLoS Genet 2011;7:e1002128. [PMID: 21738483 DOI: 10.1371/journal.pgen.1002128] [Cited by in Crossref: 196] [Cited by in F6Publishing: 182] [Article Influence: 17.8] [Reference Citation Analysis]
485 Sullivan BA, Tsuji W, Kivitz A, Peng J, Arnold GE, Boedigheimer MJ, Chiu K, Green CL, Kaliyaperumal A, Wang C, Ferbas J, Chung JB. Inducible T-cell co-stimulator ligand (ICOSL) blockade leads to selective inhibition of anti-KLH IgG responses in subjects with systemic lupus erythematosus. Lupus Sci Med 2016;3:e000146. [PMID: 27099766 DOI: 10.1136/lupus-2016-000146] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 6.5] [Reference Citation Analysis]
486 Jordan N, Lutalo PM, D'Cruz DP. Novel therapeutic agents in clinical development for systemic lupus erythematosus. BMC Med 2013;11:120. [PMID: 23642011 DOI: 10.1186/1741-7015-11-120] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
487 Hakkim A, Fürnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, Herrmann M, Voll RE, Zychlinsky A. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci USA. 2010;107:9813-9818. [PMID: 20439745 DOI: 10.1073/pnas.0909927107] [Cited by in Crossref: 824] [Cited by in F6Publishing: 792] [Article Influence: 68.7] [Reference Citation Analysis]
488 Doerner JL, Wen J, Xia Y, Paz KB, Schairer D, Wu L, Chalmers SA, Izmirly P, Michaelson JS, Burkly LC, Friedman AJ, Putterman C. TWEAK/Fn14 Signaling Involvement in the Pathogenesis of Cutaneous Disease in the MRL/lpr Model of Spontaneous Lupus. J Invest Dermatol 2015;135:1986-95. [PMID: 25826425 DOI: 10.1038/jid.2015.124] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 5.4] [Reference Citation Analysis]
489 Lee JY, Park JK, Lee EY, Lee EB, Song YW. Circulating exosomes from patients with systemic lupus erythematosus induce an proinflammatory immune response. Arthritis Res Ther. 2016;18:264. [PMID: 27852323 DOI: 10.1186/s13075-016-1159-y] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 8.3] [Reference Citation Analysis]
490 Park JK, Lee YJ, Park JS, Lee EB, Song YW. CD47 Potentiates Inflammatory Response in Systemic Lupus Erythematosus. Cells 2021;10:1151. [PMID: 34068752 DOI: 10.3390/cells10051151] [Reference Citation Analysis]
491 Joseph J, Rahmani B, Cole Y, Puttagunta N, Lin E, Khan ZK, Jain P. Can Soluble Immune Checkpoint Molecules on Exosomes Mediate Inflammation? J Neuroimmune Pharmacol 2021. [PMID: 34697721 DOI: 10.1007/s11481-021-10018-3] [Reference Citation Analysis]
492 Pan HF, Leng RX, Feng CC, Li XP, Chen GM, Li BZ, Xu WD, Zheng SG, Ye DQ. Expression profiles of Th17 pathway related genes in human systemic lupus erythematosus. Mol Biol Rep 2013;40:391-9. [PMID: 23054011 DOI: 10.1007/s11033-012-2073-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
493 Monsiváis-Urenda AE, Baranda L, Alvarez-Quiroga C, Abud-Mendoza C, González-Amaro R. Expression and functional role of HLA-G in immune cells from patients with systemic lupus erythematosus. J Clin Immunol. 2011;31:369-378. [PMID: 21188486 DOI: 10.1007/s10875-010-9496-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
494 Ruan GP, Yao X, Yang SJ, Wang JX, Shu F, Li ZA, Liu JF, Pang RQ, Pan XH. Transplanted human umbilical cord mesenchymal stem cells facilitate lesion repair in B6.Fas mice. J Immunol Res 2014;2014:530501. [PMID: 25759830 DOI: 10.1155/2014/530501] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
495 Nakatani K, Yoshimoto S, Asai O, Sakan H, Terada M, Saito Y, Nose M, Iwano M, Konishi N. Enhanced expression of the soluble form of E-selectin attenuates progression of lupus nephritis and vasculitis in MRL/lpr mice. Immun Inflamm Dis 2013;1:37-46. [PMID: 25400916 DOI: 10.1002/iid3.6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
496 Dedhia L, Pradhan V, Ghosh K, Nadkar M, Parekh S. Association of Human Leucocyte Antigen (HLA) class II with systemic lupus erythematosis (SLE) patients from western India. Meta Gene 2018;16:230-3. [DOI: 10.1016/j.mgene.2018.03.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
497 Korte EA, Gaffney PM, Powell DW. Contributions of mass spectrometry-based proteomics to defining cellular mechanisms and diagnostic markers for systemic lupus erythematosus. Arthritis Res Ther 2012;14:204. [PMID: 22364570 DOI: 10.1186/ar3701] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
498 Furie R, Petri MA, Strand V, Gladman DD, Zhong ZJ, Freimuth WW; BLISS-52 and BLISS-76 Study Groups. Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials. Lupus Sci Med 2014;1:e000031. [PMID: 25396065 DOI: 10.1136/lupus-2014-000031] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 5.9] [Reference Citation Analysis]
499 Xie Q, Zhang X, Peng S, Sun J, Chen X, Deng Y, Yi L. Identification of novel biomarkers in ischemic stroke: a genome-wide integrated analysis. BMC Med Genet 2020;21:66. [PMID: 32228489 DOI: 10.1186/s12881-020-00994-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
500 Kennedy JM, Fodil N, Torre S, Bongfen SE, Olivier JF, Leung V, Langlais D, Meunier C, Berghout J, Langat P, Schwartzentruber J, Majewski J, Lathrop M, Vidal SM, Gros P. CCDC88B is a novel regulator of maturation and effector functions of T cells during pathological inflammation. J Exp Med 2014;211:2519-35. [PMID: 25403443 DOI: 10.1084/jem.20140455] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 3.5] [Reference Citation Analysis]
501 Ferrari SM, Elia G, Virili C, Centanni M, Antonelli A, Fallahi P. Systemic Lupus Erythematosus and Thyroid Autoimmunity. Front Endocrinol (Lausanne) 2017;8:138. [PMID: 28674523 DOI: 10.3389/fendo.2017.00138] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
502 Deng GM, Liu L, Tsokos GC. Targeted tumor necrosis factor receptor I preligand assembly domain improves skin lesions in MRL/lpr mice. Arthritis Rheum 2010;62:2424-31. [PMID: 20506390 DOI: 10.1002/art.27534] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
503 Choubey D. Interferon-inducible Ifi200-family genes as modifiers of lupus susceptibility. Immunol Lett 2012;147:10-7. [PMID: 22841963 DOI: 10.1016/j.imlet.2012.07.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
504 Gupta S, Kaplan MJ. The role of neutrophils and NETosis in autoimmune and renal diseases. Nat Rev Nephrol 2016;12:402-13. [PMID: 27241241 DOI: 10.1038/nrneph.2016.71] [Cited by in Crossref: 195] [Cited by in F6Publishing: 189] [Article Influence: 32.5] [Reference Citation Analysis]
505 Kim JM, Park SH, Kim HY, Kwok SK. A Plasmacytoid Dendritic Cells-Type I Interferon Axis Is Critically Implicated in the Pathogenesis of Systemic Lupus Erythematosus. Int J Mol Sci 2015;16:14158-70. [PMID: 26110387 DOI: 10.3390/ijms160614158] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
506 Orozco G, Eyre S, Hinks A, Bowes J, Morgan AW, Wilson AG, Wordsworth P, Steer S, Hocking L, Thomson W, Worthington J, Barton A; UKRAG consortium. Study of the common genetic background for rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis 2011;70:463-8. [PMID: 21068098 DOI: 10.1136/ard.2010.137174] [Cited by in Crossref: 92] [Cited by in F6Publishing: 89] [Article Influence: 7.7] [Reference Citation Analysis]
507 Wang F, Li B, Schall N, Wilhelm M, Muller S. Assessing Autophagy in Mouse Models and Patients with Systemic Autoimmune Diseases. Cells 2017;6:E16. [PMID: 28657591 DOI: 10.3390/cells6030016] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
508 Morales JY, Young-Stubbs CM, Shimoura CG, Kem WR, Uteshev VV, Mathis KW. Systemic Administration of α7-Nicotinic Acetylcholine Receptor Ligands Does Not Improve Renal Injury or Behavior in Mice With Advanced Systemic Lupus Erythematosus. Front Med (Lausanne) 2021;8:642960. [PMID: 33928103 DOI: 10.3389/fmed.2021.642960] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
509 Wu W, Liu J, Chang H. Latent class model based diagnostic system utilizing traditional Chinese medicine for patients with systemic lupus erythematosus. Expert Systems with Applications 2011;38:281-7. [DOI: 10.1016/j.eswa.2010.06.058] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
510 van Vollenhoven RF, Petri MA, Cervera R, Roth DA, Ji BN, Kleoudis CS, Zhong ZJ, Freimuth W. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 2012;71:1343-9. [PMID: 22337213 DOI: 10.1136/annrheumdis-2011-200937] [Cited by in Crossref: 234] [Cited by in F6Publishing: 216] [Article Influence: 23.4] [Reference Citation Analysis]
511 van Leuven SI, Mendez-Fernandez YV, Wilhelm AJ, Wade NS, Gabriel CL, Kastelein JJ, Stroes ES, Tak PP, Major AS. Mycophenolate mofetil but not atorvastatin attenuates atherosclerosis in lupus-prone LDLr(-/-) mice. Ann Rheum Dis 2012;71:408-14. [PMID: 21953346 DOI: 10.1136/annrheumdis-2011-200071] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 4.0] [Reference Citation Analysis]
512 Guo X, Yang X, Li Q, Shen X, Zhong H, Yang Y. The Microbiota in Systemic Lupus Erythematosus: An Update on the Potential Function of Probiotics. Front Pharmacol 2021;12:759095. [PMID: 34887760 DOI: 10.3389/fphar.2021.759095] [Reference Citation Analysis]
513 Draborg AH, Rasmussen NS, Larsen JL, Jørgensen CS, Sandhu N, Skogstrand K, Jacobsen S, Houen G. Immune responses to an early lytic cytomegalovirus antigen in systemic lupus erythematosus patients: T-cell responses, cytokine secretions and antibody status. PLoS One 2018;13:e0193244. [PMID: 29499037 DOI: 10.1371/journal.pone.0193244] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
514 Kansal R, Richardson N, Neeli I, Khawaja S, Chamberlain D, Ghani M, Ghani QU, Balazs L, Beranova-Giorgianni S, Giorgianni F, Kochenderfer JN, Marion T, Albritton LM, Radic M. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci Transl Med 2019;11:eaav1648. [PMID: 30842314 DOI: 10.1126/scitranslmed.aav1648] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 32.5] [Reference Citation Analysis]
515 Wu GC, Li J, Leng RX, Li XP, Li XM, Wang DG, Pan HF, Ye DQ. Identification of long non-coding RNAs GAS5, linc0597 and lnc-DC in plasma as novel biomarkers for systemic lupus erythematosus. Oncotarget 2017;8:23650-63. [PMID: 28423570 DOI: 10.18632/oncotarget.15569] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 8.0] [Reference Citation Analysis]
516 Zhang W, Langefeld CD, Grunwald GK, Fingerlin TE. Testing gene-environment interactions in family-based association studies using trait-based ascertained samples. Stat Med 2014;33:304-18. [PMID: 23922213 DOI: 10.1002/sim.5930] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
517 Bazzan M, Vaccarino A, Marletto F. Systemic lupus erythematosus and thrombosis. Thromb J. 2015;13:16. [PMID: 25908929 DOI: 10.1186/s12959-015-0043-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
518 Chen XH, Shi JC, Wei JC, Chen HH, Mo HY. Increased Risk of Retinal Vasculitis in Patients With Systemic Lupus Erythematosus: A Nationwide Population-Based Cohort Study. Front Med (Lausanne) 2021;8:739883. [PMID: 34650999 DOI: 10.3389/fmed.2021.739883] [Reference Citation Analysis]
519 Williams EM, Egede L, Faith T, Oates J. Effective Self-Management Interventions for Patients With Lupus: Potential Impact of Peer Mentoring. Am J Med Sci 2017;353:580-92. [PMID: 28641721 DOI: 10.1016/j.amjms.2017.01.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
520 Ding Y, Yu X, Wu L, Tan Y, Qu Z, Yu F. The Spectrum of C4d Deposition in Renal Biopsies of Lupus Nephritis Patients. Front Immunol 2021;12:654652. [PMID: 34276649 DOI: 10.3389/fimmu.2021.654652] [Reference Citation Analysis]
521 Rajabi P, Alaee M, Mousavizadeh K, Samadikuchaksaraei A. Altered expression of TNFSF4 and TRAF2 mRNAs in peripheral blood mononuclear cells in patients with systemic lupus erythematosus: association with atherosclerotic symptoms and lupus nephritis. Inflamm Res 2012;61:1347-54. [PMID: 22847298 DOI: 10.1007/s00011-012-0535-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
522 Zou Y, Xu H. Involvement of long noncoding RNAs in the pathogenesis of autoimmune diseases. J Transl Autoimmun 2020;3:100044. [PMID: 32743525 DOI: 10.1016/j.jtauto.2020.100044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
523 Katewa A, Wang Y, Hackney JA, Huang T, Suto E, Ramamoorthi N, Austin CD, Bremer M, Chen JZ, Crawford JJ, Currie KS, Blomgren P, DeVoss J, DiPaolo JA, Hau J, Johnson A, Lesch J, DeForge LE, Lin Z, Liimatta M, Lubach JW, McVay S, Modrusan Z, Nguyen A, Poon C, Wang J, Liu L, Lee WP, Wong H, Young WB, Townsend MJ, Reif K. Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFNα-driven lupus nephritis. JCI Insight 2017;2:e90111. [PMID: 28405610 DOI: 10.1172/jci.insight.90111] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 8.0] [Reference Citation Analysis]
524 Singh RP, Hahn BH, Bischoff DS. Interferon Genes Are Influenced by 17β-Estradiol in SLE. Front Immunol 2021;12:725325. [PMID: 34733276 DOI: 10.3389/fimmu.2021.725325] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
525 Wu GC, Hu Y, Guan SY, Ye DQ, Pan HF. Differential Plasma Expression Profiles of Long Non-Coding RNAs Reveal Potential Biomarkers for Systemic Lupus Erythematosus. Biomolecules 2019;9:E206. [PMID: 31141998 DOI: 10.3390/biom9060206] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
526 Thanadetsuntorn C, Ngamjanyaporn P, Setthaudom C, Hodge K, Saengpiya N, Pisitkun P. The model of circulating immune complexes and interleukin-6 improves the prediction of disease activity in systemic lupus erythematosus. Sci Rep 2018;8:2620. [PMID: 29422675 DOI: 10.1038/s41598-018-20947-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
527 Qiu LJ, Xu K, Liang Y, Cen H, Zhang M, Wen PF, Ni J, Xu WD, Leng RX, Pan HF, Ye DQ. Decreased SOCS1 mRNA expression levels in peripheral blood mononuclear cells from patients with systemic lupus erythematosus in a Chinese population. Clin Exp Med 2015;15:261-7. [PMID: 25330931 DOI: 10.1007/s10238-014-0309-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
528 Wu BB, Ma Y, Xie L, Huang JZ, Sun ZB, Hou ZD, Guo RW, Lin ZR, Duan SX, Zhao SS, Yao-Xie, Sun DM, Zhu CM, Ma SH. Impaired decision-making and functional neuronal network activity in systemic lupus erythematosus. J Magn Reson Imaging 2018;48:1508-17. [PMID: 29537670 DOI: 10.1002/jmri.26006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
529 Rahimi H, Maurer K, Song L, Akhter E, Petri M, Sullivan KE. Aberrant regulation of the integrin very late antigen-4 in systemic lupus erythematosus. Lupus 2013;22:297-306. [PMID: 23439470 DOI: 10.1177/0961203313475691] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
530 Al Rayes H, Touma Z. Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus. Drug Des Devel Ther 2014;8:2303-10. [PMID: 25429203 DOI: 10.2147/DDDT.S49778] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
531 Gu Z, Jiang J, Tan W, Xia Y, Cao H, Meng Y, Da Z, Liu H, Cheng C. p53/p21 Pathway involved in mediating cellular senescence of bone marrow-derived mesenchymal stem cells from systemic lupus erythematosus patients. Clin Dev Immunol 2013;2013:134243. [PMID: 24151513 DOI: 10.1155/2013/134243] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
532 McCarthy EM, Sutton E, Nesbit S, White J, Parker B, Jayne D, Griffiths B, Isenberg DA, Rahman A, Gordon C, D'Cruz DP, Rhodes B, Lanyon P, Vital EM, Yee CS, Edwards CJ, Teh LS, Akil M, McHugh NJ, Zoma A, Bruce IN; British Isles Lupus Assessment Group Biologics Register. Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. Rheumatology (Oxford) 2018;57:470-9. [PMID: 29216396 DOI: 10.1093/rheumatology/kex395] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 10.8] [Reference Citation Analysis]
533 Assandri R, Monari M, Colombo A, Dossi A, Montanelli A. Pentraxin 3 Plasma Levels and Disease Activity in Systemic Lupus Erythematosus. Autoimmune Dis 2015;2015:354014. [PMID: 26613049 DOI: 10.1155/2015/354014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
534 Osman HM, Omar GM, Elameen NF, Abdel-Nasser AM. CCL21 and IP10 as serum biomarkers for pulmonary involvement in systemic lupus erythematosus. Lupus 2022;:9612033221093493. [PMID: 35380893 DOI: 10.1177/09612033221093493] [Reference Citation Analysis]
535 Flammer JR, Rogatsky I. Minireview: Glucocorticoids in autoimmunity: unexpected targets and mechanisms. Mol Endocrinol 2011;25:1075-86. [PMID: 21511881 DOI: 10.1210/me.2011-0068] [Cited by in Crossref: 85] [Cited by in F6Publishing: 78] [Article Influence: 7.7] [Reference Citation Analysis]
536 Weiss JM, Chen W, Nyuydzefe MS, Trzeciak A, Flynn R, Tonra JR, Marusic S, Blazar BR, Waksal SD, Zanin-Zhorov A. ROCK2 signaling is required to induce a subset of T follicular helper cells through opposing effects on STATs in autoimmune settings. Sci Signal 2016;9:ra73. [PMID: 27436361 DOI: 10.1126/scisignal.aad8953] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 5.7] [Reference Citation Analysis]
537 Lu A, Wu S, Niu J, Cui M, Chen M, Clapp WL, Barnes BJ, Meng G. Aim2 Couples With Ube2i for Sumoylation-Mediated Repression of Interferon Signatures in Systemic Lupus Erythematosus. Arthritis Rheumatol 2021;73:1467-77. [PMID: 33559374 DOI: 10.1002/art.41677] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
538 Migliorini A, Anders HJ. A novel pathogenetic concept-antiviral immunity in lupus nephritis. Nat Rev Nephrol 2012;8:183-9. [PMID: 22249778 DOI: 10.1038/nrneph.2011.197] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 4.1] [Reference Citation Analysis]
539 Toong C, Adelstein S, Phan TG. Clearing the complexity: immune complexes and their treatment in lupus nephritis. Int J Nephrol Renovasc Dis 2011;4:17-28. [PMID: 21694945 DOI: 10.2147/IJNRD.S10233] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
540 Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, Aranow C, Wellborne FR, Abud-Mendoza C, Hough DR, Pineda L, Migone TS, Zhong ZJ, Freimuth WW, Chatham WW; BLISS-52 Study Group., BLISS-76 Study Group. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 2012;64:2328-37. [PMID: 22275291 DOI: 10.1002/art.34400] [Cited by in Crossref: 221] [Cited by in F6Publishing: 207] [Article Influence: 22.1] [Reference Citation Analysis]
541 Parihar N, Bhatt LK. Deubiquitylating enzymes: potential target in autoimmune diseases. Inflammopharmacology 2021;29:1683-99. [PMID: 34792672 DOI: 10.1007/s10787-021-00890-z] [Reference Citation Analysis]
542 Choudhary MM, Hajj-Ali RA, Lowder CY. Gender and ocular manifestations of connective tissue diseases and systemic vasculitides. J Ophthalmol 2014;2014:403042. [PMID: 24757559 DOI: 10.1155/2014/403042] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
543 Aringer M, Johnson SR. Classifying and diagnosing systemic lupus erythematosus in the 21st century. Rheumatology (Oxford) 2020;59:v4-v11. [PMID: 33280013 DOI: 10.1093/rheumatology/keaa379] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
544 Kiener S, Ribi C, Keller I, Chizzolini C, Trendelenburg M, Huynh-Do U, von Kempis J, On Behalf Of Swiss Sle Cohort Study Sscs, Leeb T. Variants Affecting the C-Terminal Tail of UNC93B1 Are Not a Common Risk Factor for Systemic Lupus Erythematosus. Genes (Basel) 2021;12:1268. [PMID: 34440442 DOI: 10.3390/genes12081268] [Reference Citation Analysis]
545 Yan L, Wu P, Gao DM, Hu J, Wang Q, Chen NF, Tong SQ, Rao L, Liu J. The Impact of Vitamin D on Cognitive Dysfunction in Mice with Systemic Lupus Erythematosus. Med Sci Monit 2019;25:4716-22. [PMID: 31281179 DOI: 10.12659/MSM.915355] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
546 Freitas EC, de Oliveira MS, Monticielo OA. Pristane-induced lupus: considerations on this experimental model. Clin Rheumatol 2017;36:2403-14. [PMID: 28879482 DOI: 10.1007/s10067-017-3811-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
547 Liu T, Shi N, Zhang S, Silverman GJ, Duan XW, Zhang S, Niu H. Systemic lupus erythematosus aggravates atherosclerosis by promoting IgG deposition and inflammatory cell imbalance. Lupus 2020;29:273-82. [PMID: 32075511 DOI: 10.1177/0961203320904779] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
548 Richey M. The management of lupus nephritis. Nurse Pract 2014;39:1-6. [PMID: 24535304 DOI: 10.1097/01.NPR.0000443229.10476.61] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
549 Jaiyesimi S, Gregg E, Barket C, Seewoodhary R. Ocular involvement in systemic lupus erythematosus: implications for ophthalmic nursing practice. International Journal of Ophthalmic Practice 2014;5:159-66. [DOI: 10.12968/ijop.2014.5.5.159] [Reference Citation Analysis]
550 Yang H, Xie X, Song Y, Nie A, Chen H. Self-care agency in systemic lupus erythematosus and its associated factors: a cross-sectional study. Patient Prefer Adherence 2018;12:607-13. [PMID: 29731608 DOI: 10.2147/PPA.S162648] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
551 Postal M, Costallat LT, Appenzeller S. Biological therapy in systemic lupus erythematosus. Int J Rheumatol 2012;2012:578641. [PMID: 22500177 DOI: 10.1155/2012/578641] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
552 Spruill IJ, Leite RS, Fernandes JK, Kamen DL, Ford ME, Jenkins C, Hunt KJ, Andrews JO. Successes, Challenges and Lessons Learned: Community-engaged research with South Carolina's Gullah population. Gateways 2013;6. [PMID: 25364473 DOI: 10.5130/ijcre.v6i1.2805] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
553 Lewandowicz E, Zieliński T, Iljin A, Fijałkowska M, Kasielska-Trojan A, Antoszewski B. Surgical treatment of skin lesions in lupus erythematosus. Postepy Dermatol Alergol 2014;31:405-9. [PMID: 25610357 DOI: 10.5114/pdia.2014.40931] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
554 Bayry J, Negi VS, Kaveri SV. Intravenous immunoglobulin therapy in rheumatic diseases. Nat Rev Rheumatol. 2011;7:349-359. [PMID: 21556030 DOI: 10.1038/nrrheum.2011.61] [Cited by in Crossref: 92] [Cited by in F6Publishing: 70] [Article Influence: 8.4] [Reference Citation Analysis]
555 Draborg AH, Duus K, Houen G. Epstein-Barr virus and systemic lupus erythematosus. Clin Dev Immunol 2012;2012:370516. [PMID: 22811739 DOI: 10.1155/2012/370516] [Cited by in Crossref: 66] [Cited by in F6Publishing: 56] [Article Influence: 6.6] [Reference Citation Analysis]
556 Shamsi MB, Firoz AS, Imam SN, Alzaman N, Samman MA. Epigenetics of human diseases and scope in future therapeutics. J Taibah Univ Med Sci 2017;12:205-11. [PMID: 31435241 DOI: 10.1016/j.jtumed.2017.04.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
557 Liu CC, Ahearn JM. The search for lupus biomarkers. Best Pract Res Clin Rheumatol 2009;23:507-23. [PMID: 19591781 DOI: 10.1016/j.berh.2009.01.008] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 4.4] [Reference Citation Analysis]
558 Huang X, Dorta-Estremera S, Yao Y, Shen N, Cao W. Predominant Role of Plasmacytoid Dendritic Cells in Stimulating Systemic Autoimmunity. Front Immunol 2015;6:526. [PMID: 26528288 DOI: 10.3389/fimmu.2015.00526] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
559 Liu CC, Manzi S, Kao AH, Navratil JS, Ahearn JM. Cell-bound complement biomarkers for systemic lupus erythematosus: from benchtop to bedside. Rheum Dis Clin North Am 2010;36:161-72, x. [PMID: 20202597 DOI: 10.1016/j.rdc.2009.12.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
560 A Mohammed RH, Lotfy Fayed H, Ibrahim Emara N. Mortality and disease related comorbidities in systemic lupus erythematosus: Data from an Egyptian cohort. Lupus. [DOI: 10.1177/09612033221081691] [Reference Citation Analysis]
561 Fatemi A, Erlandsson BE, Emrani Z, Etehadtavakol M, Smiley A, Karbalaie A. Nailfold microvascular changes in patients with systemic lupus erythematosus and their associative factors. Microvasc Res 2019;126:103910. [PMID: 31408627 DOI: 10.1016/j.mvr.2019.103910] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
562 Ming Wang TK, Chan N, Khayata M, Flanagan P, Grimm RA, Griffin BP, Husni ME, Littlejohn E, Xu B. Cardiovascular Manifestations, Imaging, and Outcomes in Systemic Lupus Erythematosus: An Eight-Year Single Center Experience in the United States. Angiology 2022;:33197221078056. [PMID: 35238664 DOI: 10.1177/00033197221078056] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
563 Meza-Meza MR, Vizmanos-Lamotte B, Muñoz-Valle JF, Parra-Rojas I, Garaulet M, Campos-López B, Montoya-Buelna M, Cerpa-Cruz S, Martínez-López E, Oregon-Romero E, De la Cruz-Mosso U. Relationship of Excess Weight with Clinical Activity and Dietary Intake Deficiencies in Systemic Lupus Erythematosus Patients. Nutrients 2019;11:E2683. [PMID: 31698711 DOI: 10.3390/nu11112683] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
564 Bruschi M, Petretto A, Santucci L, Vaglio A, Pratesi F, Migliorini P, Bertelli R, Lavarello C, Bartolucci M, Candiano G, Prunotto M, Ghiggeri GM. Neutrophil Extracellular Traps protein composition is specific for patients with Lupus nephritis and includes methyl-oxidized αenolase (methionine sulfoxide 93). Sci Rep 2019;9:7934. [PMID: 31138830 DOI: 10.1038/s41598-019-44379-w] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
565 Bosma A, Abdel-Gadir A, Isenberg DA, Jury EC, Mauri C. Lipid-antigen presentation by CD1d(+) B cells is essential for the maintenance of invariant natural killer T cells. Immunity 2012;36:477-90. [PMID: 22406267 DOI: 10.1016/j.immuni.2012.02.008] [Cited by in Crossref: 142] [Cited by in F6Publishing: 127] [Article Influence: 14.2] [Reference Citation Analysis]
566 Guo X, Fang X, He G, Zaman MH, Fei X, Qiao W, Deng GM. The role of neutrophils in skin damage induced by tissue-deposited lupus IgG. Immunology 2018. [PMID: 29450882 DOI: 10.1111/imm.12908] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
567 Kulkarni OP, Sayyed SG, Kantner C, Ryu M, Schnurr M, Sárdy M, Leban J, Jankowsky R, Ammendola A, Doblhofer R, Anders HJ. 4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL-(Fas)lpr mice. Am J Pathol 2010;176:2840-7. [PMID: 20413687 DOI: 10.2353/ajpath.2010.091227] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
568 Rekvig OP. Autoimmunity and SLE: Factual and Semantic Evidence-Based Critical Analyses of Definitions, Etiology, and Pathogenesis. Front Immunol 2020;11:569234. [PMID: 33123142 DOI: 10.3389/fimmu.2020.569234] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
569 Liphaus BL, Kiss MH. The role of apoptosis proteins and complement components in the etiopathogenesis of systemic lupus erythematosus. Clinics (Sao Paulo) 2010;65:327-33. [PMID: 20360925 DOI: 10.1590/S1807-59322010000300014] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
570 Welcher AA, Boedigheimer M, Kivitz AJ, Amoura Z, Buyon J, Rudinskaya A, Latinis K, Chiu K, Oliner KS, Damore MA, Arnold GE, Sohn W, Chirmule N, Goyal L, Banfield C, Chung JB. Blockade of interferon-γ normalizes interferon-regulated gene expression and serum CXCL10 levels in patients with systemic lupus erythematosus. Arthritis Rheumatol 2015;67:2713-22. [PMID: 26138472 DOI: 10.1002/art.39248] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 7.2] [Reference Citation Analysis]
571 Wong RW, Chan A, Johnson RN, McDonald HR, Kumar A, Gariano R, Cunningham E Jr. Posterior scleritis in patients with systemic lupus erythematosus. Retin Cases Brief Rep 2010;4:326-31. [PMID: 25390910 DOI: 10.1097/ICB.0b013e3181e1806e] [Cited by in Crossref: 6] [Article Influence: 0.5] [Reference Citation Analysis]
572 Xiang Y, Li M, Luo H, Wang Y, Duan X, Zhao C, Zhan F, Wu Z, Li H, Yang M, Xu J, Wei W, Wu L, You H, Qian J, Yang X, Huang C, Zhao J, Wang Q, Leng X, Tian X, Zhao Y, Zeng X. Chinese SLE Treatment and Research Group Registry (CSTAR) XIII: prevalence and risk factors for chronic scarring alopecia in patients with systemic lupus erythematosus. Arthritis Res Ther 2021;23:20. [PMID: 33430947 DOI: 10.1186/s13075-020-02407-5] [Reference Citation Analysis]
573 Zhang X, Xu B, Liu Z, Gao Y, Wang Q, Liu R. Systemic lupus erythematosus with hypothyroidism as the initial clinical manifestation: A case report. Exp Ther Med 2020;20:996-1002. [PMID: 32742342 DOI: 10.3892/etm.2020.8788] [Reference Citation Analysis]
574 Shen N, Fu Q, Deng Y, Qian X, Zhao J, Kaufman KM, Wu YL, Yu CY, Tang Y, Chen JY, Yang W, Wong M, Kawasaki A, Tsuchiya N, Sumida T, Kawaguchi Y, Howe HS, Mok MY, Bang SY, Liu FL, Chang DM, Takasaki Y, Hashimoto H, Harley JB, Guthridge JM, Grossman JM, Cantor RM, Song YW, Bae SC, Chen S, Hahn BH, Lau YL, Tsao BP. Sex-specific association of X-linked Toll-like receptor 7 (TLR7) with male systemic lupus erythematosus. Proc Natl Acad Sci U S A 2010;107:15838-43. [PMID: 20733074 DOI: 10.1073/pnas.1001337107] [Cited by in Crossref: 182] [Cited by in F6Publishing: 172] [Article Influence: 15.2] [Reference Citation Analysis]
575 Fukushima K, Uchida HA, Fuchimoto Y, Mifune T, Watanabe M, Tsuji K, Tanabe K, Kinomura M, Kitamura S, Miyamoto Y, Wada S, Koyanagi T, Sugiyama H, Kishimoto T, Wada J. Silica-associated systemic lupus erythematosus with lupus nephritis and lupus pneumonitis: A case report and a systematic review of the literature. Medicine (Baltimore) 2022;101:e28872. [PMID: 35363197 DOI: 10.1097/MD.0000000000028872] [Reference Citation Analysis]
576 Baek WY, Choi YS, Lee SW, Son IO, Jeon KW, Choi SD, Suh CH. Toll-like Receptor Signaling Inhibitory Peptide Improves Inflammation in Animal Model and Human Systemic Lupus Erythematosus. Int J Mol Sci 2021;22:12764. [PMID: 34884569 DOI: 10.3390/ijms222312764] [Reference Citation Analysis]
577 Sivakumar R, Abboud G, Mathews CE, Atkinson MA, Morel L. Protective Role of Myeloid Cells Expressing a G-CSF Receptor Polymorphism in an Induced Model of Lupus. Front Immunol 2018;9:1053. [PMID: 29868014 DOI: 10.3389/fimmu.2018.01053] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
578 Da Silva CAL, Galera MF, Festi RR, Espinosa MM, Fernandes V, Blaskievicz PH, Dias EP. Association of Polymorphisms in the DNA Repair Genes XRCC1 and XRCC3 with Systemic Lupus Erythematosus. TORJ 2019;13:15-21. [DOI: 10.2174/1874312901913010015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
579 Chen X, Wang DD, Xu H, Li ZP. Population pharmacokinetics model and initial dose optimization of tacrolimus in children and adolescents with lupus nephritis based on real-world data. Exp Ther Med 2020;20:1423-30. [PMID: 32765671 DOI: 10.3892/etm.2020.8821] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
580 Williams EM, Hyer JM, Viswanathan R, Faith TD, Voronca D, Gebregziabher M, Oates JC, Egede L. Peer-to-Peer Mentoring for African American Women With Lupus: A Feasibility Pilot. Arthritis Care Res (Hoboken) 2018;70:908-17. [PMID: 29161471 DOI: 10.1002/acr.23412] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
581 Lu J, Kishore U. C1 Complex: An Adaptable Proteolytic Module for Complement and Non-Complement Functions. Front Immunol 2017;8:592. [PMID: 28596769 DOI: 10.3389/fimmu.2017.00592] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 6.4] [Reference Citation Analysis]
582 Bag-Ozbek A, Hui-Yuen JS. Emerging B-Cell Therapies in Systemic Lupus Erythematosus. Ther Clin Risk Manag 2021;17:39-54. [PMID: 33488082 DOI: 10.2147/TCRM.S252592] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
583 Chen L, Huang Z, Liao Y, Yang B, Zhang J. Association between tumor necrosis factor polymorphisms and rheumatoid arthritis as well as systemic lupus erythematosus: a meta-analysis. Braz J Med Biol Res 2019;52:e7927. [PMID: 30916218 DOI: 10.1590/1414-431X20187927] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
584 Nozaki Y. The Network of Inflammatory Mechanisms in Lupus Nephritis. Front Med (Lausanne) 2020;7:591724. [PMID: 33240910 DOI: 10.3389/fmed.2020.591724] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
585 Bengtsson AA, Trygg J, Wuttge DM, Sturfelt G, Theander E, Donten M, Moritz T, Sennbro CJ, Torell F, Lood C, Surowiec I, Rännar S, Lundstedt T. Metabolic Profiling of Systemic Lupus Erythematosus and Comparison with Primary Sjögren's Syndrome and Systemic Sclerosis. PLoS One 2016;11:e0159384. [PMID: 27441838 DOI: 10.1371/journal.pone.0159384] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 9.5] [Reference Citation Analysis]
586 Konishi K, Nakamura K, Hanada Y, Kitanaga Y, Kubo S, Kinugasa F, Yamajuku D, Maeda M, Yamamoto N, Minematsu T, Ohbuchi M, Kondo Y, Sumida T. Preclinical Characterization of ASP2713, a Novel Igβ and FcγRIIB Cross-Linking Antibody, for Prediction of Human Pharmacokinetics and Clinically Effective Dose. J Pharm Sci 2022:S0022-3549(22)00250-7. [PMID: 35700799 DOI: 10.1016/j.xphs.2022.06.006] [Reference Citation Analysis]
587 Borba HH, Funke A, Wiens A, Utiyama SR, Perlin CM, Pontarolo R. Update on Biologic Therapies for Systemic Lupus Erythematosus. Curr Rheumatol Rep 2016;18:44. [PMID: 27299782 DOI: 10.1007/s11926-016-0589-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
588 Zimmer R, Scherbarth HR, Rillo OL, Gomez-Reino JJ, Muller S. Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. Ann Rheum Dis 2013;72:1830-5. [PMID: 23172751 DOI: 10.1136/annrheumdis-2012-202460] [Cited by in Crossref: 104] [Cited by in F6Publishing: 94] [Article Influence: 10.4] [Reference Citation Analysis]
589 Olson SW, Lee JJ, Prince LK, Baker TP, Papadopoulos P, Edison J, Abbott KC. Elevated subclinical double-stranded DNA antibodies and future proliferative lupus nephritis. Clin J Am Soc Nephrol 2013;8:1702-8. [PMID: 23833315 DOI: 10.2215/CJN.01910213] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
590 Banham GD, Lee CYC, Ferdinand JR, Matthews RJ, Jing C, Smithers N, Prinjha RK, Clatworthy MR. Bromodomain Inhibitors Modulate FcγR-Mediated Mononuclear Phagocyte Activation and Chemotaxis. Front Immunol 2022;13:885101. [PMID: 35619690 DOI: 10.3389/fimmu.2022.885101] [Reference Citation Analysis]
591 Qi YY, Liu XR, He YX, Zhou M, Ning XH, Zhai YL, Zhang XX, Wang XY, Zhao YF, Cui Y, Zhao ZZ. Association of the PINX1 Variant rs6984094, Which Lengthens Telomeres, with Systemic Lupus Erythematosus Susceptibility in Chinese Populations. J Immunol Res 2021;2021:7079359. [PMID: 34337078 DOI: 10.1155/2021/7079359] [Reference Citation Analysis]
592 Pateinakis P, Pyrpasopoulou A. Targeting the B-cell pathway in lupus nephritis: current evidence and future perspectives. ScientificWorldJournal 2013;2013:745239. [PMID: 24191142 DOI: 10.1155/2013/745239] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
593 Esposito S, Bosis S, Semino M, Rigante D. Infections and systemic lupus erythematosus. Eur J Clin Microbiol Infect Dis 2014;33:1467-75. [PMID: 24715155 DOI: 10.1007/s10096-014-2098-7] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 6.1] [Reference Citation Analysis]
594 Selvananda S, Kan SL. Performance of the 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus in a multiethnic Malaysian cohort. Int J Rheum Dis 2021. [PMID: 34939743 DOI: 10.1111/1756-185X.14269] [Reference Citation Analysis]
595 Draborg AH, Lydolph MC, Westergaard M, Olesen Larsen S, Nielsen CT, Duus K, Jacobsen S, Houen G. Elevated Concentrations of Serum Immunoglobulin Free Light Chains in Systemic Lupus Erythematosus Patients in Relation to Disease Activity, Inflammatory Status, B Cell Activity and Epstein-Barr Virus Antibodies. PLoS One 2015;10:e0138753. [PMID: 26402865 DOI: 10.1371/journal.pone.0138753] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
596 Peng Y, Guo F, Liao S, Liao H, Xiao H, Yang L, Liu HF, Pan Q. Altered frequency of peripheral B-cell subsets and their correlation with disease activity in patients with systemic lupus erythematosus: A comprehensive analysis. J Cell Mol Med 2020;24:12044-53. [PMID: 32918534 DOI: 10.1111/jcmm.15836] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
597 Zhou Y, Chen H, Liu L, Yu X, Sukhova GK, Yang M, Zhang L, Kyttaris VC, Tsokos GC, Stillman IE, Ichimura T, Bonventre JV, Libby P, Shi GP. CD74 Deficiency Mitigates Systemic Lupus Erythematosus-like Autoimmunity and Pathological Findings in Mice. J Immunol 2017;198:2568-77. [PMID: 28219888 DOI: 10.4049/jimmunol.1600028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
598 Strasser DS, Froidevaux S, Sippel V, Gerossier E, Grieder U, Pierlot GM, Kieninger-Graefitsch A, Vezzali E, Stalder AK, Renault B, Ryge J, Hart A, Mentzel U, Groenen PMA, Keller MP, Trendelenburg M, Martinic MM, Murphy MJ. Preclinical to clinical translation of cenerimod, a novel S1P1 receptor modulator, in systemic lupus erythematosus. RMD Open 2020;6:e001261. [PMID: 32917831 DOI: 10.1136/rmdopen-2020-001261] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
599 Sohrabian A, Parodis I, Carlströmer-Berthén N, Frodlund M, Jönsen A, Zickert A, Sjöwall C, Bengtsson AA, Gunnarsson I, Rönnelid J. Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus. Arthritis Res Ther 2019;21:259. [PMID: 31783909 DOI: 10.1186/s13075-019-2056-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
600 Zhang L, Guan C, Ye Z, Lu Y. Unilateral branch retinal artery occlusion in a patient with systemic lupus erythematosus: A case report. Medicine (Baltimore) 2022;101:e29005. [PMID: 35451396 DOI: 10.1097/MD.0000000000029005] [Reference Citation Analysis]
601 Guo S, Liu Y, Ma Y, Zhao Q, Zhu L, Shao Y, Gao F, Wu F, Gao R, Zhang W. Systemic lupus erythematosus patients contain significantly less igm against mono-methylated lysine than healthy subjects. PLoS One 2013;8:e68520. [PMID: 23874652 DOI: 10.1371/journal.pone.0068520] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
602 Kemeny-Beke A, Szodoray P. Ocular manifestations of rheumatic diseases. Int Ophthalmol 2020;40:503-10. [PMID: 31583550 DOI: 10.1007/s10792-019-01183-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
603 Bruce IN, Urowitz M, van Vollenhoven R, Aranow C, Fettiplace J, Oldham M, Wilson B, Molta C, Roth D, Gordon D. Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care. Lupus 2016;25:699-709. [PMID: 26936891 DOI: 10.1177/0961203315625119] [Cited by in Crossref: 59] [Cited by in F6Publishing: 48] [Article Influence: 9.8] [Reference Citation Analysis]
604 Perumal MB, Dhanasekaran S. Relaxin: a missing link in the pathomechanisms of Systemic Lupus Erythematosus? Mod Rheumatol 2014;24:547-51. [PMID: 24251992 DOI: 10.3109/14397595.2013.844297] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
605 Scurt FG, Morgenroth R, Bose K, Mertens PR, Chatzikyrkou C. Pr-AKI: Acute Kidney Injury in Pregnancy – Etiology, Diagnostic Workup, Management. Geburtshilfe Frauenheilkd 2022;82:297-316. [DOI: 10.1055/a-1666-0483] [Reference Citation Analysis]
606 Heshmat TS, Khalil NM, Elhamid HA, Labib S, Mahfouz M. Assessment of premature coronary atherosclerosis in patients with systemic lupus erythematosus disease. The Egyptian Rheumatologist 2015;37:S43-7. [DOI: 10.1016/j.ejr.2015.04.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
607 Ullal AJ, Pisetsky DS. The role of microparticles in the generation of immune complexes in murine lupus. Clin Immunol 2013;146:1-9. [PMID: 23159786 DOI: 10.1016/j.clim.2012.10.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
608 Rönnblom L. The type I interferon system in the etiopathogenesis of autoimmune diseases. Ups J Med Sci 2011;116:227-37. [PMID: 22066971 DOI: 10.3109/03009734.2011.624649] [Cited by in Crossref: 70] [Cited by in F6Publishing: 72] [Article Influence: 7.0] [Reference Citation Analysis]
609 Huvé R, Fontaine P, Blais MC, Conversy B. New findings associated with presumptive systemic lupus erythematosus in a kitten. JFMS Open Rep 2020;6:2055116920979271. [PMID: 33425372 DOI: 10.1177/2055116920979271] [Reference Citation Analysis]
610 Mahlaoui N, Warnatz K, Jones A, Workman S, Cant A. Advances in the Care of Primary Immunodeficiencies (PIDs): from Birth to Adulthood. J Clin Immunol 2017;37:452-60. [PMID: 28523402 DOI: 10.1007/s10875-017-0401-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
611 Liu X, Lin J, Wu H, Wang Y, Xie L, Wu J, Qin H, Xu J. A Novel Long Noncoding RNA lincRNA00892 Activates CD4+ T Cells in Systemic Lupus Erythematosus by Regulating CD40L. Front Pharmacol 2021;12:733902. [PMID: 34707498 DOI: 10.3389/fphar.2021.733902] [Reference Citation Analysis]
612 Hile GA, Kahlenberg JM. Immunopathogenesis of skin injury in systemic lupus erythematosus. Curr Opin Rheumatol 2021;33:173-80. [PMID: 33315653 DOI: 10.1097/BOR.0000000000000770] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
613 Rekvig OP. Systemic Lupus Erythematosus: Definitions, Contexts, Conflicts, Enigmas. Front Immunol 2018;9:387. [PMID: 29545801 DOI: 10.3389/fimmu.2018.00387] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]